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Abstract 
The susceptibility of MNs to injury in amyotrophic lateral sclerosis (ALS) may result 
from excitotoxicity and subsequent dysregulation of intracellular calcium homeostasis. 
Post-transcriptional editing of the AMPA and Kainate glutamate receptor (GLUR) 
subunit(s) may alter the calcium ion permeability of the receptor pore, leading to 
neurodegeneration.  
The aims of the study are (i) to investigate GLUR2, GLUR5 and GLUR6 RNA editing 
at Q/R site and its editing enzyme ADAR2 and ADAR3 in ALS/C9ORF72-positive and 
ALS/C9OR72-negative compared to non-neurological controls, and (ii) to determine 
the aberrant expression of EAAT2 transcripts in the astrocytes of the spinal cord of 
ALS cases and controls. (iii) To characterise p-TDP43, p62, GLUR2, ADAR2, 
ADAR3 and GFAP and EAAT2 proteins in motor neurons of ALS/C9ORF72-postive 
and ALS/C9ORF72-negative cases and controls.  (iv) To develop new methodology 
to look at different levels of the mRNA expression in GLUR2, GLUR5, GLUR6, 
ADAR2, ADAR3 and EAAT2 that might exist in ALS.  
RNA was extracted from MNs and cDNA was prepared followed by amplification of 
cDNA by PCR that was used to generate amplified GLUR2, GLUR5 and GLUR6. 
These products were digested to produce cuts in the internal site of GLUR mRNA and 
differentiate edited from non-edited GLUR by analysis using agarose gel 
electrophoresis and the Agilent Bioanalyser. Independently the mRNA expression of 
ADAR2, ADAR3 and EAAT2 alternative transcripts of normal and aberrant exon 4 and 
9 were quantified by qPCR. p-TDP-43, p62, GLUR2, ADAR2, ADAR3 and GFAP 
and EAAT2 protein levels were assessed by immunohistochemistry. The mRNA 
expression of GLUR2, GLUR5, GLUR6, ADAR2, ADAR3 and EAAT2 was assessed by 
next generation sequencing.   
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It was demonstrated that GLUR2 was fully edited in the MNs of ALS/C9ORF72-
positive, ALS/C9ORF72-negative cases and controls. GLUR5 was 39% edited in MNs 
of ALS/C9ORF72-positive, 57% edited in ALS/C9ORF72-negative cases and 30% 
edited in controls. GLUR6 editing in MNs was 86% editing in the ALS/C9ORF72-
positive and 77% editing in ALS/C9ORF72-negative cases compared to 72% editing 
in controls. An elevated mRNA expression in EAAT2 aberrant and normal transcripts 
of exon 4 and exon 9 was shown, but did not reach statistical significance.  
ADAR2 immunoreactivity was associated with the nuclei of MNs, in contrast to 
ADAR3 which was exclusively associated with the neuronal cytoplasm. No significant 
differences in the pattern or distribution of immunoreactivity was detected across all 
groups. Phosphorylated TDP-43+ and p62+ skein-like bodies and compact inclusions 
were significantly elevated in both ALS/C9ORF72-positive cases and 
ALS/C9ORF72- negative cases, compared to control subjects which exhibited neither 
p-TDP-43 nor p62 expression. No significant difference in the pattern of 
immunoreactivity of EAAT2 in ALS groups and controls.   
In conclusion, full editing of GLUR2 in dissected motor neurons isolated by LCM was 
confirmed in ALS/C9ORF72-positive and ALS/C9ORF72-negative and control 
individuals. Whereas partial editing has been identified in GLUR5 and GLUR6   
receptors.  The mRNA and protein expression of ADAR2 and ADAR3 on spinal cord 
have shown similar levels between tested groups. No significant difference in the 
mRNA and protein expression of EAAT2.  
MNs in ALS cases, both with and without C9ORF72 expansion expressed pathogenic 
inclusions of phosphorylated TDP-43 and p62, which are a hallmark for ALS. ADAR2 
and ADAR3 have shown no differences in ALS groups compared to controls. 
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Chapter 1: Introduction 
1.1 History of Amyotrophic Lateral Sclerosis  
The first clinical description of motor neurons disease was credited to Aran and 
Duchenne. In 1848, Aran reported a patient with progressive muscle weakness and 
correctly suspected a neurogenic cause. Two years later, Aran published a paper 
reporting 12 cases with the syndrome and named it progressive muscular atrophy 
(PMA) (Mitsumoto, 2006). Aran was influenced by Duchenne’s opinion; and both 
concluded that PMA is a muscular disease. In 1853, Jean Baptiste Cruveilhier 
demonstrated that his patient died from a disease in the spinal cord with atrophy of 
anterior nerve roots (Mitsumoto, 2006). Bell independently confirmed previous 
findings of the description of PMA patients with degeneration in the spinal cord.  Later, 
Charcot demonstrated the involvement of both the anterior roots and lateral columns; 
in 1874, Charcot successfully defined the clinical and pathological features of 
amyotrophic lateral sclerosis (ALS) (Mitsumoto, 2006). He defined, and separated 
ALS from PMA based on differing prognosis and bulbar movement. He referred to 
PMA as protopathic or primary, and conditions with both amyotrophy and spasticity 
as deuteropathic. Progressive bulbar Palsy (PBP) was recognized by Duchenne in 1860 
and it was Charcot who linked PBP to ALS. The term motor neurone disease (MND) 
was introduced by Brain to describe PMA, PBP and ALS (Mitsumoto, 2006). 
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1.2 Clinical features 
ALS is the most common adult-onset motor neurodegenerative disease. It is 
characterised by the loss of upper motor neurons in the motor cortex and/or lower 
motor neurons in the brain stem and the spinal cord. In this context, ALS refers to 
degeneration in both upper and lower motor neurons, which is the most common form 
of MND (Shaw & Wood-Allum, 2010).  Deterioration in the upper motor neurons, 
termed as primary lateral sclerosis (PLS), which is a rare form of MND is characterised 
by limb-onset. Whereas, the loss of lower motor neurons, termed as progressive 
muscular atrophy (PMA), describes spinal cord dysfunction. The majority of PMA and 
PLS patients progress to ALS over the disease course. PMA and PLS are recognised 
as spectrum, which also includes FTD (Mitsumoto, 2006). The common initial 
symptom of ALS is weakness in the limbs, in approximately 51% to 81% of the cases, 
which is more common than bulbar onset of the disorder.  Patients with ALS-limb 
onset exhibit weakness in the arms and /or legs, hemiparesis and difficulty in walking 
(Gubbay et al., 1985; Haverkamp et al., 1995; Traynor et al., 2000). Weakness of the 
proximal and distal muscles gradually progress to spasticity and eventually severe 
physical disability (Leigh & Ray-Chaudhuri, 1994). Moreover, the symptoms of ALS-
bulbar onset include fasciculation, stiffness, cramps and salivation accompanied with 
severe bulbar symptoms due to the loss of automatic swallowing and straight head 
posture, which in turn can lead to stress and anxiety for patients (Gubbay et al., 1985; 
Leigh & Ray-Chaudhuri, 1994; Haverkamp et al., 1995; Traynor et al., 2000). 
Dysphagia is also regarded as a major problem for approximately 50-70% of cases, as 
well as difficulty with speech, choking, dehydration, weight loss and aspiration 
pneumonia (Leigh & Ray-Chaudhuri, 1994). 
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Diagnostic criteria for ALS, as outlined by El Escorial World Federation of Neurology, 
are based on the clinical history of the patient and appropriate neurological 
examination(s) to determine clinical features, which may then result in the 
classification of ALS as: suspected, possible, probable and definite.  Definitive 
diagnosis for ALS occurs when the loss of both UMN and LMN occurs involving four 
regions of the central nervous system (CNS); bulbar, cervical, thoracic and 
lumbosacral (Brooks, 1994). However, it is currently difficult to establish a technique 
or clinical measurement that is able to definitively diagnose ALS at the early stages of 
disease, and whether it is associated with UMN or LMN pathology (Miller et al., 
1999). Currently ALS patients are diagnosed approximately 12 months after the onset 
of their clinical symptoms, however, it is highly likely they would have had the disease 
for three years or even longer before their first clinical signs. This likely reflects the 
loss of motor neurons required to exceed a threshold for clinical symptoms to develop 
(Mitsumoto, 2006). 
 
1.3 Aetiology of ALS 
1.3.1 Incidence and age at onset 
The global incidence rate of ALS is 2 per 100,000 individuals, with risk of disease 
increasing in the older population (over 50 years of age) (Cleveland & Rothstein, 2001; 
Lewis & Gordon, 2007; Shaw & Wood-Allum, 2010). In the UK, the incidence of ALS 
ranges from 1.06 to 2.4 per 100,000 individuals (Hoppitt et al., 2011).  Based on 
epidemiological studies, the incidence of ALS among European and US populations 
is 2.1 per 100,000 people (McGuire et al., 1996; Logroscino et al., 2010). ALS cases 
are more prevalent in men than women, with an odds ratio of 1.5:1 (Leigh & Ray-
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Chaudhuri, 1994). Several studies have reported that the mean age of onset is 40 years 
with a survival range from 3-5 years (Rowland & Shneider, 2001; Johnston et al., 
2006; Chen et al., 2007). Recent reports have suggested that the incidence of ALS in 
the elderly population (over 75 years of age) decreases,  which may either reflect the 
shorter survival interval associated with disease in the elderly or that ALS is not merely 
a result of ageing (Dykens, 1994; Logroscino et al., 2010; Turner et al., 2012). Young-
onset sporadic ALS occurs in those aged 20 years old or younger which is similar to 
age of onset in juvenile patients, those expressing ALS symptoms before age 25 years 
carrying a defined genetic risk factor (Reaume et al., 1996; Sabatelli et al., 2008). To 
date it is unclear whether ALS disease is an age related disease that specifically occurs 
as part of the ageing process (Turner et al., 2012). 
 
1.3.2 Genetic risk factors 
The majority of ALS patients are sporadic (90-95%) (SALS), the disease occurring 
with unknown genetic risk factors with no family history of ALS (Cleveland & 
Rothstein, 2001) and about 5-10% of ALS patients are familial (FALS), the disease 
resulted from an inherited genetic mutation. Of these familial ALS cases, 20% of the 
patients have mutation in the gene that encodes zinc superoxide dismutase 1 (SOD1). 
Genetic mutations associated with FALS have been shown to exist in some SALS 
cases at low frequencies of about 0.61% (Shatunov et al., 2010).  Mutations associated 
with SALS are difficult to study due to a lack of indication of mutations in the family 
history.  
Several further genes have been identified to be linked to FALS (See table 1) that are 
inherited in an autosomal dominant manner, including mutations in, TAR DNA 
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binding protein (TARDBP), Fused in sarcoma or translocated in liposarcoma 
(FUS/TLS) and Chromosome 9 Open Reading Frame 72 (C9ORF72). However, some 
mutations can also be inherited recessively or as X-linked (See table 1.1) (Ince et al., 
2011a). The genes responsible for most ALS cases are known, but a complete 
understanding is lacking. Further investigation of genetic associated disease may 
contribute to the understanding of some of the key mechanisms likely to be involved 
in ALS.  
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Table 1.1: Genetic subtypes linked to familial ALS. 
Genes Genetic subtypes Chromosomal 
locus 
Onset/ 
inheritance 
ALS 
Pathogenesis 
References 
Cu/Zn superoxide 
Dismutase (SOD1) 
ALS1 21q22.1 Adult/AD Oxidative stress (Rosen et al., 
1993) 
Alsin (ALS2) ALS2 2q33 Juvenile/AR Vesicle 
trafficking, 
guanine-
nucleotide 
exchange factor 
(GEF). 
(Yang et al., 2001) 
Unknown ALS3 18q21 Adult/AD ........................ (Hand et al., 2002) 
Senataxin (SETX) ALS4 9q34.13 Juvenile/AD RNA processing (Chen et al., 2004) 
Spatacsin/ spastic 
paraplegia 11  
(SPG11) 
ALS5 15q14 Juvenile/AR ………………. (Orlacchio et al., 
2010) 
Fused in sarcoma 
(FUS) 
ALS6 16q11.2 Adult/AD RNA processing (Vance et al., 
2009) 
Unknown ALS7 20p13 Adult/AD Unknown (Sapp et al., 2003) 
VAMP-associated 
membrane protein 
B (VAPB) 
ALS8  20q13.33  Adult/AD Intracellular 
Membrane 
trafficking, 
calcium 
metabolism 
(Nishimura et al., 
2004) 
Angiogenin (ANG) ALS9 14q11.1 Adult/AD RNA processing (Greenway et al., 
2006) 
TAR-DNA 
binding protein 
(TARDBP) 
ALS10 1p36.22 Adult/AD RNA processing (Sreedharan et al., 
2008) 
Polyphosphoinosit
ide phosphatase 
(FIG4) 
ALS11 6q21 Adult/AD Endoplasmic 
trafficking and  
cell signalling 
(Chow et al., 
2009) 
Optineurin 
(OPTN) 
ALS12 10p15-p14 Adult/AD 
   &AR 
Endoplasmic 
Trafficking & cell 
signalling 
(Maruyama et al., 
2010) 
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Ataxin 2 (ATXN2) ALS13 12q23-q24.1 Adult/AD RNA processing (Elden et al., 
2010)  
Valosin-
containing protein 
(VCP) 
ALS14 9q13-p12 Adult/AD Protein 
degradation 
(Johnson et al., 
2010) 
Ubiquillin 
(UBQLN2) 
ALS15 Xp11.21 Adult/X-linked Protein 
degradation 
(Deng et al., 2011) 
A σ Non-opioid 
receptor 1 
(SIGMAR1) 
ALS16 9p13.3 Adult/AD 
Juvenile/AR 
Calcium 
homeostasis 
(Luty et al., 2010) 
(Al‐Saif et al., 
2011) 
Charged 
multivesicular 
body protein 2B 
(CHMP2B) 
ALS17 3p11.2 Adult/AD   Vesicle 
trafficking 
(Parkinson et al., 
2006) 
Profilin 1 (PFN1) ALS18 17p13.3 
 
Adult/AD Cytoskeleton 
arrangement  
(Wu et al., 2012) 
v-erb-b2 avian 
erythroblastic 
leukemia viral 
oncogene homolog 
4 (ERBB4) 
ALS19 2q33.3-q34 Adult/AD ........................ (Takahashi et al., 
2013) 
Heterogeneous 
nuclear 
ribonucleoprotein 
A1(HNRNPA1) 
ALS20 12q13.1 Adult/AD Protein 
degradation 
(Kim et al., 2013) 
Matrin 3 (MATR3) ALS21 5q31.2 Adult/AD RNA processing (Johnson et al., 
2014) 
Chromosome 9 
open reading 
frame 72 
(C9ORF72) 
ALS/FTD 9p21-p22 Adult/AD RNA processing (Renton et al., 
2011) 
(DeJesus-
Hernandez et al., 
2011) 
coiled-coil-helix-
coiled-coil-helix 
domain containing 
10 (CHCHD10) 
ALS/FTD 22q11.23 Adult/AD Mitochondrial 
dysfunction 
(Bannwarth et al., 
2014) 
SQSTM1/p62 ALS 5q35 
 
Adult/AD Protein 
degradation 
(Fecto et al., 2011) 
Dynactin1 
(DCTN1) 
ALS 2p13 
 
Adult 
 
Vesicle trafficking (Münch et al., 
2004)  
D-amino-acid 
oxidase (DAO) 
ALS 12q24 Adult/AD Glutamate 
excitotoxicity 
(Mitchell et al., 
2010) 
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1.3.2.1 SOD1 
Mutation(s) in the zinc/copper (Zn/Cu) superoxide dismutase1 encoded gene (SOD1) 
located on chromosome 21 were the first identified causative gene for ALS,  
accounting for approximately 20% of familial cases (Rosen et al., 1993) and 5% of 
SALS cases (Rowland & Shneider, 2001; Rothstein, 2009). SOD1 is a cytosolic protein 
that act as a homodimer to bind with equal affinity to zinc and copper atoms (Shaw, 
2005) and catalyses the superoxide (O2
-) radicals, produced by errors within 
mitochondria, to hydrogen peroxide and water. It protects neuronal cells from 
oxidative stress by regulating levels of reactive oxygen species (ROS) (Yamanaka & 
Cleveland, 2005). The majority of SOD1 related ALS cases are inherited in an 
autosomal dominant pattern. However, the exact mechanism(s) by which mutant SOD1 
cause ALS is, as yet, unknown. More than 114 mutations in SOD1 have been reported 
and none of these mutations have a clear impact on decreased SOD1 activity. The 
pathogenicity of mutant SOD1 is independent of its dismutase activity (Yamanaka & 
Cleveland, 2005; Boillée et al., 2006). This was established when inactivation or total 
absence of SOD1 gene by deletion did not cause ALS in mice whereas, transgenic mice 
with mutant SOD1 gene developed muscle wasting and progressive paralysis without 
affecting enzyme activity (Deng et al., 1993; Gurney et al., 1994). Several theories 
have attempted to explain toxic mutant SOD1 mediated ALS, including the 
accumulation of unstable misfolded SOD1 protein in the cytosol and within 
mitochondria in the spinal cord of both animal models and familial ALS patients (Liu 
et al., 2004; Pasinelli et al., 2004; Vijayvergiya et al., 2005). It has also been shown 
to enhance damage within motor neurons and subsequently, if compounded by 
impaired non-neuronal neighbouring cells,  could accelerate disease progression (Sato 
et al., 2005). 
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1.3.2.2 TARDBP 
 Transactive response DNA binding protein-43 (TDP-43) is an RNA binding protein, 
that is ubiquitously expressed, highly conserved, and normally acts as a nuclear 
protein. However, pathogenic TDP-43 is transferred to the cytoplasm under the 
following conditions: cell stress (granules); over expression; interference with TDP-
43 nuclear localisation signal; transporting pathogenic mutations subsequently leading 
to fragmentation, phosphorylation and/or aggregation (Neumann et al., 2006b). TDP-
43 mutations have been found in approximately 7% of FALS cases and 1-5% of SALS 
cases (Beleza-Meireles & Al-Chalabi, 2009). TDP-43 is involved in multiple steps of 
RNA processing including, regulation of alternative splicing, transcription, RNA 
stabilization, microRNA processing (Neumann et al., 2006b).  It has been reported that 
TDP-43 protein binds to UG repeats in large introns, to 3`UTR of mRNA, other mRNA 
binding sites and RNA processing genes, resulting in the broad dysfunctional 
mechanisms caused by mutation of TDP-43 in ALS (Sreedharan et al., 2008; Sephton 
et al., 2011). 
 
1.3.2.3 FUS/TLS 
Fused in sarcoma (FUS) or translocated in liposarcoma (TLS), is a ribonucleoprotein 
that is expressed in the nucleus of neuronal cells and can be found in limited 
proportions in the cytoplasm of most cells (Kwiatkowski et al., 2009). It has an 
important role in the regulation of gene expression, including exon splicing, DNA 
damage repair and maintaining genomic structure. Like TDP-43, FUS is also involved 
in alternative splicing, transcription, and microRNA processing (DeJesus‐Hernandez 
et al., 2010), and mutations in FUS have been identified in approximately 4% of FALS 
cases and 1% of sporadic cases (Kwiatkowski et al., 2009 ; DeJesus-Hernandez et al., 
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2010). Evidence has shown abnormal cytoplasmic inclusions immunoreactive of FUS 
but not TDP-43 in neurons and glia of some ALS patients (Kwiatkowski, et al. 2009), 
suggesting that FUS has an independent role in neurodegeneration (Vance, et al. 
2009). The exact mechanism(s) by which FUS and TARDBP mutations cause 
neurodegeneration is, as yet, unknown. Nonetheless, based on functional data, a 
number of hypotheses have been generated. TDP-43 sequestration into inclusions 
could cause a loss of function resulting in transcriptional deregulation and aberrant 
splicing of pre-mRNA. The loss of TDP-43 activity could disrupt the low molecular 
weight neurofilament mRNA via a direct interaction with the 3′UTR, thus changing 
the stoichiometry of neurofilament subunits and consequently leading to the formation 
of neurofilament aggregates as observed in ALS (Strong et al., 2007). Alternatively, 
the aggregation of C-terminal domain of TDP-43 could cause toxic gain of function 
by altering TDP-43 splicing regulatory function (Forman et al., 2007).  
The persistence of pathogenic cytoplasmic FUS inclusions impairs the proteolytic 
process by inhibiting protein tagging by ubiquitin and p62 (Baumer et al. 2010; 
Neumann et al. 2009). Ubiquitin and p62 covalently tags proteins for degradation by 
the ubiquitin-proteasome system. Sequestosome 1 (also known as SQSTM1) binds 
ubiquitinated proteins and targets them for degradation by proteasome and autophagy 
process. Mutations in SQSTM1 have been identified as a rare cause of ALS (Rubino et 
al. 2012). 
In vitro experiments using cultured cells have shown that FUS prion domain mutation 
causes an increase in its propensity to aggregate and form intranuclear inclusion. 
However, pathology studies from patients with prion domain mutant FUS are still 
lacking (Dormann et al. 2010; Kino et al. 2011; Nomura et al. 2014). Interestingly, 
this is similar to the case for TDP-43, which the majority of ALS-causing mutations 
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cluster in its prion domain and may not directly affect its nuclear localization, but 
rather increase its aggregation propensity in vitro (Johnson et al. 2009). 
FUS mutations in ALS families suggest that mutations result in either a novel, toxic 
gain of function or create a dominant negative effect that interferes with the normal 
activity of wild type FUS. The FUS-positive cytoplasmic inclusions found in 
degenerating MNs of patients may play a role in the pathogenesis of the disease; they 
could be toxic directly to the cell independent of normal FUS activity, or they might 
sequester, and functionally deplete wild type FUS in abnormal cytoplasmic aggregates 
(Kwiatkowski, et al. 2009; Vance, et al. 2009). 
 
1.3.2.4 C9ORF72 
A mutational event in the Chromosome 9 Open Reading Frame 72 (C9ORF72) gene 
was recently identified as the most common causative gene of frontotemporal 
dementia (FTD) and ALS. FTD is a progressive neurodegenerative disease 
characterised by neuronal loss in the frontal and anterior temporal lobes, which leads 
to language impairment and  personality changes (McKhann et al., 2001). FTD is 
clinically recognised in 5% of ALS cases although some sort of cognitive impairment 
is seen in up to 50% of ALS cases (Ferrari et al., 2011). FTD and ALS can clinically 
co-occur, and share many similarities at both the genetic and the neuropathological 
level, and are proposed to constitute the same spectrum disorder (Lillo & Hodges, 
2009). The mutation change in C9ORF72 comprises a large intronic hexanucleotide 
(GGGGCC) repeat expansion between two non-coding exons,  and is present in 
approximately 40 % of FALS and 7% of SALS patients (DeJesus-Hernandez et al., 
2011; Renton et al., 2011; Mahoney et al., 2012; van Rheenen et al., 2012). In a healthy 
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population, less than 30 repeats are found, however, ALS-FTD patients have large 
expansions carrying potentially hundreds or even thousands of repeats. It is thought 
that C9ORF72 mutations in SALS cases  arise from an inherited genomic instability 
in the repeat region, whereas familial C9ORF72 cases are brought about in an 
autosomal dominant manner (Fratta et al., 2012). Examination of post-mortem brain 
and spinal cord tissues from ALS-FTD patients with the C9ORF72 mutation have 
demonstrated immunoreactive TDP-43 cytoplasmic inclusions in neurons and glia 
(Stewart et al., 2012). A recent study has shown that all C9ORF72 positive patients 
display similar neuropathology compared to the C9ORF72 negative patients. 
However, the same study showed that patients with the C9ORF72 mutation exhibited 
a significantly shorter disease duration compared to their counterparts (Cooper-Knock 
et al., 2012). It has been suggested that the C9ORF72 expansion could contribute to 
the pathogenesis of ALS by three possible mechanisms: i) the sequestration of 
important RNA binding-proteins by sense and/or antisense toxicity of repeat RNA, ii) 
the toxic function of dipeptide-repeat proteins (DPR) that are generated by repeat-
associated non-ATG (RAN) translation, or iii) the reduced expression of C9ORF72 
(Fratta et al., 2012; Harms et al., 2013). The latter possible mechanism is thought to 
be the least likely, because of the absence of a C9ORF72 coding mutation (Fratta et 
al., 2012; Mizielinska et al., 2014) and the lack of severe phenotype in cases with a 
homozygous mutation (Harms et al., 2013). RNA aggregates (RNA foci) that are 
formed from sense and antisense repeat transcripts are frequently found in C9ORF72-
FTD-ALS patient brains (Gendron et al., 2013; Lagier-Tourenne et al., 2013; Lee et 
al., 2013; Mizielinska et al., 2013; Zu et al., 2013). The GGGGCC expanded repeats 
can be transcribed bi-directionally in an unpredictable fashion in the absence of an 
initiating codon (RAN translation) producing detectable expression of sense and 
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antisense transcripts (Gendron et al., 2013). To date, little is known about the function 
of the normal C9ORF72 protein and how it might contribute to disease pathogenesis.  
 
1.3.3 Environmental risk factors  
The cause of the fatal multifactorial ALS is largely unknown due to its increased 
complexity and association with one or more environmental risk factors. Sex, age at 
onset (usually after the age of 40 years) (Rowland & Shneider, 2001),  and residence 
in specific parts of the western pacific region  are linked with motor neuron diseases 
(Leigh & Ray-Chaudhuri, 1994). Several studies have suggested possible 
environmental cause(s) for ALS, these include smoking  (Armon, 2009; Weisskopf et 
al., 2010), head injury (Chen et al., 2007), exposure to toxins such as pesticides used 
in farming (Armon et al., 1991) (Muddasir Qureshi et al., 2006), and heavy physical 
activities (Kurtzke, 1991; Chancellor & Warlow, 1992; Veldink et al., 2005). Previous 
infection with Retrovirus and Poliovirus (Jubelt, 1992; Swingler et al., 1992; Cermelli 
et al., 2003) raise the incidence of ALS when accompanied with other environmental 
risk factors and the potential accumulation of reactive oxygen species (ROS) leading 
to critical metabolic alteration (Gros-Louis et al., 2006). Another environmental risk 
factor associated with ALS patients is physical trauma (Chen et al., 2007),  as well as 
consumption of a dietary excitotoxin, i.e. β-N-methylamino-L-alanine (L-BMAA) 
found in cycad flour (Nelson et al., 2000). 
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1.4 Pathological factors associated with ALS 
1.4.1 Glutamate excitotoxicity 
One of the leading concepts of a cause of ALS is excitotoxicity, a term that was first 
proposed in 1969 to describe the increased activation of post-synaptic receptors by 
excessive release of glutamate (Olney, 1969). Glutamate is the major excitatory 
neurotransmitter in the mammalian central nervous system. During the process of 
normal glutamatergic neurotransmission, glutamate is released from presynaptic 
neuronal terminals into the synaptic cleft where it activates glutamate receptors on the 
post-synaptic terminal (Laake et al., 1995). The excitatory neurotransmitter signal is 
terminated by active removal of glutamate by the glutamate re-uptake system like the 
excitatory amino acid transporters (EAAT). EAAT family consist of EAAT1, EAAT2, 
EAAT3 and EAAT4. EAAT1 and EAAT2 are mainly expressed by astrocytes whereas 
EAAT3 and EAAT4 are associated with neurons (Lin et al., 1998). EAAT2 is thought 
to be the predominant glutamate transporter which plays a central role in maintaining 
neurotransmitter levels in the synapse. EAAT2 is also known as solute carrier family 
1 (glial high affinity glutamate transporter, member 2 (SLC1A2)). However, for the 
purpose of this thesis EAAT2 will be used throughout. Within glial cells, glutamate is 
converted to glutamine then transported back to presynaptic neurons where glutamine 
is reconverted to glutamate by glutamine synthetase (Shaw & Ince, 1997; Doble, 1999) 
(See figure 1.1).  
Excitotoxic mechanisms may include elevated extracellular glutamate levels resulting 
in abnormal glutamate receptor activity and/or aberrant glutamate reuptake 
mechanisms. High concentrations of intracellular Ca+2 resulting from increased 
glutamate receptor activation may alter cellular Ca+2 homeostasis and activate Ca+2 
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dependent pathways to restore Ca+2 homeostasis by compartmentalization, 
transportation, and sequestration into organelles (Heath & Shaw, 2002; Van Den 
Bosch et al., 2006b; Bezprozvanny, 2009). Studies have shown a significant increase 
of glutamate levels in the CSF of ALS patients (Rothstein et al., 1990; Shaw et al., 
1995a). These glutamate receptors are composed of AMPA, kainate and NMDA 
receptors (see table 1.2) (Laake et al., 1995). 
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 Table 1.2: Glutamate receptors and function. 
Summary of AMPA, KA and NMDA receptors subunit. Each receptor named after their 
unique agonist, their possible editing sites, and distribution on MNs and glia as well as their 
specific functions. 
 
 
 
 
 
 
 
 
 
 
Glutamate 
receptors 
AMPA KA NMDA References 
Subunits GLUR1, GLUR2,  GLUR3 
and GLUR4 
GLUR5, GLUR6,  
GLUR7, KA1 and KA2 
NR1, NR2A, NR2B,  
NR2C and NR2D 
(Barbon et al., 2003) 
(Van Den Bosch et 
al., 2006) 
Editing sites GLUR2-Q/R (Arg607) 
GLUR2- R/G (764Gly) 
GLUR5-Q/R (636Arg) 
GLUR6-Q/R (621Arg),  
GLUR6-Y/C (571 Cys)  
GLUR6- I/V (567 Val) 
 
n/a 
(Köhler et al., 1993), 
(Lomeli et al., 1994),   
(Sommer et al.,1991), 
(Kwak & Kawahara, 
2005) 
Location Widely distributed on 
postsynaptic neurons and 
glia 
Limited distribution on 
pre/post synaptic 
neurons 
Widely distributed  on 
post-synaptic neurons 
and some presynaptic 
and glia 
 
 
 
(Barbon et al., 2003) 
(Van Den Bosch et 
al., 2006b) 
Permeability Impermeable to Ca+2 Impermeable to  Ca+2 Permeable to  Ca+2 
Function Fast synaptic transmission Fast synaptic 
transmission 
Slow synaptic 
transmission 
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The AMPA receptor is a heterotetramer composed of a mixture of the four possible 
subunits; GLUR1, GLUR2, GLUR3 and GLUR4. These subunits have similar protein 
structure with the major difference being associated with the GLUR2. This glutamate 
receptor, ionotropic, AMPA 2 is also known as GRIA2. However, the GLUR2 name 
will be used throughout the thesis. Whereas, GLUR5 is a glutamate receptor, 
ionotropic, kainate 1 also known as GRIK1 and GLUR6 is another glutamate receptor, 
ionotropic, kainate 2 also known as GRIK2. However, the GLUR5 and GLUR6 names 
will be used throughout the thesis. GLUR2 is the only subunit of the AMPA receptor 
that is edited as well as GLUR5 and GLUR6 of the KA receptor. Abnormal editing of 
the GLUR2 subunit increases Ca
+2 permeability of the receptor channel and the reduce 
expression of calcium buffering proteins in motor neuron contributes to neuronal 
mediated toxicity in ALS (Carriedo et al., 1996; Van Damme et al., 2007; Kwak et al., 
2010) (see figure 1.4).  
It has been reported that the abnormal function and expression of astrocytic glutamate 
re-uptake system EAAT2 in ALS cases contributes to motor neuron vulnerability to 
excitotoxic neuronal injury (Rothstein et al., 1992; Rothstein et al., 1995; Lin et al., 
1998). Because of the apparent decrease in the efficacy of synaptic clearance of 
glutamate, neuronal cells are exposed to elevated levels of extracellular glutamate. 
Any defect in the astrocyte mechanism of glutamate clearance may have an impact on 
motor neurons.   
Studies have shown that a loss of EAAT2 protein is associated with 30-95% of SALS 
patients (Rothstein et al., 1992; Shaw, 1994; Rothstein et al., 1995; Haugeto et al., 
1996; Rothstein et al., 1996). Additionally, abnormal Na+-dependent glutamate 
transporter systems have also been reported in the synaptosomal preparation of post-
mortem ALS tissue isolated from spinal cord and motor cortex (Rothstein et al., 1992). 
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Immunoblotting studies using anti-peptide polyclonal antibodies to measure EAAT2 
protein levels in the homogenates of CNS tissue have shown a large decrease in the 
astrocytic EAAT2 protein in the spinal cord and motor cortex of ALS patients 
(Rothstein et al., 1995). The loss of EAAT2 may arise as a result of: (i) aberrant 
transcripts producing truncated proteins, or (ii) inhibition of EAAT2 transcription (Sue 
et al., 2003).  
Aberrant mRNA species might be produced by mechanisms such as intron-retention 
and exon-skipping (Lin et al., 1998; Meyer et al., 1998; Meyer et al., 1999). Aberrant 
mRNA transcripts have been detected in the motor cortex and spinal cord of SALS 
patients, but not in other brain regions including cerebellum and hippocampus (Lin et 
al., 1998). These transcripts have been shown to be absent in other neurological 
diseases such as in Spinal muscular atrophy, Huntington’s disease and Alzheimer’s 
disease (Lin et al., 1998). One study showed that the intron 7 retention and exon 9 
skipping protein was not detected in the motor cortex or spinal cord of ALS cases. The 
inability to detect these aberrant transcripts could be the result of unstable and/or 
degraded EAAT2 protein in the post-mortem tissue (Lin et al., 1998).  
However, these aberrant mRNA transcripts have also been detected in non-
neurological control tissue (Meyer et al., 1999; Honig et al., 2000; Flowers et al., 
2001). In one study, the splice variant of EAAT2 involving the skipping of exon 4 was 
reported to be highly expressed in control rat brains (Lee et al., 2011). Human exon 4 
encodes transmembrane 3 (TM3) region of EAAT2 and consists of a motif that plays 
the role of a hinge that pulls extracellular glutamate into the astrocytes (Reyes et al., 
2009), indicating the important role of EAAT2 in the regulation of glutamate in the 
synaptic terminal. Defect in the astrocytic glutamate re-uptake system of EAAT2 leads 
to excitotoxicity, impaired RNA processing, mitochondrial dysfunction or oxidative 
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damage that may contribute to a range of neuronal injury in stroke, neurotrauma, 
epilepsy and other neurodegenerative disorders, including ALS (Bruijn et al., 1997; 
Doble, 1999; Trotti et al., 1999; Van Den Bosch et al., 2006b; Ferraiuolo et al., 2011). 
 
 
Figure 1.1: Normal glutamate neurotransmission process.  
Glutamate is released from the vesicles into the synaptic cleft where it activates 
glutamate receptors on post synaptic neuronal terminal. Excess glutamate is taken up 
by EAAT2 located on the astroglia that convert the glutamate to glutamine by 
glutamate synthetase, thereby removing excess glutamate from the extracellular space, 
modified from (Heath & Shaw, 2002) with permission 3512500882980. 
 
 
 
 
` 
20 | P a g e  
 
1.4.2 Oxidative stress 
Oxidative stress plays a vital role in the pathogenesis of ALS and in several other 
neurodegenerative diseases. The correlation between oxidative stress and neuronal 
death has been extensively investigated. Oxidative stress can damage DNA, RNA, 
proteins and lipids and may lead to the opening of mitochondrial permeability 
transition pore which can stimulate the production of further reactive oxygen species 
(ROS). The imbalance between the creation and depletion of ROS or the failure to 
repair ROS induced damage leads to oxidative stress (Nicholls, 2004). Increased free 
radicals can cause excess release of excitotoxic glutamate, inhibition of glutamate 
removal, and cause an increase in Ca+2 influx (Law et al., 2001).  In vitro studies of 
the NSC-34 murine motor neuronal cell line transfected with the human Q331K 
mutation in  TDP-43 showed elevated toxicity, which is associated with abnormal 
phosphorylation of the TDP-43 protein (Duan et al., 2010). Increased levels of toxic 
free radicals have been identified in the brain and in spinal cord of SALS and FALS 
patients,  providing  in vivo evidence of oxidative stress in ALS patients (Tohgi et al., 
1999a; b; Shaw, 2005). Oxidative damage, an early feature of neurodegeneration, can 
be associated with other pathophysiological factors underlying neurodegenerative 
diseases, including mitochondrial dysfunction, excitotoxicity, and protein aggregation 
(Andersen, 2004; Ferraiuolo et al., 2011). 
 
1.4.3 Mitochondrial dysfunction 
The Mitochondria are the centre of energy production and Ca+2 buffering in the cell.  
They act as the site of oxidative phosphorylation, cellular respiration and initiation of 
apoptosis. Changes in mitochondrial functions have major consequences on signalling 
pathways and cell survival (Dong et al., 2009). For example, abnormally increased 
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uptake of Ca2+ or ROS production promotes the activation of the mitochondrial 
permeability transition and results in the release of proapoptotic factors and Ca2+ into 
the cytosol. These factors in turn activate caspase-dependent apoptosis or 
autophagocytosis by activating DNases and degrading proteins involved in DNA 
repair and the breakdown of cytoskeletal proteins. Autophagy can also be 
cytoprotective, in that stress induced mitochondrial depolarization during the 
permeability transition selectively removes damaged mitochondria. Other processes 
can also promote mitochondrial permeability transition such as stress ER stress and 
DNA damage (Dong et al., 2009). 
Abnormal mitochondrial shape is reported in SALS patients’ anterior horn of spinal 
cord and proximal axons. Furthermore, muscle biopsies of ALS patients exhibited 
increased mitochondrial Ca2+ and volume. Observations on the function of 
mitochondria have produced evidence consistent with the morphological observations 
(Manfredi & Xu, 2005). The modification of the mitochondrial activity was 
concomitant with a decrease in citrate synthase (CS) activity, a mitochondrial marker 
in the spinal cord of these patients (Wiedemann et al., 2002; Manfredi & Xu, 2005).  
Mitochondrial dysfunction and oxidative stress are closely linked and any changes in 
the bioenergetics capacity of the mitochondria generates damaging ROS leading to 
neurodegeneration of motor neurons (Menzies et al., 2002; Andersen, 2004; Shaw, 
2005).  
 
1.4.4 Dysregulation of RNA processing 
Aberrant RNA processes have been shown to contribute to motor neuron injury in ALS 
affecting several pathways including loss of the normal nuclear functions of TDP-43 
and FUS or by toxic gains of function. TDP-43 and FUS may be involved in mRNA 
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transport and when mutated, could thereby contribute to motor neuron injury through 
failure of appropriate axonal mRNA transport (Sephton et al., 2011). It has been 
suggested that Transportin (Trp), which is a nuclear transport receptor, may mediate 
nuclear import of FUS by binding to the C-terminal of FUS. Knockdown of both Trp1 
and Trp2, which are two closely related proteins, results in impaired nuclear import of 
FUS (Dormann et al., 2010), whilst knockdown of either one of the transportin 
receptors has no impact on the nuclear import. Mutation in TDP-43 and FUS leads to 
the formation of cytoplasmic aggregates disturbing cellular function in regulating 
transcription, alternative splicing and microRNA processing (Mackenzie et al., 2010). 
Evidence has shown that TDP-43 binds to UG repeats in large introns, to the 3`UTR 
of mRNA, other mRNA binding sites and RNA processing genes, resulting in the 
broad dysfunctional states caused by pathogenic TDP-43 protein in ALS (Sephton et 
al., 2011).  
 
1.4.5 Glial cell dysfunction 
Glial cells of the CNS provide the metabolic, structural and trophic support that 
neurons require to function. As discussed earlier, astrocytes fine-tune synaptic activity 
by regulating neurotransmitter activity and also play a key role in maintaining the 
blood-brain barrier, therefore astroglial  dysfunction may either directly or indirectly 
contribute to the development of ALS  (Ince et al., 2011b). Microglia, the resident 
macrophages of the CNS, have crucial role in mediating phagocytosis and secrete pro-
inflammatory molecules including ROS, cytokines and  nitric oxide (Gonzalez-
Scarano & Baltuch, 1999). Activation of microglia is an early event in the pathogenesis 
of ALS, which has been detected in brain and spinal cords of ALS patients  and in 
mutant SOD1 mice models (Engelhardt & Appel, 1990; Hall et al., 1998), suggesting 
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a role in motor neuron degeneration. There is evidence that astrocytes mediate 
glutamate neurotoxicity by reduction in EAAT2 transporter expression in spinal cord 
of SOD1-G85R transgenic mice model and in SOD1-G93A transgenic rats (Brujin et 
al., 1997). The release of ROS from inflammatory mediators may cause damage by 
increased activation of glial cells and thus reduce the trophic support glial cells provide 
to neurons. Furthermore, activated glial cells release ROS and activate their 
neighbouring cells, which may inhibit the ability of glutamate reuptake by astrocytes 
(Zhao et al., 2004). This process has been proposed to lead to a neurotoxic effect and 
progressive neuronal damage (Banati et al., 1993). 
 
1.4.6 Protein aggregation 
Neuropathological protein aggregates such as ubiquitinated compact and skein-like 
inclusions are the hallmark of ALS pathology (Ince et al., 1998a; Ince et al., 1998b; 
Piao et al., 2003). Pathogenic inclusions are exported from the nucleus and accumulate 
in the cytoplasm (Neumann et al., 2006b). To date, the causes of the protein 
aggregations are not fully understood, and whether they contribute to disease or are a 
consequence of pathology is unknown. TDP-43 inclusions may impact the normal 
physiological nuclear function or promote toxic gain of function due to excessive 
accumulation in the cytoplasm (Dormann et al., 2010).  
There is evidence that misfolded proteins accumulate in ALS due to endoplasmic stress 
(Yamagishi et al., 2007). Furthermore, the production of misfolded proteins has been 
shown to occur at the early stages of ALS, along with both ER resident chaperones 
and the unfolded protein response in the mutated SOD1 mice model and in samples 
from human SALS patients (Atkin et al., 2006; Atkin et al., 2008).  SOD1 inclusions 
have been found within motor neurons of FALS patients and transgenic models of 
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disease (G93A and G85R lines), and small eosinophilic Bunina bodies are observed in 
MNs in the majority of cases (Shibata et al., 1996; Piao et al., 2003; Okamoto et al., 
2008).  In ALS patients with FUS mutations, cytoplasmic inclusions of the protein are 
observed in the spinal cord (Hewitt et al., 2010). The resulting protein aggregates are 
reported to contain peripherin and neurofilament heavy chain (Ferraiuolo et al., 2011). 
A greater understanding of the composition of the protein aggregates will provide 
invaluable information about disease pathogenesis. 
 
1.4.7 Impaired axonal transport 
Neurofilaments are the major component of neuronal cytoskeleton which provides 
structural support for axons and regulate axonal diameter. Neurofilament proteins are 
synthesized in the motor neuron cell body, and transported through the axon by slow 
axonal transport. Motor neurons have long axons, which can be in excess of 1m in 
length; therefore they require transport of RNAs, proteins and organelles to axonal 
compartments (Shaw, 2005). Microtubule-dependent-kinesins are the axonal 
molecules that mediate the anterograde transport of axonal products towards the 
neuromuscular junction (NMJ), whereas cytoplasmic dynein has a retrograde transport 
activity towards the cell body to provide an effective intracellular transport system 
(Kieran et al., 2005; De Vos et al., 2007; Bilsland et al., 2010). The accumulation of 
abnormal neurofilament rich inclusions, including compact inclusions and Lewy body, 
is one of the hallmarks of ALS (Shaw, 2005). Mutations in the genes encoding 
microtubule associated tau protein, neurofilament heavy chain and  intermediate 
filament protein (peripherin) have been identified in ALS patients (Hutton et al., 
1998). Transgenic mice with mutant SOD1 have demonstrated reduced neurofilament 
protein and a concomitant decline of the axon calibre in the spinal  cord, suggesting 
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correlation between impaired axonal transport and defective neurofilament proteins 
(Zhang et al., 1997; Beaulieu et al., 1999). As a result, oxidative damage, 
mitochondrial dysfunction and any other defective cellular mechanisms, may 
contribute to motor neuronal toxicity in ALS (see figure 1.2).   
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Figure 1.2: The pathogenic mechanisms that contribute to motor neuron injury 
in ALS 
The underlying neurodegenerative pathology of ALS is multifaceted involving 
molecular and genetic pathways. For instance, the dysfunctional regulation of the 
excitatory amino acid transporter 2 (EAAT2) leads to glutamate-induced 
excitotoxicity because of the reduced reuptake of glutamate in the synaptic cleft. 
Glutamate-induced excitotoxicity promotes the generation of free radicals and the 
influx of Na+ and Ca2+ ions, which ultimately leads to neurodegeneration. 
Additionally, mutations in TARDBP, FUS and C9ORF72 can contribute to the 
formation of harmful intracellular aggregates. Furthermore, the mutation of SOD1 is 
known to promote mitochondrial dysfunction, oxidative stress and intracellular 
aggregates that inhibit neurofilaments and axonal transport process. Increased 
activation of glial cells promotes the release of ROS from proinflammatory cytokines 
that may reduce the trophic support of glial cells to neurons, which may inhibit the 
ability of glutamate reuptake by astrocytes. This process has been proposed to 
contribute to neurodegeneration, obtained from (Vucic et al., 2014) with permission 
3512501326588 (Kiernan et al., 2011).  
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1.5 Aberrant RNA editing of glutamate receptors in ALS 
Adenosine deaminase acting on RNA (ADAR) was first discovered in Xenopus laevis 
and calf thymus using a non-specific dsRNA deamination assay (Hough & Bass, 1994; 
Kim et al., 1994; O'Connell & Keller, 1994). The ADAR family of enzymes in 
mammals consists of three structurally related isoforms; ADAR1, ADAR2 and ADAR3, 
and each of them have two or three double stranded RNA binding domains in the N-
terminus and one deaminase domain in the C-terminus (Bass, 2002) (see figure 1.3). 
ADAR1 and ADAR2 are predominantly expressed in the nucleus of most tissues 
especially in the CNS, in contrast to ADAR3 that is expressed in the brain, mostly in 
the cerebellum and thalamus, and can also be found in the cytoplasm (Keegan et al., 
2001; Bass, 2002; Keegan et al., 2004). RNA editing is a post-transcriptional 
modification catalysing the conversion of adenosines into inosines which are then 
translated to guanosines. The common type of RNA editing is Adenosine-to-Inosine 
(A-to-I) catalysed by ADAR2 which, for example, occurs in the pre-mRNA of AMPA 
receptor subunit GLUR2 at Q/R site (Bass, 2002; Keegan et al., 2004). Both ADAR1 
and ADAR2 edits GLUR2 at the Q/R site as determined in general ADAR2 knock out 
mice.  ADAR2 enzymatic activity was inhibited by exchanging exon 4, the enzyme 
functional adenosine deaminase domain, with PGK-neo cassette (Higuchi et al., 2000). 
Knockout mice containing the inactive mutant ADAR2 resulted in reduced GLUR2 
RNA editing compared to wild-type mice. This would suggest that ADAR2 is the main 
RNA editing enzyme at the Q/R site, and the residual low level of Q/R site editing in 
GLUR2 pre-mRNA is perhaps mediated by ADAR1, for which the gene expression 
was unaltered in ADAR2 knockout mice (Higuchi et al., 2000).  
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In the adult it is thought that the AMPA receptor subunit GLUR2 is fully edited at the 
Arg607 (Q/R) site, protecting neuronal cells by causing a change from a glutamate to 
an arginine residue on the receptor channel. Failure to edit at this site could result in 
increased channel permeability to Ca+2, further anion conductance, as well as alteration 
of current/voltage kinetics and only allow Na+ influxes (Barbon et al., 2003; Kwak & 
Kawahara, 2005) (see figure 1.4). It has been demonstrated that deficient or absence 
of GLUR2 RNA editing occurs specifically in motor neurons of SALS cases, and not 
in other neuronal cells such as spinocerebellar and Purkinje cells, leading to the 
hypothesis that altered GLUR2 editing may be motor neurone specific (Kawahara et 
al., 2003; Kawahara et al., 2004; Kwak & Kawahara, 2005). It has been suggested that 
abnormal GLUR2 is specific to motor neurons of SALS patients and it is not linked to 
other motor neuron diseases such as spinal and bulbar muscular atrophy and SOD1-
associated ALS (Kawahara et al., 2003; Kawahara et al., 2004; Kwak & Kawahara, 
2005; Kawahara et al., 2006). However, another study found that abnormal GLUR2 
editing at Q/R site can occur in a wide spectrum of  non-motor neurological diseases 
including the prefrontal cortex of Alzheimer's disease (AD), prefrontal cortex and 
striatum of schizophrenic patients as well as the striatum of patients with Huntington's 
disease (HD) (Akbarian et al., 1995). GLUR2 RNA editing of  > 99 %  maintains 
healthy motor neurons (Seeburg et al., 1998). Mice with deficient RNA editing of 
GLUR2 are born with epilepsy and die about 3 weeks after birth. The unedited GLUR2 
receptor at Q/R site participates in the slow death of motor neurons, which can be 
rescued by restoring RNA editing (Brusa et al., 1995; Higuchi et al., 2000).  
GLUR5 and GLUR6 of kainate (KA) receptor subunits also undergo Q/R site editing 
by ADAR2 in the channel pore forming the so-called P-loop (at 636Arg and 621Arg, 
respectively) (Caracciolo et al., 2013).These subunits were found to be partially 
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permeable to Ca+2 and unlike GLUR2 are not fully edited at the Q/R site (Köhler et al., 
1993; Seeburg et al., 1998). GLUR5 and GLUR6 editing at the Q/R site is 
developmentally regulated. The editing of GLUR5 and GLUR6 reach values of up to 
55% in the rat embryo and 85% in the adult rat brain. The extent of GLUR5 editing at 
the Q/R site was differentially modulated in the control human brain of 50% editing in 
spinal cord and cerebellum reaching to 70% of edited GLUR5 at the thalamus, 
amygdala and hippocampus (Barbon et al., 2003). GLUR6 editing levels in control 
human brain were differentially regulated and reported to be above 67% editing in 
thalamus, cerebellum, amygdala and hippocampus, whilst the spinal cord showed 31% 
editing of GLUR6 (Barbon et al., 2003). The edited forms of GLUR5 and GLUR6 have 
markedly reduced anion channel permeability and low single channel conductance 
(Caracciolo et al., 2013). 
A-to-I RNA editing of GLUR2 can also occur at other editing sites including at 
764Gly, where an arginine (R) is replaced by glycine (G) changing the desensitisation 
kinetics of receptors containing edited subunits (Sommer et al., 1991; Lomeli et al., 
1994). The R/G editing of GLUR2 is largely unedited in the embryonic brain and rises 
after birth. 
Other editing sites were found at GLUR6; I/V site, where isoleucine can be substituted 
with valine (at 567Val) and Y/C site, where tyrosine can be replaced by cysteine (at 
571Cys) located in the transmembrane 1 domain (TM1) (Bass, 2002) (see table 1.2). 
Editing at these sites in cooperation with Q/R site modulates finer regulation of Ca+2 
permeability in the Q/R site. The mechanism of interaction among Q/R, Y/C and I/V 
sites remains to be elucidated (Köhler et al., 1993; Barbon et al., 2003). A study 
showed that editing of GLUR6 at Q/R and Y/C site in the spinal cord of control human 
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brain had similar levels of 31% editing. Whereas, editing of GLUR6 at I/V was reduced 
to 20% of editing (Barbon et al., 2003). 
Impaired or absent ADAR2 may also contribute to the pathogenesis of ALS.  Hideyama 
and colleagues have reported lowered GLUR2 editing at Q/R site.  One method used 
was the Cre-loxP recombination system to inhibit and restore ADAR2 activity by 
exchanging the point mutated allele with wild type allele of ADAR2 (Hideyama et al., 
2010). The other method was a general ADAR2 knock out mouse, functional null 
alleles are generated by completely removing the ADAR2 enzyme and cannot be 
restored by replacing exon 4 that encodes for functional adenosine deaminase motif 
with PGK-neo cassette to delete ADAR2 enzyme and thus stop its function (Higuchi et 
al., 2000). In both cases either inhibition or absence of ADAR2 activity has led to the 
same observation: which is lowered GLUR2 RNA editing in mice models (Brusa et 
al., 1995; Higuchi et al., 2000; Hideyama et al., 2010; Hideyama & Kwak, 2011). 
Reduced ADAR2, but not ADAR1 and ADAR3, has been demonstrated in the motor 
neurons of SALS patients (Hideyama et al., 2012b). Interestingly, deficient ADAR2 
is associated with mislocalisation of TDP-43, similar to the TDP-43 pathology seen in 
SALS patients (Aizawa et al., 2010; Hideyama et al., 2012a; Hideyama et al., 2012b).  
ADAR3 is structurally similar to ADAR2 containing one deamination domain and two 
double-stranded RNA binding motifs (dsRBMs) required for RNA editing. However, 
ADAR3 is found to be catalytically inactive and unable to bind dsRNA of GLUR2 at 
Q/R or R/G site, as determined by studies using purified recombinant ADAR3 proteins 
carrying an epitope-tagged peptide FLAG at the N-terminus and produced in Sf9 insect 
cells in vitro (Chen et al., 2000). The function of ADAR3 is as yet unknown. However, 
studies have suggested that ADAR3 might have a role in ALS with C9ORF72 
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expansion repeats. In experiments using induced pluripotent stem cells differentiated 
into neurons (iPSNs), a group has found ADAR3 within the complex of the C9ORF72 
repeats in the iPSNs tissue of ALS C9ORF72 without further characterisation of the 
role of ADAR3 in ALS with C9ORF72 nor its relation to RNA editing (Almeida et al., 
2013; Donnelly et al., 2013; Todd & Paulson, 2013). Therefore, future studies needed 
to investigate the impact of ALS cases with the C9ORF72 expansion on ADAR3 as a 
member of the ADAR family. 
  
Figure 1.3: ADAR2 deamination of GLUR2 at Q/R site. 
(a) Hydrolytic deamination mediates A-I conversion. (b) Members of ADAR family 
showing catalytic domain required for editing, double stranded binding motifs 
(dsRBM), Nuclear export signal (NES), Nuclear localisation sequence (NLS), Alu 
sequences (Alu). (c) ADAR2 catalyses of GLUR2 at Q/R site (A-I conversion) within 
dsRNA in coding region consisting of intron 11 and exon 11 complementary sequence 
(ESC) in coding and non-coding region. Figure a. was obtained from (Farajollahi & 
Maas, 2010) with permission 3512491421010 (b) Figure b and c. was modified from 
(Hideyama & Kwak, 2011).   
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Figure 1.4: Permeability of GLUR2 at Q/R site.  
AMPA receptor subunit GLUR2 located on the second transmembrane domain (M2) 
showing impermeable Ca+2 influx caused by edited GLUR2 (R) at Q/R site. 
(a).Whereas unedited form of GLUR2 within AMPA receptor is showing lack of edited 
GLUR2 (Q) at Q/R site resulting in permeable AMPA receptor, modified from 
(Hideyama & Kwak, 2011).   
 
 
 
 
  
` 
33 | P a g e  
 
1.6 Aims and Hypothesis  
Glutamate excitotoxicity plays a key role in a range of neurodegenerative pathologies, 
including ALS. Possible explanations underlying excitotoxicity in motor neurons in 
ALS include (i) impaired RNA editing of glutamate receptors (ii) reduced ADAR2 
activity, responsible for editing of GLUR2, GLUR5 and GLUR6 at multiple sites, and 
(iii) aberrant transcripts of EAAT2. Therefore, the current study hypothesised that (i) 
altered glutamate receptor editing in motor neurons in ALS is relevant to pathogenesis. 
(ii) There is no relationship between mRNA expression of ADAR2 and ADAR3. (iii) A 
decrease in EAAT2 mRNA expression contributes to the excitotoxicity associated with 
ALS. (iv) MNs from ALS/C9ORF72-positive patients have more inclusions than 
ALS/C9ORF72-negative patients. (v) GLUR2 protein levels dose not contribute to 
GLUR2 editing.  (vi) Decreased ADAR2 and EAAT2 expression in ALS contributes 
to excitotoxicity mediated MN loss. (vii) Altered ADAR3 expression is not linked to 
ADAR2 and GLUR2 editing. (viii) Use of next generation sequencing will allow in-
depth analysis of the GLUR2, GLUR5 and GLUR6 as well as ADAR2, ADAR3 and 
EAAT2 RNA species. 
The aims of this study were (i) to investigate RNA editing of GLUR2, GLUR5 and 
GLUR6 in the pathogenesis of ALS disease and determine the differences between 
edited RNA levels of glutamate receptors in controls compared to ALS/C9ORF72-
positive and ALS/C9ORF72-negative patients. (ii) To determine the ADAR2 and 
ADAR3 gene expression in the spinal cord from ALS versus control cases.  Because 
of the emerging roles of astrocytes in excitotoxic pathway leading to 
neurodegeneration this study also aimed (iii) to determine the normal and aberrant 
alternative transcripts particularly, exon 4 and 9 in ALS/C9ORF72-positive and 
ALS/C9ORF72-negative patients compared to controls. (iv) Identify the 
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neuropathological features of motor neurons and astrocytes in the thoracic spinal cord 
of a well characterised cohort of ALS/C9ORF72-positive and ALS/C9ORF72-
negative compared to non-neurological controls. (v) To develop new methodology to 
look at different levels of expression that might exist in ALS. 
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Chapter 2: Materials and Methods 
 
2.1 Materials and their suppliers 
 
Table 2.1: Equipment, chemicals and enzymes, antibodies and solutions. 
Equipment Suppliers 
The Arcturus Laser  Capture Microdissection 
System 
Applied Biosystems Life Technologies 
Antigen access unit MenaPath 
Nikon Eclipse Ni  microscope Nikon 
Autostainer Intellipath 
Cryostat   Leica 
Microscope slides Leica, UK 
Arcturus® CapSure® Macro LCM Caps Applied Biosystems Life Technologies 
Thermo Cycler  MJ Research  
M3000P Qpcr Agilent Technologies 
Homogeniser Kontes Glass, Anechem LTD. 
Flash gel system Lonza 
NanoDrop 1000 Spectrophotometer Labtech International, UK 
DNA chip 1000  Agilent Technologies 
BioAnalyser Agilent 
Geni box Syngene 
Next generation sequencing (Hi scan SQ system) Illumina 
Agencourt AMPure XP beads  cat number A63881, Beckman Coulter 
Chemicals and enzymes Suppliers 
Ethylenediaminetetra- acetic acid (EDTA) AnalaR, BDH Laboratory Supplies 
Tri-sodium citrate (TSC) Fisher Chemical 
Access revelation TSC pH. 6  MenaPath 
Xylene Fisher scientific 
Tris Fisher scientific 
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Ethanol Fisher scientific 
Ethidium bromide Fluka 
DPX mounting media Leica 
The VECTASTAIN® Elite® ABC system VECTOR Laboratories 
Haematoxylin and eosin Leica 
Toluidine blue Sigma 
RNA PicoPure Isolation kit Applied Biosystems Life Technologies 
RNAqueous®-Micro Kit Ambion 
NucleoSpin kit  Macherey -Nagel 
NEBNext mRNA second strand synthesis  NEB, cat number E6111, New England 
Biolabs 
Nextera XT DNA sample preparation kit   Illumina 
KAPA Illumina library quantification kit  cat number KK4824, Anachem 
qscript™ cDNA supermix Quanta Biosciences 
QuantiTect reverse Transcription QIAGEN 
Dream Taq Green PCR master mix Thermo Scientific 
Brilliant III SYBR® Green qPCR Master Mix  Agilent Technologies; 
QlAquick Gel Extraction QlAGEN 
RNase-free water  QIAGEN 
Hyperladder V Bioline 
Agarose  powder Melford 
Primers Eurofins, mwg operon (Germany) 
BbVI restriction enzyme Fermentas 
Affinity script cDNA synthesis  Agilent Technologies 
MessageBOOSTER Whole Transcriptome cDNA 
Synthesis  
Epicentre kit, cat number MBWT80510 
Illumina Nextera XT kit cat number 15031942, Illumina  
Antibodies Suppliers 
p-TDP-43 CosmoBio (2B scientific) 
p62 BD (610833) 
Polyclonal Rabbit Anti- 
Glial Fibrillary Acidic Protein (GFAP) 
DAKO cytomation 
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Polyclonal mouse Anti-RED1 Abcam 
Polyclonal Rabbit Anti-ADARB2  Sigma 
Monoclonal Mouse Anti-EAAT2 Leica Biosystems  
AntiMouse IgG, VECTASTAIN Elite ABC Kit Vector Laboratories 
Antirabbit IgG, VECTASTAIN Elite ABC Kit Vector Laboratories 
Solutions  
Tris- acetate-EDTA (TAE) (1X)  
40mM Tris base, 20mM acetic acid, 1mM EDTA, pH 8.0 
Tris-buffered saline (TBS) (1x) 
50mM Tris, pH 7.6, 150mM NaCl 
Trisodium Citrate buffer (TSC) (1L) 
11.6mM Na3C6H5O7, made up to 1L with deionized water, pH6 
Ethylenediaminetetra- acetic acid (EDTA) (1L) 
1mM of C10H16N2O8,  made up in 1L of dH2O, pH to 8 
Avidin-biotin peroxidase complex 
Vectastain Elite ABC Kit in 50mM TBS 
Scotts Tap water (2.5L) 
41mM of sodium bicarbonate (NaHCO3) and 166mM magnesium sulphate (MgSO4), made up in 
2.5L deionized water 
Gill’s haematoxylin  
 6g of haematoxylin, 4.2g of aluminium sulphate, 1.4g of citric acid 1.4g, 0.6g sodium iodate, 
269ml of ethylene glycol, made up in 680ml of dH2O. 
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2.2 Human CNS tissue 
Post-mortem human CNS tissue was obtained from the Sheffield Brain Tissue Bank 
located at the Royal Hallamshire Hospital, following ethical approval (MRC 
no.12/007) (see appendix I). Brain tissue of sporadic ALS patients and subjects free 
from neurological disorders were donated and consented by informed next of kin.  
Research was carried out in accordance with the approval of Ethics Committee of 
University of Sheffield.  
Formalin fixed paraffin embedded (FFPE) tissue was obtained from readily available 
lumber spinal cord sections of one familial ALS that carry C9ORF72 repeat expansion 
(FALS/C9ORF72-positive case), thoracic spinal cord section of one apparently 
sporadic ALS patient which have subsequently been shown to carry C9ORF72 repeat 
expansion (SALS/C9ORF72-positive case) and cervical spinal cord sections of one 
sporadic ALS case that do not carry any known genetic mutations associated with ALS 
(SALS case) (see table 2.2). For the purpose of this thesis, FALS/C9ORF72-positive, 
SALS/C9ORF72-positive case and SALS will be used. 
Snap-frozen tissue was obtained from frontal cortex of 3 SALS cases and 5 controls 
free from neurological disease, motor cortex of 4 SALS cases and 3 non-neurological 
controls, thalamus, cerebellum, temporal cortex and motor cortex of one case with 
Pick’s disease (see table 2.2). Snap-frozen readily available lower thoracic spinal cord 
(T11) from 5 apparently sporadic ALS patients which have subsequently been shown 
to carry C9ORF72 repeat expansion (5 C9ORF72-related ALS (ALS/C9ORF72-
positive) and 5 sporadic ALS patients that do not carry any known genetic mutations 
associated with ALS (ALS/C9ORF72-negative) and 5 non-neurological controls (see 
table 2.2). For the purpose of this thesis ALS/C9ORF72-positive and ALS/C9ORF72-
` 
40 | P a g e  
 
negative cases will be used throughout. Donated brains were dissected following a 
standard protocol (Ince et al., 1995) and histologically blindly assessed by consultant 
neuropathologists. Detailed clinical information for all the cases, PMI, gender and age 
at onset and age at death was recorded (see Table 2.2).  
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Table 2.2: Detailed clinical information for ALS cases and controls. 
FFPE thoracic spinal cord from ALS patients  
 
Case 
number 
Clinical 
Diagnosis 
Area/level PMI  in 
hours 
Sex Age at 
onset 
Age at 
death 
Length of  
illness 
ALS 
273/99 
(TBP0096) 
 
FALS/C9ORF72 Bulbar 31 M  66 68 14 months 
336/90 
(TBP0048) 
SALS/C9ORF72 Limb 6 M 63 64 11 months 
113/08 
(TBP0075) 
SALS Multifocal 9 F 68 70 31 months 
Frozen frontal cortex from ALS patients and controls 
Case 
number 
Clinical 
Diagnosis 
Area/level PMI  in 
hours 
Sex Age at 
onset 
Age at 
death 
Length of  
illness 
ALS 
TBP0074 SALS Bulbar 19 M 71 75 37 months 
113/08 
(TBP0075) 
SALS Multifocal 9 F 68 70 31 months 
136/97 SALS n/a 16 F 76 78 13 months 
Controls 
136/95 Control n/a 10 F n/a 87 n/a 
147/95 Control n/a 15 M n/a 47 n/a 
178/95 Control-
Ischaemic Heart 
disease 
n/a 24 F n/a 63 n/a 
35/96 Control n/a 14 F n/a 87 n/a 
95/96 Control n/a n/a n/a n/a n/a n/a 
Frozen motor cortex from ALS patients and controls 
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Case 
number 
Clinical 
Diagnosis 
Area/level PMI  in 
hours 
Sex Age at 
onset 
Age at 
death 
Length of  
illness  
ALS 
  53/96 
(TBP0070) 
SALS/C9ORF72 Bulbar 7 F 61 64 40 months 
159/96 
(TBP0078) 
SALS Bulbar 20 M 41 43 23 months 
137/96 
(TBP0076) 
SALS/UMN Multifocal 9 F 56 65 99 months 
57/97 
(TBP0083) 
SALS/PLS Bulbar 18 F 76 78 26 months 
Controls 
66/96 
(TBP0071) 
Control Bulbar 10 F 70 73 37 months 
144/96 Control n/a n/a n/a n/a n/a n/a 
194/96 Control n/a n/a n/a n/a n/a n/a 
Frozen tissue from different CNS regions of one case with PICK’s disease 
Case 
number 
10/96 
Clinical 
Diagnosis 
Area/level PMI  in 
hours 
Sex Age at 
onset 
Age at 
death 
Length of  
illness 
Temporal 
cortex 
Pick’s disease 
 
n/a 22 F n/a 63 n/a 
Cerebellum 
Thalamus 
Motor 
cortex 
              FFPE and frozen thoracic spinal cord from ALS cases and controls 
Case 
number 
Block  
Number 
Area/Level Site of 
onset 
PMI  in 
hours 
Sex Age  at 
onset 
Age   at 
death 
ALS/C9ORF72-positive cases 
LP83/10 34 T11 Limb 13 Male 67 79 
LP081/09 29 T11 Limb 60 Male 57 59 
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Available thoracic spinal cord, motor cortex and frontal cortex blocks were identified 
for the study and these cases were characterised by neuropathologists who were blind 
to any clinical information. Cases were categorised into FALS, SALS and apparently 
sporadic ALS with C9ORF72 repeat expansion (ALS/C9ORF72-positive) and 
sporadic ALS without C9ORF72 repeat expansion (ALS/C9ORF72-negative) and 
non-neurological controls. Cases were matched as closely as possible in their clinical 
diagnosis, PMI in hours, age and gender except for one patients with PICK disease 
that was initially identified as a control and later appeared to be a PICK patient. 
Abbreviation: N/A- not available. 
 
LP041/04 
(TBP0110) 
6 T11 Bulbar 48 Male 62 64 
LP039/11 26 T11 Limb 96 Male 70 72 
LP040/11 25 T11 Limb 10 Female 72 77 
ALS/C9ORF72-negative cases 
LP014/11 24 T11 Limb n/a Male 49 51   
LP005/11 30 T11 Limb 40 Female 62 67  
LP023/10 7 T11 Limb 24  Female 34 42 
LP005/10 23 T11 Limb 96 Male 38 40 
LP094/09 25 T11 Bulbar 48 Male 62 63 
Controls 
LP005/07 13 T11 n/a 12 Male -n/a 64 
LP085/07 25 T11 n/a 5 Female -n/a 82 
LP098/07 25 T11 n/a 63 Male -n/a 67 
035/96 8 T11 n/a 14 Female -n/a 87 
117/04 n/a n/a n/a n/a Male -n/a 58 
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2.3 RNA applications 
2.3.1 FFPE and frozen tissue preparation 
The post-mortem FFPE spinal cord was fixed in 10% formalin for 24 hours up to 48 
hours then washed twice in 70% ethanol for 1hour, 80% ethanol for 1hour and 95% 
ethanol and finally washed three times in 100% ethanol for 1.5 hours to remove any 
water. Tissue blocks were then immersed three times in xylene for 1.5 hours and 
embedded in paraffin. The FFPE tissue blocks were sectioned into 7µm and collected 
on glass slides, dried overnight at 50ºC and stored at room temperature. Whereas, the 
post-mortem frozen tissue blocks were embedded in mounting media (OCT) and 
sectioned (7μm) in a cryostat at -20oC. Sections were collected on uncoated, sterile 
microscope slides, and warmed to room temperature (RT) for approximately 30 
seconds.  
 
2.3.2 Histological staining of spinal cord for Laser Capture 
Microdissection (LCM) 
To visualise motor neurons for microdissection, FFPE and frozen spinal cord sections 
were stained with toluidine blue. FFPE sections were dewaxed twice in xylene for 5 
minutes followed by rehydration of the material by graded alcohol: 100% ethanol ×2 
for 3 minutes, 95% ethanol for 3 minutes and 70% ethanol for 3 minutes. Tissue 
sections were then immersed in toluidine blue for 40 seconds, washed in diethyl 
pyrocarbonate (DEPC)-treated water, dehydrated through graded series of ethanol for 
30 seconds. Once tissue sections were dehydrated, sections were cleared twice in 
xylene for 5 minutes and air dried for 1 hour, making them ready for LCM.  
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The frozen spinal cord sections were fixed in acetone for 3 minutes, immersed in 
toluidine blue for 40 seconds, washed in DEPC-treated water, dehydrated through 
graded series of ethanol for 30 seconds each and cleared in xylene twice for 5 minutes 
before being air dried for 1 hour.   
Approximately 200 motor neurons from each case were picked by LCM.  
Astrocytes were isolated by LCM combined with a rapid immunoprotocol to identify 
astrocytes (Waller et al., 2012). Following sectioning of the spinal cord to 7μm and its 
collection onto uncharged glass slides, tissue sections were warmed to RT for 30 
seconds, then fixed in cold acetone for 3 minutes and blocked in 2% normal serum for 
3 minutes at RT. Section were incubated with GFAP antibody (1:50 dilution), washed 
with TBS before being incubated with 5% biotinylated secondary antibody for 3 
minutes at RT.  Sections were washed with TBS then incubated with 4 % ABC-HRP 
reagent for 3 minutes at RT.  Sections were washed with TBS then DAB was used to 
visualise where the antibody had bound.  The reaction was quenched in water, and the 
sections dehydrated through increasing concentrations of alcohol for 30s, cleared in 
xylene twice for 5 minutes and air dried for at least 1 hour. Approximately 1000 
astrocytes were picked followed by RNA extraction. 
2.3.3 RNA extraction from FFPE tissue 
RNA extractions from FFPE tissue sections were optimised using RNAqueous-Micro 
kit from Ambion. According to the manufacturer’s protocol, a 100μl of lysis solution 
was added to the sample and incubated for 30 minutes at 42°C. Samples were briefly 
vortex and centrifuged to collect the fluid at the bottom of the tube. Micro Filter 
Cartridge was wet with 30μl of lysis solution and incubated for 5 minutes then 
centrifugation of the prewetted filter for ~30 seconds at top speed to remove liquid. 
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3μl of the LCM Additive solution was added to the lysate and mixed well by vortexing. 
129μl of 100% ethanol was added to the lysate and mixed by gently vortexing. Lysate 
mixture was passed through Micro Filter Cartridge by centrifuge for 1 minute at 10,000 
x g to bind the RNA to the filter. An 180μl of wash solution 1 was added to the filter 
and centrifuged for 1 minute at 10,000 x g. Followed by another two washes with wash 
solution 2 by adding 180μl to the filter and centrifuge for 1 minute at 13,000 x g. The 
flow-through was discarded and the filter was centrifuged for 1 minute at 13,000 x g. 
RNA was eluted in 10μl of preheated elution solution to 95°C, then incubate for 5 
minutes at RT and centrifuged for 1 minute at 13,000 x g.  
 
2.3.4 RNA extraction from frozen total spinal cord  
RNA extractions were carried out on one section of a 20μm of spinal cords using 
NucleoSpin kit (Macherey -Nagel), according to the manufacturers` instructions. All 
centrifugation in the protocol was performed for 1 minute at 11,000xg, unless 
otherwise stated. 50µm tissue sections were suspended in 350µl of Guanidinium 
thiocyanate (RA1) and 3.5µl of B-mercaptoethanol. The cell suspension was added to 
a NucleoSpin® column and centrifuged. The flow through was mixed with 350µl of 
70% ethanol and loaded into a NucleoSpin column, centrifuged and washed with 350µl 
of membrane desalting buffer (MBD) by centrifugation. The column was loaded with 
95µl of the DNase reaction mixture and incubated at RT for 15 minutes. 200µl of the 
Guanidinhydrochloride-Ethanol buffer (RAW2) was added to the column and 
centrifuged. The column was washed twice in washing buffer (RA3), firstly with a 
volume of 600µl and then with 250µl. The column was dried by centrifugation for 2 
minutes and the RNA eluted in 60µl of RNase-free water by centrifugation.  
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2.3.5 RNA extraction from LCM-isolated motor neurons and 
astrocytes 
On average 200 motor neurons were picked from 10  frozen tissue sections by LCM 
and 1000 astrocytes were isolated from 7 frozen tissue sections of the spinal cord. The 
RNA was extracted from LCM isolated motor neurons or astrocytes using the RNA 
PicoPure (Arcturus) Isolation kit, according to the manufacturer’s protocol. The film 
was carefully removed from the LCM cap using sterile tweezers and placed in a sterile 
0.2 ml eppendorf.  50µl of extraction buffer was added to the captured cells and 
incubated at 42°C for 30 minutes on the thermocycler, followed by centrifugation at 
800xg for 2 minutes at RT, at this stage the cell extracts could be stored at -80ºC.  To 
isolate RNA from the samples, RNA purification columns were pre-conditioned with 
250µl of conditioning buffer for 5 minutes at RT, then centrifuged at 16,000xg for 1 
minute. 50µl of 70% ethanol was added to the sample extract and mixed thoroughly 
by pipetting up and down. The mixture of sample extract and ethanol was added to the 
pre-conditioned purification column and centrifuged at 100xg for 2 minutes at RT, 
enabling RNA to bind to the column. The columns were centrifuged at 16000xg for 30 
seconds and the flow through discarded.  100µl of wash buffer 1 was added to the 
purification column and centrifuged at 8000xg for 1 minute at RT. 100µl of wash 
buffer 2 was added to the purification column and centrifuged at 8000xg at 1 minute. 
An additional centrifugation step of 16,000xg for 1minute was performed to remove 
any remaining buffer from the column. The RNA column was transferred to a sterile 
1.5 ml microcentrifuge tube, and the total RNA was eluted in 11µl of RNase-free water 
at 12,000xg for 1 minute.  
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2.3.6 RNA integrity and cDNA synthesis 
The amount of total RNA was quantified using the NanoDrop 1000 Spectrophotometer 
and the RNA quality assessed on the Pico chip Bioanalyser. 50ng of RNA was added 
to 4μl qScript™ cDNA super mix (thawed on ice) and RNase-free water was added to 
make a total reaction volume of 20µl. The mixture was incubated in the thermal cycler 
to amplify cDNA for 5 minutes at 25ºC, followed by 30 minutes  at 42ºC, and finally 
the reaction was deactivated for 5 minutes at 85ºC.  
 
2.4 Designing primers  
 The primer sequence for GLUR2, GLUR5 and GLUR6 was identified using National 
Centre for Biotechnology information website (NCBI) then inputted into the Primer3 
plus website (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi).  
(see figure 2.1- 2.3). Forward and reverse primers were selected (see table 2.3).  
 
Figure 2.1:GLUR2 (NM-000826) sequence showing editing at Q/R site.  
GLUR2, also called GRIA2, gene is located on chromosome 4q 32.1. Forward primers 
are highlighted in blue and reverse primers are highlighted in red. The BbvI (BseXI) 
highlighted in green recognizes GCAGC editing site and cut GLUR2 at Q607 (CTG) 
to R (CGG).  
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Figure 2.2:GLUR5 (NM-000830) sequence showing editing at Q/R site.  
GLUR5 also called GRIKI gene is located on chromosome 21q22.11, forward primers 
are highlighted in blue and reverse primers are highlighted in red. The BbvI (BseXI) 
highlighted in green recognizes GCAGC editing site and cut GLUR5 at Q636 (CAG) 
to R (CGG).  
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Figure 2.3:GLUR6 (NM-021956) sequence showing editing at Q/R site.  
GLUR6, also called GRIK2, gene is located on chromosome 6q16.3, forward primers 
are highlighted in blue and reverse primers are highlighted in red. The BbvI (BseXI) 
highlighted in green recognizes GCAGC editing site and cut GLUR6 at Q621 (CAG) 
to R (CGG). 
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Table 2.3: Sequence of GLUR2, GLUR5 and GLUR6 primers used in the study. 
 
 
 
 
 
 
 
 
 
 
 
Primers Sequence 
reference 
Position Primer Sequence 
External GLUR2 NM-000826.3 Forward TTCCTGGTCAGCAGATTTAGCC 
Reverse GTGCGGAAGTCCAAAGGGAA 
External GLUR5 NM-000830.3 Forward CGTGGTGGAAAACAATTTTACTTT 
Reverse TCTGGCTGCCTTCTTGACAG 
Nested GLUR5 Forward ATGCAACCCTGACTCAGACG 
Reverse TGCCCAAAGCTCTATCGACC 
External GLUR6 NM-021956 Forward TTGGGTGTCAGTTGTGTGCT 
Reverse ACCAGGATAGTGGGAGGCAT 
Nested GLUR6 Forward TTGCAACCCTGACTCAGACG 
Reverse TCCACCAGGATAGTGGGAGG 
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2.5 Reverse transcription-polymerase chain reaction (RT-
PCR) 
50ng of cDNA was added to 10µl of Dream Taq Green PCR master and 5pM of 
forward and reverse primers to give a final volume of 20µl. Primers concentrations 
were reduced from 10 pmol/µl to 5 pmol/µl to eliminate primer dimer formation that 
might interfere with the correct identification of the product of interest on DNA Chip 
BioAnalyser. Samples were run on the following thermal cycling conditions; initial 
denaturation at 95°C for 3 minutes followed by 40 cycles of denaturation at 95°C for 
30 seconds, annealing at 60°C for 1 minute and extension at 72°C for 1 minutes. Final 
extension was at 72°C for 15 minutes.  To visualise the product, samples were run on 
a 2% agarose gel for 40 minutes at 120V. 
 
2.5.1 Gel purification 
Following the manufacturer’s protocol, DNA fragments were excised from the agarose 
gel with a clean scalpel, weighed and 3 volumes of QG buffer were added. The gel 
was incubated at 50ºC for 10 minutes or until the gel completely dissolved.  1 gel 
volume of isopropanol was added to the sample and mixed before being added to a 
QLAquick spin column placed in 2 ml collection tube. The column was centrifuged 
for 1 minute at 17.900×g at RT and the flow through discarded.  The QlAquick spin 
column was placed back in to the collection tube and 500µl of QC buffer was added 
then centrifuged for 1 minute at 17.900×g at RT. 750µl of PE buffer was added to the 
column, centrifuged for 1minute at 17.900×g, flow through was discarded. To ensure 
all the buffer was removed, the column was centrifuged for 1 minute at 17.900×g at 
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RT. DNA was eluted in 30 µl of dH2O, centrifuged for 1 minute at 17.900×g, collected 
in a sterile tube. 
An alternative method to purify PCR before digestion was flash gel system that 
enabled the purification of PCR products and removal of primer dimers without loss 
of DNA after band excision. There are two types of wells in the flash gel ™ cassette: 
loading wells and recovery wells, which were both flooded with water prior to sample 
loading.  5µl of hyper ladder V and 10µl of PCR products were loaded into the flash 
gel cassette. The Flash gel ™ cassette was placed on the flash gel ™ dock and the light 
switched on to visualize running of the samples from the loading wells to the recovery 
wells. Samples were run for 5 minutes at 275 V and collected from the recovery wells.  
The flashGel™ Mask was placed under the recovery wells enabling sample 
visualization, then 10µl of water was loaded into recovery well to collect samples. 
Recovered samples were subsequently digested with restriction enzyme, as detailed 
below. 
 
2.6 Restriction enzyme digest 
The PCR product can be digested using BbvI or BseXI restriction enzymes (see figure 
2.4). Both of these enzymes are able to digest double stranded DNA at a unique 
sequence of nucleotides in the DNA strand at the centre of the recognition sequence 
GCAGC), different sized fragments, when compared to the full length PCR product, 
classified as edited and non-edited RNA, respectively.  Briefly, 1 unit of BbvI 
restriction enzyme was used to digest 7 µl of PCR reaction by incubating at 37°C for 
90 minutes, followed by inactivation at 65°C for 20 minutes. DNA cuts were visualised 
on DNA chip BioAnalyser.  
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The DNA chip was used to analyse and compare the RT-PCR products prior to 
digestion and restriction enzyme digests for the separation of nucleic acid fragments 
based on their sizes. Following manufacturer’s protocol, the gel was prepared by 
adding 25 µl of dye concentrate to the DNA gel matrix, following centrifugation for 
15 minutes at 2,400xg at 4ºC. 9 µl of the gel was loaded into the G-well then pressure 
plunging was applied to distribute the gel. The DNA chip was placed into the priming 
station and the plunger was positioned at 1ml. Additional two 9 µl were loaded into 
the gel wells. 1µl of sample (~50ng/µl) was loaded into each well, in addition to 5µl 
of marker. The application running time was approximately 35 minutes. Samples were 
then detected by their absorbance and translated to standard gel-like images and 
electropherograms. 
 
Figure 2.4: Restriction digest enzymes 
BbvI and BseXI are restriction enzymes that recognizes the same site of GCAGC and 
both cut at the CAG (Q) site that result in CGG (R). Hence fully edited GLUR2 will 
not be digested by the enzyme.  
 
2.6.1 Quantification of editing levels 
The editing level of GLUR2, GLUR5 and GLUR6 transcripts were quantified using 
Agilent 2100 expert DNA chip software.  Analysis of electropherogram obtained from 
post digestion with restriction enzyme was performed. The percentage of editing was 
calculated as: concentration of edited transcripts/ sum of edited and non-edited 
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transcripts x100. The average of editing from each group was calculated in 
GraphPrism 6.  
 
2.7 Quantitative PCR (qPCR) experiments 
As previously stated, RNA was extracted from total spinal cord and from LCM-
isolated motor neurons/astrocytes (see section 2.3.4-2.3.5). RNA was then converted 
to cDNA  then primers were added (see section 2.4) and mixed in 2X Brilliant III 
SYBR® Green (see table 2.5). ADAR2 and ADAR3 primers were optimised to 10pmol 
and the cDNA concentration was optimised to 50ng/µl.  All EAAT2 primers (5pmol) 
and cDNA concentration (12ng/µl) were optimised previously. A qPCR was 
performed on the following genes; ADAR2, ADAR3, EAAT2 (EAAT2+4 (exon 3-4), 
EAAT2+9 (exon 8-9) and EAAT2Δ4 (exon 3-5), EAAT2Δ9 (exon 8-10) (see figure 
2.5)). 
All reactions were performed in triplicate along with no template control for each of 
the primer pairs. The reaction conditions was as follows: initial denaturation at 95°C 
for 10 minutes, denaturation at  95°C for 30 seconds followed by at 60°C for 1 minute 
repeated in 40 cycles. At the end of those cycles, another cycle carried out at 95°C for 
1 minute, 55°C for 30 seconds and 95°C for 30 seconds extension.  
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Figure 2.5: Primers of EAAT2 transcripts (NM-004171); exon 4 and exon 9.  
Exons are coloured differently in green and in black; Exon 4 and exon 9 containing 
sequences were labelled as EAAT2+4 and EAAT2+9, and primers that skip exon 4 and 
exon 9 were labelled as EAAT2Δ4 and EAAT2Δ9. Primer pairs highlighted in green 
are forward and reverse of exon 4Δ and exon 9Δ excluding sequences; forward primers 
contained bases across the exon boundaries of exon 4 and 9 and first few bases of exon 
10 and exon 5 respectively. Exon boundaries marked in bold. The reverse primers of 
exon 4Δ and 9Δ were designed on exons 10 and 5 respectively. Primers highlighted in 
yellow are exon 4+ and exon 9+ including sequences covered segments of exon 3 to 4 
and exon 8 to 9; spanning exon – exon junctions. 
 
 
EAAT2 sequence 
      481 gctcctctta aataccgctc ccggccgcac ttcgcgctca ccccggcgtc cgctttctcc 
      541 ctcgcccaca gctgccggat agtgctgaag aggagggggc gttccccaga ccatggcatc 
      601 tacggaaggt gccaacaata tgcccaagca ggtggaagtg cgaatgcacg acagtcatct 
      661 tggctcagag gaacccaagc accggcacct gggcctgcgc ctgtgtgaca agctggggaa 
      721 gaatctgctg ctcaccctga cggtgtttgg tgtcatcctg ggagcagtgt gtggagggct 
      781 tcttcgcttg gcatctccca tccaccctga tgtggttatg ttaatagcct tcccagggga 
      841 tatactcatg aggatgctaa aaatgctcat tctccctcta atcatctcca gcttaatcac 
      901 agggttgtca ggcctggatg ctaaggctag tggccgcttg ggcacgagag ccatggtgta 
      961 ttacatgtcc acgaccatca ttgctgcagt actgggggtc attctggtct tggctatcca 
     1021 tccaggcaat cccaagctca agaagcagct ggggcctggg aagaagaatg atgaagtgtc 
     1081 cagcctggat gccttcctgg accttattcg aaatctcttc cctgaaaacc ttgtccaagc 
     1141 ctgctttcaa cagattcaaa cagtgacgaa gaaagtcctg gttgcaccac cgccggacga 
     1201 ggaggccaac gcaaccagcg ctgttgtctc tctgttgaac gagactgtga ctgaggtgcc 
     1261 ggaggagact aagatggtta tcaagaaggg cctggagttc aaggatggga tgaacgtctt 
     1321 aggtctgata gggtttttca ttgcttttgg catcgctatg gggaagatgg gagatcaggc 
     1381 caagctgatg gtggatttct tcaacatttt gaatgagatt gtaatgaagt tagtgatcat 
     1441 gatcatgtgg tactctcccc tgggtatcgc ctgcctgatc tgtggaaaga tcattgcaat 
     1501 caaggactta gaagtggttg ctaggcaact ggggatgtac atggtaacag tgatcatagg 
     1561 cctcatcatc cacgggggca tctttctccc cttgatttac tttgtagtga ccaggaaaaa 
     1621 ccccttctcc ttttttgctg gcattttcca agcttggatc actgccctgg gcaccgcttc 
     1681 cagtgctgga actttgcctg tcacctttcg ttgcctggaa gaaaatctgg ggattgataa 
     1741 gcgtgtgact agattcgtcc ttcctgttgg agcaaccatt aacatggatg gtacagccct 
     1801 ttatgaagcg gtagccgcca tctttatagc ccaaatgaat ggtgttgtcc tggatggagg 
     1861 acagattgtg actgtaagcc tcacagccac cctggcaagc gtcggcgcgg ccagtatccc 
     1921 cagtgccggg ctggtcacca tgctcctcat tctgacagcc gtgggcctgc caacagagga 
     1981 catcagcctg ctggtggctg tggactggct gctggacagg atgagaactt cagtcaatgt 
     2041 tgtgggtgac tcttttgggg ctgggatagt ctatcacctc tccaagtctg agctggatac 
     2101 cattgactcc cagcatcgag tgcatgaaga tattgaaatg accaagactc aatccattta 
Exon1 
Exon 2 
Exon 3 
Exon 4 
Exon 5 
Exon 7 
Exon 9 
Exon 6 
Exon 8 
Exon10 
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Table 2.4: Primers used. 
 
Table 2.5: QPCR conditions. 
 
2.10.1 Statistical analysis 
The threshold cycle number for product detection (ΔCT) was used to calculate the 
relative expression levels. Relative quantification (ΔΔCt) was normalized to β-actin to 
determine differences in the targeted gene expression. Statistical analysis was 
performed using one way ANOVA (GraphPad Prism 6). 
 
Primers Sequence 
reference 
Position Primer sequence 
ADAR2 NM-001112 Forward TCGCTAATCCCATCCTCAGA 
Reverse GATGAAAGAGGAGCTGAGAGAAG 
ADAR3 NM-018702 Forward TGCTGTTTCACAGACTGGTAG 
Reverse CATCCCGGCTCTGCAAG 
EAAT2Δ4 (exon 3-5) NM_004171.3 Forward TCATCTCCAGCTTAATCACAGATTC 
Reverse TCTTAGTCTCCTCCGGCACC 
EAAT2Δ9 (exon 8-10) Forward GTGACTGTAAGGGACAGGATGAGA 
Reverse ATGCACTCGATGCTGGGAG 
EAAT2+4 (exon 3-4) Forward TCTCCCATCCACCCTGATGT 
Reverse GGCCACTAGCCTTAGCATCC 
EAAT2+9 (exon 8-9) Forward AGCCGCCATCTTTATAGCCC 
Reverse GGCTGTCAGAATGAGGAGCA 
Primers cDNA  
Concentration 
Primers 
Concentration 
2X Brilliant III 
SYBR® Green 
Total  volume 
ADAR2 50 ng 10 pM for forward and 
reverse primers 
 
 
10µl 
 
 
 
20μl 
ADAR3 
EAAT+4 (exon 3-4) 12.5 ng 5 pM for forward and 
reverse primers EAATΔ4 (exon 3-5) 
EAAT+9 (exon 8-9) 
EAATΔ9 (exon 8-10) 
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2.8 Immunohistochemistry (IHC) 
Immunodetection of specific antigens was performed on FFPE material (see table 2.2). 
Brain blocks were fixed in 10% formalin for ~48h before being processed: 70% 
ethanol x2 for 1hour, 80% ethanol for 1hour and 95% ethanol for 1hour and absolute 
ethanol for 1.5 hours. The tissue was immersed in xylene three times for 1.5 hrs and 
embedded in paraffin. 5μm sections were collected on poly-L-lysine coated, charged 
glass slides, dried overnight at 50ºC and stored at RT until required. Prior to staining 
sections were dewaxed in xylene twice and re-hydrated to water through a graded 
series of ethanol for 5 minutes; 100%, 95% then 70%. Sections were incubated in 3% 
hydrogen peroxide (H2O2) in methanol for 20 minutes to block endogenous peroxidase 
activity. Antigen unmasking was performed using an appropriate antigen retrieval 
method, either pressure cooker (high temperature and high pressure) or microwave 
(high temperature) (see table 2.6). Sections were washed in TBS and then blocked with 
1.5% relevant normal serum diluted in TBS for 30 minutes at RT to prevent non-
specific binding of the secondary antibody.   
An optimized concentration of primary antibody diluted in blocking solution was 
applied to the sections for 1hour at RT. Negative controls were incubated in TBS in 
absence of primary antibody or with the relevant concentration of an IgG control. 
Sections were washed in TBS for 5 minutes at RT, and incubated with 0.5% 
biotinylated secondary antibody (either biotinylated anti-Mouse IgG or biotinylated 
anti-Rabbit IgG, depending on the species of the primary antibody) for 30 minutes at 
RT. Sections were washed thoroughly in TBS for 5 minutes, and incubated with 1.5% 
Avidin-Biotinylated horseradish peroxidase complex (ABC) for 30 minutes. ABC 
reagent was prepared 30 minutes prior to use by adding 2 drops of reagent A and 2 
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drops of reagent B to 10ml TBS. Then sections were washed in TBS for 5 minutes at 
RT. The antibody was visualized by incubating the sections with the peroxidase 
substrate DAB for 5 minutes at RT. To prepare DAB, 2 drops of buffer solution, 4 
drops of DAB stock and 2 drops of hydrogen peroxide were mixed in 5ml of dH2O. 
The reaction was quenched using water and the sections were counterstained for 1 
minute with Gill’s haematoxylin. Gill’s haematoxylin was prepared by adding 6g of 
haematoxylin to 4.2g of aluminium sulphate, 1.4g of citric acid 1.4g, 0.6g sodium 
iodate, 269ml of ethylene glycol and mixed in 680ml of dH2O. The slides were rinsed 
in tap water and blued in Scott’s Water for 1 minute. Finally, the sections were 
dehydrated in a graded series of ethanol (70%, 95%, and 100%), cleared in xylene then 
cover slipped using DPX permanent mounting media. 
Table 2.6: Antibodies used in the study, their antigen retrieval method and 
dilution of primary antibody. 
 
Antibodies Antigen retrieval method  Antibody dilution/Incubation 
time  
Supplier 
p-TDP-43 Pascal pressure chamber with TSC (pH6) 
buffer for 30 seconds at 125ͦC and 22 psi 
1:4000/30 minutes Cosmobio (2B) 
p62 Pascal pressure chamber with TSC (pH6) 
buffer for 30 seconds at 125ͦC and 22 psi 
1:200/30 minutes BD (610833) 
GLUR2 Pascal pressure chamber with TSC (pH6) 
buffer for 30 seconds at 125ͦC and 22 psi 
1:50 16 hours Sigma 
ADAR2 Pascal pressure chamber with TSC (pH6) 
buffer for 30 seconds at 125ͦC and 22 psi 
1:100/ 1hour Abcam 
ADAR3 Pascal pressure chamber with TSC (pH6) 
buffer for 30 seconds at 125ͦC and 22 psi 
1:200/ 1hour Sigma 
GFAP Microwave with TSC (pH.6.5) buffer for 10 
minutes 
1:20/ 1 hour 
 
Dako 
cytomation 
EAAT2 Pascal pressure chamber with  EDTA 
(pH.8) buffer for 30 seconds at 125ͦC and 
22 psi 
1:2000/ 1 hour 
 
Leica 
biosystems 
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2.8.1 Statistical analysis  
Images were captured and analysed using an upright Olympus BX61 microscope and 
Cell^R imaging software. Five random images were taken from the grey matter of the 
spinal cords of each case using a Hamamatsu ORCA-ER digital camera. Analysis^D 
software was used and the percentage area immunoreactivity in the area of interest in 
all cases was analysed using one-way ANOVA (GraphPad Prism 6). 
 
2.9 Next generation sequencing 
RNA extraction was carried out on dissected 200 motor neurons (7µm) using RNA 
PicoPure (Arcturus) Isolation kit (see section 2.3.5). RNA extraction was repeated 3 
times to improve the RNA quality.  Step 2.12.1 to 2.12.6 was repeated 3 times to 
optimise single stranded and double stranded RNA and then step 2.12.7 which is 
library preparation was repeated twice to get sufficient cDNA for sequencing. Samples 
were handed to the technical team for just running the experiments on the Illumina.  
 
2.9.1 First-strand cDNA synthesis 
10ng of total RNA in 3µl was added to 0.5µl of Message Booster Whole Transcriptome 
primers and 1.5µl of Rnase-Free Water. This was incubated at 65°C for 5 minutes in 
a thermocycler then chilled on ice for 1 minute and briefly centrifuged First-strand 
cDNA was prepared by mixing 1.25µl of Message Booster Reverse Transcriptase 
buffer, 0.25µl DTT, 0.25µl RiboGuard RNase Inhibitor and 0.25µl of MMLV-Reverse 
Transcriptase. This was added to the RNA plus primers mixture and incubated at RT 
for 10 minutes followed by a second incubation at 37°C for 60 minutes.  
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2.9.2 Second-strand cDNA synthesis 
First-strand cDNA was added to 4.5µl of MessageBooster DNA Polymerase premix 
and 0.5µl of Message Booster DNA Polymerase. This mixture was incubated at 65°C 
for 10 minutes then 80°C for 3 minutes. 1µl of Message Booster cDNA finishing 
solution was added to the reaction and then incubated at 37 °C for 10 minutes followed 
by another incubation at 80°C then centrifugation for 1 minute. 
 
2.9.3 In vitro transcription 
The following reagents were mixed: 2µl of MessageBooster T7 Transcription buffer, 
14µl of NTP premix, 2µl of DTT and 2µl of Message Booster T7 RNA Polymerase. 
Then, the mixture was added to the reaction and incubated at 42°C for 4 hours and 2µl 
of RNase-Free DNase 1 was added to the reaction and incubated at 37°C for 15 
minutes.  
 
2.9.4 Round one, RNA purification 
1µl of Poly (I) was added to each reaction and RNA was purified and eluted in 8µl of 
RNase-Free water.  
 
2.9.5 Round-two, first-strand cDNA synthesis 
To each purified RNA sample, 2µl of the random primers was added, incubated at 
65°C for 5 minutes, chilled on ice for 1 minute and briefly centrifuged. 1.5µl of the 
Message Booster Reverse Transcription, 0.25µl and 0.25µl of MMLV-RT were added 
to the reaction and incubated at 37°C for 60 minutes.  
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2.9.6 Second strand cDNA synthesis  
The first strand cDNA synthesis (20 µl) generated by MessageBooster was heat 
inactivated on ice and 48μl of Nuclease-Free Water was added to the reaction. To this 
was added 8μl of 10X second strand synthesis reaction and 4μl of second strand 
synthesis enzyme mix from the NEBNext mRNA second strand synthesis kit. The total 
volume for the reaction was 80μl. The reaction was mixed thoroughly and incubated 
for 2.5 hours at 16°C. The cDNA was purified using a PCR column purification from 
New England Biolabs and eluted in 20µl elution buffer. Samples were cleaned up 
using the basic Agencourt magnetic beads. 36µl of magnetic beads were added to the 
cDNA, then the reaction was mixed and incubated for 5 minutes at RT. The reaction 
was placed on Agencourt SPRIPlate 96 Super Magnet Plate for 2 minutes to separate 
the reaction from beads. While the reaction plate is situated on the magnet plate, the 
supernatant was discarded leaving 5μl of supernatant behind to avoid disturbing the 
beads. This was followed by washing the reaction with 200µl of 70% ethanol then the 
reaction was incubated for 30 seconds at RT before the supernatant containing ethanol 
was discarded. The reaction plate was removed from the magnet plate and 40µl of 
elution buffer was added to each sample then incubated for 2 minutes at RT. The 
reaction plate was placed back on the magnet plate for 1 minute to separate beads from 
the solution and the eluted reaction was transferred away in to new plate. 1µl of the 
reaction was measured by NanoDrop. 
 
2.9.7 Library preparation 
2.9.7.1 Tagmentation of genomic DNA  
The sample DNA was fragmented and tagged with adaptor sequences to the ends using 
Nextera XT DNA sample preparation kit. The following mix was prepared and loaded 
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into Nextera XT Tagment Amplicon plate: 10μl of Tagment DNA Buffer, 5μl of input 
cDNA at 1ng/μl and 5μl of Amplicon Tagment Mix. The reaction plate covered with 
microseal and centrifuge at 280xg at 20°C for 1 minute. The reaction was then placed 
in a thermocycler and incubated at 55°C for 5 minutes and hold at 10°C.  Then, 5μl of 
Neutralize Tagment Buffer was added to each well of the reaction plate. The reaction 
samples were mixed and centrifuged at 280xg at 20°C for 1 minute then reaction plate 
was incubated at RT for 5 minutes.  
 
2.9.7.2  PCR amplification 
A TruSeq Index Plate was used and index primers were arranged as follows: index 1 
(i7) primers were arranged in order horizontally (orange caps), so that N701 is in 
column 1 and N712 is in column 12. Index 2 (i5) primers (white caps) were arranged 
in order vertically, so that S501 (Seq-TAGATCGC) is in row A and S508 (Seq-
CTAAGCCT) is in row H. These positions were recorded. Then, 15µl Nextera PCR 
master mix was added to the reaction plate followed by adding 5µl of index primer 1 
and 5µl of index primer 2 to the plate. The sample plate was covered with a microseal 
film and centrifuged at 280xg at 20°C for 1 minute. Then, PCR was performed on the 
following program: one step of initial denaturation at 72°C for 3 minutes followed by 
denaturation at 95°C for 30 seconds then 12 cycles of denaturation at 95°C for 10 
seconds, annealing at 55°C for 30 seconds and extension at 72°C for 30 seconds and a 
final extension at 72°C for 5 minutes. 
   
2.9.7.3 PCR clean up 
Following the PCR amplification, the reaction was centrifuged at 280xg for 1 minute 
and library DNA was purified using AMPure XP beads.  50µl of the PCR product was 
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transferred to new plate and 30µl of beads were added and PCR reaction was mixed 
on shaker plate at 1.800 rpm for 2 minutes then incubated at RT for 5 minutes. The 
reaction plate was placed on magnet plate for 2 minutes. The supernatant was 
discarded, the beads were washed with 200µl of 80% of ethanol then the supernatant 
containing ethanol was discarded after incubation for 30 seconds. While the plate is 
on the magnet plate, beads were air dried for 15 minutes then sample plate was 
removed from the magnet stand and 52.5µl of resuspension buffer was added to the 
beads. Following incubation at RT for 2 minutes then sample plate was placed on the 
magnet stand for 2 minutes. 50µl of the purified PCR products were transferred to new 
plate and 1µl of NGS library was measured in NanoDrop, Bioanlayser High sensitivity 
DNA chip and qPCR using KAPA library quantification kit and samples were run on 
Illumina Hi scan SQ system by the in-house technical team..  
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Chapter 3: RNA editing of glutamate receptors in SALS 
patients 
 
3.1 Introduction 
As discussed in the Introduction while some of the key mechanisms that contribute to 
ALS have been identified, very little is known about the basis for the selective loss of 
motor neurons. The co-existence of neurons with other cell types in the central nervous 
system suggests that their survival depends on a complex interplay of intrinsic cellular 
attributes and extrinsic environmental factors. So the question remains why are motor 
neurons selectively vulnerable to death, possibly by excitotoxicity, in ALS? One 
explanation may be due to the excitotoxicity caused by an increased proportion of 
Ca+2-permeable ion channels, which are activated upon rapid release of presynaptic 
glutamate (Heath & Shaw, 2002). In addition inefficient glutamate re-uptake may 
partly contribute to the accumulation of excitotoxic Ca+2. Previous studies have 
implicated the AMPA and kainate receptors in ALS (Heath & Shaw, 2002; Van Den 
Bosch et al., 2006b).  This suggests the hypothesis that AMPA and kainate receptors 
contribute to the pathogenesis of ALS, despite the fact that AMPA and kainate 
receptors in certain conformations are generally less permeable to Ca2+ than the 
NMDAR (Van Den Bosch et al., 2006b). The AMPA and kainate receptors are thought 
to mediate motor neuron injury in a subpopulation of central neurons which are 
directly permeable to Ca2+ (Kwak & Kawahara, 2005).  In normal situations the AMPA 
receptors are composed of heteromeric complexes of four receptor subunits: GLUR1, 
GLUR2, GLUR3 and GLUR4. In contrast, hetero-multimeric kainate receptors  (KA) 
are composed of GLUR5-7 and KA1-KA2 which have distinct role at the synapse 
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compare to other glutamate receptors (Lerma et al., 2001). The GLUR5-7 subunits 
have low affinity to glutamate and are capable of forming functional homomeric 
channels. In contrast to GLUR5-7 subunits, KA1-KA2 have high affinity to glutamate 
but require co-assembly with one or more GLUR5-7 subunits to form functional 
channels. Like many other ion channels the hetero-multimeric assembly leads to the 
formation of receptors with unique pharmacological and functional properties, also 
through their action at both pre- and postsynaptic sites. KARs have also been shown 
to modulate synaptic transmission and neuronal excitability through their action at 
both pre- and postsynaptic sites (Lerma et al., 2001).  
The physiologic properties of AMPA and KA receptors are controlled by post-
transcriptional mechanisms such as RNA editing, which modifies one or more 
translation codons, thus leading to functionally distinct proteins from a single gene 
(Seeburg et al., 1998; Barbon et al., 2003). The predominant type of RNA editing in 
mammals is adenosine-to-inosine (A–I) catalyzed by the adenosine deaminase acting 
on RNA (ADAR). In particular, the GLUR2 subunit of the AMPA receptor and the 
GLUR5 and GLUR6 subunits of KA receptor are subject to RNA editing at the Q/R 
site, which results in glutamine being substituted by arginine at a position located in 
the channel pore (Caracciolo et al., 2013). The Q/R site in GLUR2, GLUR5 and 
GLUR6 is in different positions for each receptor; 607Arg, 636Arg and 621Arg, 
respectively. For instance, when edited GLUR2 (R) is present in the AMPA receptor 
complex, AMPA receptors become impermeable to Ca+2. Whereas, AMPA receptors 
containing the unedited form of GLUR2 (Q) have high Ca+2 permeability (Hollmann 
et al., 1991). Normally, this editing process occurs with virtually 100% efficiency from 
the embryonic stage onwards. It has been demonstrated that motor neurons express 
relatively lowered quantities of GLUR2 in ALS patients (Shaw et al., 1999; Van 
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Damme et al., 2002). A study using laser microdissection showed that single motor 
neurons had an editing efficiency that was approximately 56 % incomplete in sporadic 
ALS patients compared to 100% editing efficiency observed in controls (Kawahara et 
al., 2004). This incomplete editing of motor neurons in SALS patients at Q/R site 
correlates with decreased ADAR2 activity (Aizawa et al., 2010; Hideyama et al., 
2012b; Yamashita et al., 2012b; Yamashita & Kwak, 2013; Kubota-Sakashita et al., 
2014).  
RNA editing can also occur at other sites in the mRNA of glutamate receptor subunits 
including the R/G site of GLUR2, where arginine can be substituted for glycine, and 
two positions prone to mRNA editing have been identified in the M1 segment of 
GLUR6: the I/V site, where a valine can be substituted for an isoleucine and the Y/C 
site, where a tyrosine can be substituted for a cysteine. Therefore, editing at these 
positions modulates the effect of editing at the Q/R site in calcium flow such that the 
fully edited subunit inhibit Ca+2 entry to anion channel. However, further studies are 
required to determine the mechanism of interaction among these three sites (Köhler et 
al., 1993; Barbon et al., 2003).  
Previous work has also shown that ADAR2 itself is regulated post-translationally by 
peptidyl-prolyl isomerase NIMA interacting protein 1 (Pin1) and WW domain-
containing protein 2 (WWP2). Pin1 is a positive regulator for ADAR2 that causes 
conformational changes to ADAR2 that alters the catalytic stability and subcellular 
localisation. ADAR2 without Pin1 translocate to the cytoplasm where it is unable to 
edit pre-mRNA of GLUR2 at the Q/R or R/G site. WWP2 is a negative regulator for 
ADAR2 where the binding results in ADAR2 ubiquitination and subsequent 
degradation, therefore, increased expression of WWP2 leads to decreased ADAR2 
protein levels (Marcucci et al., 2011). 
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Like ADAR2, ADAR3 has  all the key residues required for catalysis however, it lacks 
the motif for deamination activity on double-stranded RNA (dsRNA) on specific 
substrates such as GLUR2 (Melcher et al., 1996; Chen et al., 2000). ADAR3 has the 
ability to bind not only dsRNA but also single-stranded RNA (ssRNA) in the N-
terminus, through an arginine rich domain, making it distinct from the other members 
of ADAR family (Chen et al., 2000). The function of ADAR3 is unknown however, it 
has been speculated that ADAR3 is a negative regulator for ADAR1 and ADAR2 in vitro 
when ADAR3 has appeared to inhibit the activities of RNA editing enzymes of the 
ADAR gene family (Chen et al., 2000). ADAR3 might compete for dsRNA substrates 
preventing the binding of the other ADAR enzymes (Tomaselli et al., 2013).  A recent 
study had shown that ADAR3 does not compete with ADAR2 in its binding to dsRNA 
substrates at least for certain edited mRNAs. For instance, it has been shown that 
ADAR3 binds to Lam-2 and pop-1 mRNAs, which are known edited mRNA, in the 
presence or absence of ADAR2. It has been suggested that ADAR3 might  function  to 
promote ADAR2 editing by binding to mRNA and then either alter binding of the 
ADAR2 to specific regions and/or regulate the catalytic activity of ADAR2  
(Washburn, 2014). 
As previously mentioned, the loss of EAAT2 protein in ALS might be explained by 
aberrant alternative splicing and production of truncated mRNA of exon 4 and exon 9 
found in motor cortex but not in the cerebellum or hippocampus of ALS patients (Lin 
et al., 1998). Evidence has shown that aberrant EAAT2 protein was not detected in the 
motor cortex or the spinal cord of ALS patients which may be caused by rapid 
degradation of truncated proteins (Lin et al., 1998), but later studies also identified 
these mRNA splice variants in control tissue (Meyer et al., 1999; Flowers et al., 2001). 
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Defect in the astrocytic glutamate re-uptake system of EAAT2 leads to excitotoxicity 
that may contribute to neuronal injury in ALS (Ferraiuolo et al., 2011).  
 
Hypothesis: 
 Altered glutamate receptor editing in motor neurons in ALS is relevant to 
disease pathogenesis 
 There is no relationship between mRNA expression of ADAR2 and ADAR3 
 A decrease in EAAT2 mRNA expression contributes to the excitotoxicity 
associated with ALS 
 
Aims: 
 To investigate RNA editing of GLUR2, GLUR5 and GLUR6 in the 
pathogenesis of ALS disease and the differences between edited RNA levels 
of glutamate receptors in controls compared to ALS/C9ORF72-positive and 
ALS/C9ORF72-negative patients. 
 To determine the ADAR2 and ADAR3 gene expression in  the spinal cord from 
ALS versus control cases  
 To determine the aberrant expression of EAAT2 transcripts in the astrocytes of 
the spinal cord of ALS cases and controls 
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3.2 Results 
3.2.1  Optimisation development 
The laser capture microdissection (LCM) of MNs was optimised in in FFPE sections 
of spinal cord tissue of 3 ALS patients; FALS/C9ORF72-positive, SALS/C9ORF72-
positive and SALS (see table 3.1). In order to visualise MNs for LCM, sections were 
stained with toluidine blue and ~400 MNs were picked. RNA extraction was carried 
out using RNA aqueous micro kit from Ambion and the RNA concentration was 
measured by Nanodrop (see table 3.2). Nanodrop data showed an RNA concentration 
of ~234-340ng/µl. RNA was converted to a cDNA and RT-PCR was performed. 
However, RT-PCR of ALS case did not show any peaks in the DNA chip bioanalyser 
because of the low RNA quality (see figure 3.1). The expected RT-PCR sized 270bp.  
Table 3.1: FFPE sections obtained from spinal cord of ALS patients  
The FFPE spinal cord sections was obtained from different spinal cord regions; Case 
no.273/99G was obtained from lumber spinal cord, case no. 336/90J was obtained 
from thoracic spinal cord and case no. 113/08A was obtained from cervical spinal cord.   
 
 
 
 
 
 
 
Case 
number 
Clinical Diagnosis Area/level PMI  in 
hours 
Sex Age at 
onset 
Age at 
death 
Length of  
illness 
273/99G 
(TBP0096) 
 
FALS/C9ORF72 Bulbar 31 M  66 68 14 months 
336/90J 
(TBP0048) 
SALS/C9ORF72 Limb 6 M 63 64 11 months 
113/08AC SALS Multifocal 9 F 68 70 31 months 
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Table 3.2: Nanodrop of spinal cord sections of ALS patients 
Nanodrop data showed RNA concentration of 3 ALS patients. A260: The absorbance 
reading at 260nm, A280: The absorbance reading at 280nm, 260/280: A ratio for 
pure RNA is ~2 and 260/230: A ratio for pure RNA is ~2-2.2. 
 
 
 
Figure 3.1: DNA chip bioanalyser of PCR of ALS 
DNA chip bioanalyser of PCR reaction of ALS case did not show any DNA product. 
The expected DNA product sized 270bp.  
 
 
 
Sample ID RNA concentration A260 A280 260/280 260/230 
273/99G 
(TBP0096) 
234ng/µl 5.850 12.424 0.47 0.91 
336/90J 
(TBP0048) 
340ng/ µl 8.0504 15.966 0.53 3.01 
113/08AC 244 ng/µl 6.124 13.020 0.47 1.19 
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MNs dissection by LCM was also was also optimised in frozen spinal cord tissue 
because of the low quality of the extracted RNA from FFPE tissue (0.47/260/280 see 
table 3.2). In order to visualise MNs for LCM, sections were stained with toluidine 
blue and varying numbers of MNs were isolated (see figure 3.2). The first attempt to 
isolated RNA in frozen tissue was carried out with 10 MNs and then 20 MNs, which 
gave a low RNA concentration and quality as measured by Nanodrop (data are not 
shown) and Picochip (see figure 3.3). However, increasing the number of isolated MNs 
to 200 gave an increased RNA concentration of 22.7pg/µl (see figure 3.3).  
The PCR reactions for GLUR2, GLUR5 and GLUR6 were optimised using human 
universal reference RNA as well as optimising the digestion of PCR product to identify 
the editing efficacy of glutamate receptors at the Q/R site. Prior to digestion with the 
restriction enzyme BseXI, RT-PCR of the three glutamate receptors was expected to 
produce PCR products sized 240bp for GLUR2 (see figure 3.4a), 227bp for GLUR5 
(see figure 3.4b) and 117bp for GLUR6 (see figure 3.4c). GLUR2, GLUR5 and GLUR6 
were first amplified by RT-PCR with a temperature gradient from 52°C to 60°C. 
However, GLUR2 annealing temperature was increased to 67ºC to eliminate primer 
dimer formation. GLUR2 was optimally amplified at 67°C as demonstrated by a single 
clear band without the expression of a primer dimer compared to the other annealing 
temperatures (see figure 3.4a). The optimal annealing temperature for GLUR5 was 
determined to be 55°C, as this temperature increased the purity of the single product 
compared to other temperatures tested (see figure 3.4b). The annealing temperature for 
GLUR6 was optimised at 60°C, because at this temperature there was increased 
product and reduced non-specific bands relative to other temperatures tested (see 
figure 3.4c). Increasing the annealing temperature was associated with reduced primer 
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dimer formation. Minimising primer dimer formation was vital to determine RNA 
editing levels.  
In order to distinguish between the edited and unedited GLUR2 mRNA at the Q/R site 
the restriction enzyme BseXI was used to cut GLUR2 cDNA once, creating two 
fragments sized 191bp and 49bp. In addition, BseXI cuts -unedited GLUR2 into three 
fragments sized 100, 91, and 49bp (see figure 3.5a). The fragments were analysed 
using a DNA chip bioanalyser, which showed complete editing (100%) of GLUR2 at 
the Q/R site in the universal reference tissue (see figure 3.5b). GLUR5 RNA editing 
was also optimised using restriction digest BseXI that cuts the PCR product of GLUR5 
at Q/R site. The DNA chip bioanalyser showed three peaks; the first two peaks were 
sized 93bp and 143bp and were the edited GLUR5 whereas, the third peak was sized 
227bp and was the non-edited form of GLUR5 (see figure 3.6b).  In addition to the 
optimisation of GLUR2 and GLUR5 restriction digests, GLUR6 digestion resulted in 
three peaks; the first two peaks were sized 31bp and 88bp representing the edited form 
(R) and the 117bp representing the non-edited form (Q) of GLUR6 in the universal 
reference RNA (see figure 3.7b).  
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Figure 3.2: Microdissection of MNs by LCM. 
Panel a. shows MN stained with toluidine blue prior LCM. Panel b. shows MN after 
LCM (red arrow). Panel c. shows isolated MNs on cap scale bar= 50 µm. 
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Figure 3.3: RNA concentration of MNs of ALS patients.  
Pico chip bioanalyser showed RNA concentration of 200 MNs from one ALS patient 
with high RNA concentration of 22.7pg/µl (a). Another SALS patient sample was used 
to isolate 20 MNs and showed low RNA concentration of 1.3pg/µl (b).  
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Figure 3.4: PCR optimisation of GLUR2, GLUR5 and GLUR6 primers.  
Agarose gel electrophoresis analysis of PCR optimisation products using the human 
universal reference RNA GLUR2 (a), GLUR5 (b) and GLUR6 (c). PCR products were 
observed in all the indicated temperatures.   The optimal annealing temperature which 
gave a single PCR product was 67 ºC for GLUR2 (a),  55 ºC for GLUR5 and (b) 60 ºC 
for GLUR6 (c).  
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Figure 3.5: Restriction digest analysis of GLUR2 editing. 
 A schematic representation of BseXI restriction enzyme digests to differentiate 
between edited and unedited GLUR2 mRNA at Q/R site (a). DNA chip bioanalyser 
showed two peaks of edited GLUR2 (191bp, 49bp) in human universal reference RNA 
(b). 
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Figure 3.6: Restriction digest analysis of GLUR5 editing.  
A schematic representation of BseXI restriction enzyme digests to differentiate 
between edited and unedited GLUR5 mRNA at Q/R site (a). DNA chip bioanalyser 
showed two peaks of edited (93bp and 143bp) and a single peak of unedited (227bp) 
GLUR5 in human universal RNA (b). 
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Figure 3.7: Restriction digest analysis of GLUR6 editing.   
A schematic representation of BseXI restriction enzyme digests to differentiate 
between edited and unedited GLUR6 mRNA at Q/R site (a). DNA chip bioanalyser 
showed two peaks of edited (31bp and 88bp) and a single peak of unedited (117bp) 
GLUR6 in human universal RNA (b). 
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3.2.2 RNA editing of glutamate receptor subunits in 
different CNS regions 
RNA editing levels of GLUR2, GLUR5 and GLUR6 were determined in the motor 
cortex of 4 SALS patients and in 3 control subjects. GLUR2, GLUR5 and GLUR6 RNA 
editing levels were also studied in the frontal cortex of 3 SALS cases in comparison to 
5 controls (see table 3.3). Additionally, GLUR2, GLUR5 and GLUR6 RNA editing was 
examined in temporal cortex, cerebellum, and thalamus and in motor cortex of one 
patient of PICK disease. 
Table 3.3: Multiple CNS regions of several ALS patients and one PICK patient 
Frozen motor cortex from ALS patients and controls 
Case 
number 
Clinical 
Diagnosis 
Area/level PMI  in 
hours 
Sex Age at 
onset 
Age at 
death 
Length of  
illness 
TBP0070 
(53/96) 
SALS/C9ORF72 Bulbar 7 F 61 64 40 months 
TBP0078 
(159/96) 
SALS Bulbar 20 M 41 43 23 months 
TBP0076 
(137/96) 
SALS/UMN Multifocal 9 F 56 65 99 months 
TBP0083 
(57/97) 
SALS/PLS Bulbar 18 F 76 78 26 months 
TBP0071 
(66/96) 
Control Bulbar 10 F 70 73 37 months 
144/96 Control n/a n/a n/a n/a n/a n/a 
194/96 Control n/a n/a n/a n/a n/a n/a 
Frozen frontal cortex from ALS patients and controls 
Case 
number 
Clinical 
Diagnosis 
Area/level PMI  in 
hours 
Sex Age at 
onset 
Age at 
death 
Length of  
illness 
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TBP0074 SALS Bulbar 19 M 71 75 37 months 
TBP0075 SALS Multifocal 9 F 68 70 31 months 
136/97 SALS n/a 16 F 76 78 13 months 
136/95 Control n/a 10 F n/a 87 n/a 
147/95 Control n/a 15 M n/a 47 n/a 
178/95 Control-
Ischaemic Heart 
disease 
n/a 24 F n/a 63 n/a 
35/96 Control n/a 14 F n/a 87 n/a 
95/96 Control n/a n/a n/a n/a n/a n/a 
Frozen tissue from different CNS regions of one case with PICK’s disease 
Case 
number 
Clinical 
Diagnosis 
Area/level PMI  in 
hours 
Sex Age at 
onset 
Age at 
death 
Length of  
illness 
Temporal 
cortex 
Pick’s disease 
 
n/a 22 F n/a 63 n/a 
Cerebellum 
Thalamus 
Motor 
cortex 
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New primers had to be designed because of the PCR reaction that showed evidence of 
contamination as evidenced by the presence of a band in the negative control. Since 
the intensity of this product decreased with lower primer concentration it was 
concluded that the primers had become contaminated. The new primers were designed 
to be larger than the contaminated product. RT-PCR of GLUR2, GLUR5 and GLUR6 
showed PCR products sized 487bp for GLUR2 (see figure 3.8), 114bp for GLUR5 (see 
figure 3.9) and 132bp for GLUR6 (see figure 3.10). GLUR2, GLUR5, GLUR6 were 
optimised at 60ºC, which showed increased PCR products and reduced non-specific 
bands. Some PCR products had strong primer dimer that had to be removed by 
cleaning the PCR product prior to digestion with restriction enzymes.  Instead of using 
agarose gel extraction method an alternative approach was used which is a flash gel 
system that allowed isolation of cleaned PCR product without cutting the gel from 
available recovery wells on the flash gel (see section 2.8.1).    
 In order to distinguish between the edited and non-edited mRNA at Q/R site, the 
restriction enzyme BbVI was used because it has a similar cut site as BseXI but was 
found to be more efficient (see figure 2.4). DNA chip bioanalyser showed a single 
peak representing predigest RT-PCR (see figure 3.11b) and two peaks (252bp and 
235bp) representing fully edited GLUR2 at Q/R site in the motor cortex of the SALS 
patient (see figure 3.11c).  
Editing of the kainate receptor subunits GLUR5 and GLUR6 were calculated after 
digestion with restriction enzyme BbVI. When it is edited, BbVI cuts GLUR5 digest 
into two fragments (82bp and 32bp) compared to the unedited GLUR5 sized 114bp 
(see figure 3.12c). GLUR6 has similar fragments sized 102bp and 30bp if edited and 
one fragment sized 132bp when it is unedited (see figure 3.13c). 
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The analysis of GLUR2 RNA editing in the frontal cortex of SALS cases (n=3) and in 
the motor cortex of SALS cases (n=4) compared to controls showed 100% editing at 
Q/R site (see figure 3.14a). GLUR5 RNA editing of the same SALS cases (n=3) in the 
frontal cortex was 83 ± 9% similar to controls (n=5) that had 82 ± 7% editing at Q/R 
site. Whereas, the analysis of GLUR5 editing in the motor cortex had shown 79 ± 11% 
editing in 4 SALS cases and 66 ± 21% editing in 3 controls (see figure 3.15a). GLUR6 
RNA editing of GLUR6 was also analysed in the frontal cortex of 3 SALS cases and 5 
controls, both groups had shown 88 ± 9% and 86 ± 6% editing, respectively. 
Additionally, RNA editing of the GLUR6 in the motor cortex of SALS cases (n=4) and 
in controls (n=3) both had shown similar editing values of 90 ± 4% and 90 ± 8%, 
respectively (see figure 3.16a). 
RNA editing was also studied in GLUR2, GLUR5 and GLUR6 of one case with Pick’s 
disease in the motor cortex, temporal cortex, cerebellum and thalamus (see table 3.3). 
Editing of GLUR2 in the motor cortex of this case decreased from 100% to 84% editing 
efficiency. Both the thalamus and temporal cortex had higher GLUR2 editing of 91% 
compared to 22% in the cerebellum and 84% in the motor cortex (see figure 3.14b). 
Like GLUR2, GLUR5 had also variable levels of RNA editing in cerebellum, thalamus, 
temporal cortex and motor cortex, ranging from 71% to 33% (see figure 3.15b). This 
patient also had a similar editing profile in the GLUR6 of these CNS regions, ranging 
from 66% to 50% (see figure 3.16b). This case was originally included as a control but 
subsequently characterised as a Pick’s case. As shown in figure 3.14b, 3.15b and 
3.16b, data did not have error bars because it represent only one case with PICK 
disease.  
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Figure 3.8: Screening GLUR2 RNA in the motor cortex of SALS patients  
Agarose gel electrophoresis of PCR products obtained from motor cortex of SALS 
patients and controls using GLUR2 primer sequence, see sequence information in 
methods figure 2.1. Positive control was whole spinal cord of control case and the 
negative control was the PCR mixture lacking DNA. Primer dimer was seen. 4 SALS 
patients and 3 controls were used.  
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Figure 3.9: Screening GLUR5 RNA in the motor cortex of SALS patients.  
Agarose gel electrophoresis of PCR products obtained from motor cortex of SALS 
patients and controls using GLUR5 primer sequence, see sequence information in 
methods figure 2.2. Positive control was whole spinal cord of control case and the 
negative control was the PCR mixture lacking DNA. 4 SALS patients and 3 controls 
were used. 
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Figure 3.10: Screening GLUR6 RNA in the motor cortex of SALS patients.  
Agarose gel electrophoresis of PCR products obtained from motor cortex of SALS 
patients and controls using GLUR6 primer sequence, see sequence information in 
methods figure 2.3. Positive control was whole spinal cord of control case and the 
negative control was the PCR mixture lacking DNA. Primer dimer was seen. Cases 
were 4 SALS patients and 3 controls.  
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Figure 3.11: Restriction digest analysis of GLUR2 editing.  
A schematic representation of BbVI restriction enzyme digests to differentiate 
between edited and unedited GLUR2 mRNA at Q/R site (a). DNA chip bioanalyser 
showed a single peak GLUR2 predigest sized 487bp (b). GLUR2 edited at 252bp and 
235bp in motor cortex of SALS patients and controls (c).  
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Figure 3.12: Restriction digest analysis of GLUR5 editing.  
A schematic representation of BbVI restriction enzyme digests to differentiate 
between edited and unedited GLUR5 mRNA at Q/R site (a). DNA chip bioanalyser 
showed a single peak of GLUR5 predigest sized 114bp (b), two peaks of non-edited 
(82bp and 32bp) and edited (114bp) GLUR5 in the motor cortex of SALS patients and 
controls (c).
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Figure 3.13: Restriction digest analysis of GLUR6 editing.  
A schematic representation of BbVI restriction enzyme digests to differentiate 
between edited and unedited GLUR6 mRNA at Q/R site (a). DNA chip bioanalyser 
showed a single peak of GLUR6 predigest sized 132bp (b), two peaks of non-edited 
(102bp and 30bp) and edited (132bp) GLUR6 in the motor cortex of SALS patients 
and controls (c). 
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Figure 3.14: Percentage of GLUR2 RNA editing.  
RNA editing of GLUR2 in frontal and motor cortex of controls and SALS patients (a), 
RNA editing of different CNS regions in one patient with PICK’s disease (b). 
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Figure 3.15: Percentage of GLUR5 RNA editing. 
RNA editing of GLUR5 in frontal and motor cortex of controls and SALS patients (a), 
RNA editing of different CNS regions in one patient with PICK’s disease (b). 
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Figure 3.16: Percentage of GLUR6 RNA editing.  
RNA editing of GLUR6 in frontal and motor cortex of controls and SALS patients (a), 
RNA editing of different CNS regions in one patient with PICK’s disease (b). 
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3.2.3 RNA editing of glutamate receptors in MNs of ALS  
This study aimed to investigate the level of mRNA editing of GLUR2, GLUR5 and 
GLUR6 in whole tissue of frozen thoracic spinal cord and in laser captured motor 
neurons of ALS/C9ORF72-positive patients, ALS/C9ORF72-negative patients and 
controls (n=15) (see table 3.4).  
Table 3.4: Frozen thoracic spinal cord from ALS cases and controls 
 
Case 
number 
Block  
Number 
Area/Level Site of onset PMI  in 
hours 
Sex Age  at 
onset 
Age   at 
death 
ALS/C9ORF72-positive cases00 
LP83/10 34 T11 Limb 13 Male 67 79 
LP081/09 29 T11 Limb 60 Male 57 59 
LP041/04 6 T11 Bulbar 48 Male 62 64 
LP039/11 26 T11 Limb 96 Male 70 72 
LP040/11 25 T11 Limb 10 Female 72 77 
ALS/C9ORF72-negative cases 
LP014/11 24 T11 Limb n/a Male 49 51   
LP005/11 30 T11 Limb 40 Female 62 67  
LP023/10 7 T11 Limb 24  Female 34 42 
LP005/10 23 T11 Limb 96 Male 38 40 
LP094/09 25 T11 Bulbar 48 Male 62 63 
Controls 
LP005/07 13 T11 n/a 12 Male n/a 64 
LP085/07 25 T11 n/a 5 Female n/a 82 
LP098/07 25 T11 n/a 63 Male n/a 67 
035/96 8 T11 n/a 14 Female n/a 87 
70/96  2 C7 n/a n/a n/a n/a n/a 
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The RNA editing of GLUR2 at Q/R site showed 100% editing in the spinal cord and 
in MNs of controls, ALS/C9ORF72-positive cases and ALS/C9ORF72-negative cases 
(see figure 3.17 & 3.18).   
The RNA editing of GLUR5  in the spinal cord of ALS cases and controls showed 
similar levels of RNA editing of 38 ± 24% (mean ± SD) and 21 ± 26% , respectively 
(see figure 3.19a). The RNA editing of GLUR5 was also determined in the spinal cord 
of ALS/C9ORF72-positive cases and ALS/C9ORF72-negative cases compared to 
controls showing 21 ± 26% in controls, 41 ± 20% in C9ORF72 negative cases and 35 
± 29% in C9ORF72-positive cases (see figure 3.19b). 
The RNA editing of GLUR5 in MNs of ALS cases and controls showed 48 ±19% in 
ALS cases and 30 ± 25% in controls (see figure 3.20a). The editing efficiency of 
GLUR5 in MNs was 39 ± 17% in ALS/C9ORF72-positive cases, 57 ± 19% editing in 
ALS/C9ORF72-negative cases and 30 ± 25% in controls (see figure 3.20b).  
The RNA editing levels of GLUR6 in the spinal cord showed 33 ± 9.4 % in ALS 
patients to 32 ± 18% in controls (see figure 3.21a). Additionally, the editing efficiency 
of GLUR6 in the spinal cord of ALS/C9ORF72-positive cases and ALS/C9ORF72-
negative cases was 36 ± 8% and 30 ± 1%, respectively compared to controls that 
showed 32 ± 18% editing (see figure 3.21b). 
The RNA editing of GLUR6 in MNs showed 81 ± 36% editing in ALS and 72 ± 42% 
in controls (see figure 3.22a). Furthermore, the editing levels of GLUR6 in MNs were 
increased from 77 ± 43% editing in ALS/C9ORF72 -negative cases to 86 ± 32% 
editing in ALS/C9ORF72-positive cases compared to 72 ± 42% in controls (see figure 
3.22b). 
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Figure 3.17: RNA editing of GLUR2 in the spinal cord of ALS cases. 
RNA editing efficiency of GLUR2 in the spinal cord of controls and ALS patients (a) 
in controls, ALS/ C9ORF72-negative cases and ALS/C9ORF72-positive cases (b). 
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Figure 3.18: RNA editing of GLUR2 in MNs of ALS 
Percentage of RNA editing of GLUR2 in MNs of controls and ALS cases (a) in 
controls, ALS/C9ORF72-negative cases and ALS/C9ORF72-positive cases (b). 
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Figure 3.19: RNA editing of GLUR5 in the spinal cord of ALS cases. 
RNA editing efficiency of GLUR5 in the spinal cord of controls and ALS patients (a) 
in controls, ALS/ C9ORF72-negative cases and ALS/C9ORF72-positive cases (b). 
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Figure 3.20: RNA editing of GLUR5 in MNs of ALS 
Percentage of RNA editing of GLUR5 in MNs of controls and ALS cases (a) in 
controls, ALS/C9ORF72-negative cases and ALS/C9ORF72-positive cases (b). 
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Figure 3.21: RNA editing of GLUR6 in the spinal cord of ALS cases. 
RNA editing efficiency of GLUR6 in the spinal cord of controls and ALS patients (a) 
in controls, ALS/ C9ORF72-negative cases and ALS/C9ORF72-positive cases (b). 
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Figure 3.22: RNA editing of GLUR6 in MNs of ALS 
Percentage of RNA editing of GLUR6 in MNs of controls and ALS cases (a) in 
controls, ALS/C9ORF72-negative cases and ALS/C9ORF72-positive cases (b). 
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Table 3.5: GLUR editing at Q/R site of ALS patients. 
The percentage of the RNA editing of GLUR2, GLUR5 and GLUR6 was calculated using this formula [% of RNA editing= non-
edited/edited+ non-edited concentrations]. The mean and SD were analysed using One-way ANOVA and student T-Test. Abbreviations: 
Cntr - control, C9ORF72-- C9ORF72-negative, C9ORF72+- C9ORF72- positive, MNs-motor neurons, GLUR- glutamate receptors, SD- 
standard deviation 
 
Percentage (%)  of editing of one patient with PICK’S disease at Q/R site 
 GLUR2 GLUR5 GLUR6 
Regions Number of patients SALS 
Temporal  
               1 
 
91 36 66 
Thalamus 91 47 50 
Motor cortex 84 33 59 
Cerebellum 22 22 54 
Percentage (%) of editing of SALS patients at Q/R site 
 GLUR2 GLUR5 GLUR6 
Regions No of patients Cntr SALS Cntr SALS Cntr SALS 
Frontal cortex 3 100 100 82 ± 7 83 ± 9 86 ± 6 88 ± 9 
Motor cortex 4 100 100 79 ± 11 66 ± 21 90 ± 8 90 ± 4 
Percentage (%)  of editing in ALS/C9ORF72-negative and ALS/C9ORF72-positive patients at Q/R site 
 GLUR2 GLUR5 GLUR6 
 No of patients Cntr ALS C9ORF72- C9ORF72+ Cntr  ALS C9ORF72- C9ORF72+ Cntr ALS C9ORF72- C9ORF72+ 
Spinal cord 5 100 100 100 100 21 ± 26 38 ±24 41 ± 20 35 ± 29 32 ± 18 33 ±9.4 30 ± 1 36 ± 8 
MNs 5 100 100 100 100 30 ± 25 48 ±19 57 ± 19 39± 17 72 ± 42 81 ±36 77 ± 43 86 ± 32 
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3.2.4 ADAR mRNA expression in ALS  
This study investigated the correlation between the expression of ADAR2 and ADAR3 
in spinal cord of ALS/C9ORF72-positive cases and ALS/C9ORF72-negative cases 
compared to controls. Quantitative real-time PCR was used to determine the mRNA 
expression of ADAR2 and ADAR3 relative to an internal reference GAPDH mRNA. 
The data was further analysed using student T-test and one-way ANOVA.   
The mRNA expressions of ADAR2 in the spinal cord of ALS cases was increased (2.1 
± 0.87) (mean ± SD) compared to controls (1 ± 0.1) however, this data did not reach 
statistical significance (p= 0.1151) (see figure 3.23a). ADAR2 expression was also 
examined in the spinal cord of ALS/C9ORF72-positive cases and ALS/C9ORF72-
negative cases, it showed increased ADAR2 expression of 1.7 ± 0.7% in 
ALS/C9ORF72-positive cases and 2.2 ± 0.5% in ALS/C9ORF72-negative cases 
compared to 1 ± 0.1% in controls. However, the relative expression of ADAR2 
between ALS and controls did not reach statistical significance (p=0.9177) (see figure 
3.23b). 
The mRNA expressions of ADAR3 in the spinal cord of ALS cases was similar to 
controls (1 ± 0.3) with no statistical significance between ALS cases and controls, (p= 
0.8038) (see figure 3.24a). The expression of ADAR3 in ALS cases in particular 
ALS/C9ORF72-positive cases (1 ± 0.2), ALS/C9ORF72-negative cases (1 ± 0.3) and 
controls (1 ± 0.2) did not show any statistical significance (p=0.9498) (see figure 
3.24b). 
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Figure 3.23: The relative expression of ADAR2 in spinal cord of ALS cases. 
The analysis of ADAR2 mRNA expression in spinal cord of ALS patients and controls 
(a) and ALS/C9ORF72-positive cases and ALS/C9ORF72-negative cases compared 
to controls (b).  Student T-Test revealed non statistical significance between ALS 
cases and controls of ADAR2, p= 0.1151. One-way ANOVA showed no significant 
difference in the expression of ADAR2, p=0.1977 across the 3 groups. 
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Figure 3.24: The relative expression of ADAR3 in spinal cord of ALS cases 
The analysis of ADAR3 mRNA expression in the spinal cord of ALS patients and in 
controls (a) ALS/C9ORF72-positive cases and ALS/C9ORF72-negative cases 
compared to controls (b). Student T-Test revealed non statistical significance between 
ALS cases and controls of ADAR3, p= 0.8038. One-way ANOVA showed no 
significant difference in the expression of ADAR3, p= 0.9498 across the 3 groups.  
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3.2.5 The potential role of normal and aberrant 
alternative transcripts of EAAT2 in astrocytes 
To investigate the alternatively spliced variants of EAAT2, exon 4 and exon 9 retaining 
and skipping transcripts in controls and in ALS patients. The normal EAAT2 
transcripts (also called EAAT2 retaining transcripts) are EAAT2+4 and EAAT2+9. 
Whereas, the aberrant EAAT2 transcripts (also called EAAT2 skipping transcripts) are 
EAAT2Δ4 and EAAT2Δ9. All EAAT2 transcripts were measured by quantitative real-
time PCR. The mRNA of these normal and aberrant EAAT2 transcripts were 
normalised to an internal reference GAPDH mRNA and analysed using student T-test 
and one-way ANOVA.   
Examining the relative expression of the EAAT2+4 in the astrocytes of all ALS cases 
versus controls showed 3.25 ± 2.36 (mean ± SD) in ALS cases compared to 1.69 ± 1.4 
in controls (see figure 3.25a). Additionally, the expression of EAAT2+4 transcript in 
astrocytes showed 4 ± 3.7 in ALS/C9ORF72-positive and 2.7 ± 0.6 in ALS/C9ORF72-
negative cases relative to 1.6 ± 1.4 in controls (see figure 3.25b). An increases in the 
EAAT2+4 expression was observed in ALS patients to controls (p=0.3151) or 
ALS/C9ORF72-negative cases and ALS/C9ORF72-positive cases compared to 
controls (p=0.533), though this was not significance. 
Examining the relative expression of the EAATΔ4 in the astrocytes of  ALS cases 
versus controls showed 2.70 ± 1.9 in ALS cases compared to 2.1 ± 1.66 in controls 
(see figure 3.26a). The expression of the EAATΔ4 transcript was 3 ± 2.6 in 
ALS/C9ORF72-positive cases and 2.1 ± 0.1 in ALS/C9ORF72-negative cases relative 
to 2.1 ± 1.5 in controls (see figure 3.26b). The difference between the expression of 
EAATΔ4 transcript of ALS cases and controls did not reach statistical significance 
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(p=0.6663). The expression of EAATΔ4 transcripts was increased in ALS cases with 
and without C9ROF72 expansion compared to controls (p=0.8205), though this was 
not significant. 
The relative expression of  EAAT2+9 in the astrocytes of all ALS cases versus controls 
showed 1.86 ± 0.9 in ALS cases compared to  1.21 ±  0.4 in controls (see figure 3.27a). 
An increase in the expression of EAAT2+9 transcript of ALS cases compared to 
controls was observed, p=0.2818, though this was not significant. The relative 
expression of EAAT2+9 transcript was also examined in the astrocytes of 
ALS/C9ORF72-positive cases (2 ± 3.7) and in ALS/C9ORF72-negative cases (1.7 ± 
0.7), compared to controls (1.2 ± 0.4), p=0.244 (see figure 3.27b). However, the 
difference in EAATΔ9 transcript of ALS cases particularly between ALS cases with 
and without C9ORF72 expansion relative to  controls did not reach statistical 
significance, p=0.4376. EAAT2+9 transcripts in the astrocyte of ALS/C9ORF72-
positive cases exhibited a large error due to variability in cases and RNA quality.   
The relative expression of EAAT2Δ9 in the astrocytes of ALS cases versus controls 
showed 2.8 ± 3.5 in ALS cases compared to 1.14 ± 0.5 in controls (see figure 3.28a). 
Furthermore, the expression of EAAT2Δ9 transcript in the astrocytes was 4 ± 5 in 
ALS/C9ORF72- positive cases, 1.7 ± 1.9 in ALS/C9ORF72-negative cases and 1.1 ± 
0.4 in controls (see figure 3.28b). Overall expression of EAAT2Δ9 transcripts in ALS 
and controls (p=0.4376) or in ALS/C9ORF72- positive cases, ALS/C9ORF72-
negative cases and controls did not show any statistical significance (p=0.5092). 
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Figure 3.25: The mRNA expression of EAAT+4 in the grey matter of the spinal 
cord of ALS cases. 
The expression of EAAT+4 transcript showed non statistical significance between 
ALS cases and controls (p=0.3151) (a). This test was carried out by student T-Test. 
Using one-way ANOVA, the expression of EAAT+4 was also analysed in controls, 
ALS/C9ORF72-negative cases and ALS/C9ORF72-positive cases. It showed no 
statistical significance between ALS cases with and without C9ORF72 expansion and 
controls (p=0.533). 
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Figure 3.26: The mRNA expression of EAATΔ4 skipping in the grey matter of the 
spinal cord of ALS cases. 
The expression of EAATΔ4 showed non statistical significance between ALS cases 
and controls (p=0.6663) (a). This test was carried out by student T-Test. Using one-
way ANOVA, the expression of EAATΔ4 was also analysed in controls, 
ALS/C9ORF72-negative cases and ALS/C9ORF72-positive cases. It showed no 
statistical significance between ALS cases with and without C9ORF72 expansion and 
controls (p= 0.8205). 
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Figure 3.27: The mRNA expression of EAAT+9 in the grey matter of the spinal 
cord of ALS cases. 
A student T-test revealed an increase in the EAAT+9 of ALS patients compared to 
controls (p=0.2818), though this was not significant. Using one-way ANOVA, there 
was no statistical significance between controls, ALS/C9ORF72-negative cases and 
ALS/C9ORF72-positive cases (p=0.244) (b).  
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Figure 3.28: The mRNA expression EAATΔ9 in the grey matter of the spinal cord 
of ALS cases.  
A student T-test revealed an increase in the expression of EAATΔ9 in ALS patients 
compared to controls (p=0.4376), though this was not significant. Using one-way 
ANOVA, there was no statistical significance between controls, ALS/C9ORF72-
negative cases and ALS/C9ORF72-positive cases in the expression of EAATΔ9 (p= 
0.5092) (b).  
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3.3 Discussion 
The current study determined the levels of RNA editing in GLUR2, GLUR5 and 
GLUR6  in ALS patients compared to controls. The RNA editing of GLUR2 at Q/R 
site was 100% edited in the frontal cortex, motor cortex, spinal cord and in MNs of 
ALS cases and controls. Whereas, RNA editing efficiency of GLUR5 at Q/R site was 
less in the frontal cortex, motor cortex, spinal cord and in MNs of both 
ALS/C9ORF72-negative and ALS/C9ORF72-positive cases compared controls. 
Similarly, GLUR6 RNA editing at Q/R site showed similar levels of editing to GLUR5 
in the frontal cortex, motor cortex, spinal cord and in MNs of ALS/C9ORF72-negative 
and ALS/C9ORF72-positive compared controls. 
Several lines of evidence support the theory that MNs in the spinal cord of SALS are 
differentially more vulnerable to AMPA receptor-mediated excitotoxicity than other 
neuronal subsets, both in vitro (Rothstein et al., 1993; Carriedo et al., 1996) and in 
vivo (Nakamura et al., 1994; Kwak & Nakamura, 1995). Studies have suggested that 
increased Ca+2 influx through Ca+2-permeable AMPA receptor not containing subunit 
GLUR2 might be the mechanism by which these effects occur (Carriedo et al., 1996; 
Van Den Bosch et al., 2000). It has been shown that AMPA receptors lacking GLUR2 
have high levels of Ca+2 influx whereas, AMPA receptor containing GLUR2 have a 
low Ca+2 influx (Hollmann et al., 1991; Verdoorn et al., 1991). Particularly, those 
AMPA receptors containing edited GLUR2 at Q/R site, since when edited GLUR2 (R) 
is present in the AMPA receptor complex, AMPA receptors become impermeable to 
Ca+2. Whereas, when AMPA receptors contain the unedited form of GLUR2 (Q), their 
Ca+2 permeability remains high (Sommer et al., 1991). Therefore, both deficiency in 
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GLUR2 expression and abnormal editing levels of GLUR2 mRNA can induce AMPA 
receptor-mediated neuronal death (Hollmann et al., 1991; Wright & Vissel, 2012).  
Although most attention has been focused on the GLUR2 of the AMPA receptor 
subunit, the involvement of other glutamate receptors such as KA receptor subunits 
GLUR5 and GLUR6 in ALS has been reported (Heath & Shaw, 2002). Studies had 
shown that KA receptors are thought to mediate motor neuron injury when they 
become permeable to Ca2+ (Carriedo et al., 1996; Vincent & Mulle, 2009). These 
subunits are  also subject to RNA editing by ADAR2 on a dsRNA structure, usually 
formed between the exonic editing site and a downstream intron sequence (Lomeli et 
al., 1994; Higuchi et al., 2000).  
In attempt to study a control case when we were blinded to any clinical information, 
we studied RNA editing of one case which was later reported as a case of Pick’s 
disease. Pick’s disease is a form of frontotemporal dementia characterized by 
shrinking of the frontal and temporal anterior lobes of the brain and progressive 
deterioration of social skills leading to impairment of intellect, memory, and language 
(Gustafson, 1987). Pick’s disease is characterised by loss of neurons and gliosis of 
white matter in the frontal cortex and temporal cortex (Yamakawa et al., 2006), and 
abnormal accumulation of tau protein resulting in Pick bodies. (Mimuro et al., 2010). 
It has been demonstrated that these Pick bodies are immunoreactive for HO-1, an 
oxidative stress marker, in the cerebellar cortex compared to controls. The damage 
caused by oxidative stress and free radicals may further lead to excitotoxicity which 
have been implicated in wide range of neurodegenerative diseases including 
Alzheimer’s disease, Pick’s disease and ALS (Castellani et al., 1995; Van Den Bosch 
et al., 2006a).  Pick cases have not been previously examined in GLUR2 editing and 
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future work would require increasing number of cases and studying RNA editing of 
GLUR2 in other editing sites. 
GLUR2 was fully edited at Q/R site in the motor cortex, frontal cortex, and spinal cord 
and in MNs of a series ALS cases and controls.  This finding is in agreement with 
previous studies that showed complete GLUR2 editing in various CNS regions of the 
cerebellum, hippocampus, MNs, motor cortex and temporal cortex of control groups 
(Kwak et al., 2008; Zhu et al., 2012) (see table 3.6).  
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Table 3.6: Summary of GLUR editing at Q/R site of various diseases. 
 RNA editing levels of GLURs in SALS patients and other neurodegenerative diseases such as epilepsy and spinal muscular atrophy. Abbreviation: 
 N/A-not available, GLUR- glutamate receptors, Q/R site- glutamate/arginine, MNs-motor neurons, SBMA-spinal and bulbar muscular atrophy, 
SALS-sporadic ALS.  
 
Percentage (%) of editing of  GLUR2 at Q/R 
 Purkenji 
cells 
MNs Motor cortex Hippocampus Cerebellum Temporal cortex Frontal cortex References 
 
Control  100 100 100 100 100 100 100 (Kwak et al., 2008; Zhu et al., 2012) 
SALS  100 0-100 100 N/A N/A N/A N/A (Kwak & Kawahara, 2005; 
Kawahara et al., 2006; Kwak et al., 
2008) 
SBMA N/A 100 N/A N/A N/A N/A N/A 
Epilepsy N/A N/A N/A 100 N/A 100% N/A (Kortenbruck et al., 2001) 
Percentage (%) of editing of  GLUR5 at Q/R 
 Motor cortex Hippocampus Cerebellum Temporal  cortex Frontal cortex  
Control  57-70 N/A 43 60 60 (Zhu et al., 2012) 
Epilepsy N/A 33-66 N/A 49-75 N/A (Kortenbruck et al., 2001; Vissel et 
al., 2001) 
Percentage (%) of editing of  GLUR6 at Q/R 
  Motor cortex Hippocampus Cerebellum Temporal  cortex Frontal cortex  
Control 80 N/A 81 81 81 (Zhu et al., 2012) 
Epilepsy N/A 41-80 N/A 65-84 N/A (Kortenbruck et al., 2001; Vissel et 
al., 2001) 
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The observed complete editing of ALS/C9ORF72-positive patients and 
ALS/C9ORF72-negative patients are in agreement with previous reports that show 
complete GLUR2 editing in motor cortex of SALS (Kwak et al., 2008). However, the 
level of GLUR2 editing in the MNs of ALS patients is in disagreement with previous 
report indicating that altered GLUR2 editing was specific to MNs of SALS patients 
(Takuma et al., 1999; Kawahara et al., 2004). Different data might be because of the 
following (i) these reports had focused on GLUR2 editing in the spinal cord 
specifically the ventral and dorsal horn of the grey matter of the spinal cord as whole 
tissue in SALS cases and controls (ii) they also examined less number of MNs (n=10 
to 17 cells) from 5 cases (iii) their SALS cohort was not well defined (Takuma et al., 
1999; Kawahara et al., 2004). However, we were able provide  a consistent  levels of 
a complete GLUR2 editing in  more ALS patients, characterised ALS cases with and 
without C9ORF72 expansion, more MNs were also isolated (n=200 cells). All these 
factors may contribute to different GLUR2 editing quantification.   
Studies had also reported complete GLUR2 editing at Q/R site of non-ALS diseases 
such as spinal  and bulbar muscular Atrophy (SBMA) and  epileptic patients (Kwak et 
al., 2008). In disagreement with previous studies, our findings showed less edited 
GLUR2 of 84% in the motor cortex of a Pick’s disease patient. We have also shown 
less edited GLUR2 in other CNS regions including thalamus, temporal and cerebellum 
of this patient however, these data demonstrate a single PCR of one patient. Future 
work of an increased number of Pick’s cases is required to confirm editing levels of 
GLUR2 as well as investigating GLUR2 editing in spinal cord and in MNs to determine 
whether this data is reproduced. 
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In the study of GLUR5 and GLUR6, variable RNA editing levels were observed in the 
spinal cord and in MNs of ALS/C9ORF72-positive and ALS/C9ORF72-negative 
patients and in controls. The observed variability within RNA editing of GLUR5 and 
GLUR6 in our data were also reported in the hippocampus of epileptic patients 
showing 33-66% editing and 41-80% editing respectively (Kortenbruck et al., 2001; 
Zhu et al., 2012) (see table 3.6). This might be explained by variations from tissue to 
tissue and/or variations between cases. However, GLUR5 and GLUR6 RNA editing 
found in epilepsy had similar levels to ALS, suggesting that these subunits are not 
specifically linked to certain region or ALS disease nor it is linked to excitotoxicity in 
ALS. 
Studies have suggested that deficient ADAR2 activity in MNs of SALS patients occurs 
before abnormal GLUR2 RNA editing at the Q/R site, consequently resulting in Ca
+2 
permeable AMPA receptor- mediated mechanisms (Aizawa et al., 2010; Hideyama et 
al., 2012a; Yamashita & Kwak, 2013; Kubota-Sakashita et al., 2014). In the current 
study the mRNA expression of ADAR2 in spinal cord was increased in the ALS cases, 
which might be due to faulty regulation in ALS to compensate for a reduced level of 
ADAR2 expression by the editing of its own pre mRNA. Auto-editing of ADAR2 has 
been proposed to be a mechanism for ADAR2 to balance its own expression (Rueter et 
al., 1999; Feng et al., 2006; Wahlstedt et al., 2009). Studies have shown that ADAR2 
editing its own pre-mRNA at a site within intron 4 that creates an alternative splice 
site (Rueter et al., 1999) and the splicing at this alternative site (-1) resulted in loss of 
ADAR2 protein, ADAR2 auto-edits itself to regulate and control protein expression 
(Wahlstedt et al., 2009).  
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Interestingly, the expression levels of ADAR3 were not altered in SALS with and 
without C9ORF72 expansion compared to controls. One possible reason maybe that 
ADAR3 is mainly expressed in the thalamus and amygdala and less expressed in the 
spinal cord (Chen et al., 2000). Another possible reason is the small numbers of cases 
used in this study. This may suggest that ADAR3 does not compete or enhance ADAR2 
expression (Savva et al., 2012; Tomaselli et al., 2013; Washburn, 2014). Therefore, 
ADAR3 does not appear to play a role in RNA editing of GLUR2, GLUR5 and GLUR6 
and that there is no obvious relationship between mRNA expression of ADAR2 or 
ADAR3.  
Aberrant alternative splicing of EAAT2 may contribute to glutamate-mediated 
excitotoxicity in ALS. In a previous study, truncated mRNA species of exon 4 and 
exon 9 have been detected in the motor cortex of ALS patients (Lin et al., 1998). 
However, later studies have shown these aberrant transcripts detected in both ALS 
patients and control samples (Meyer et al., 1999; Flowers et al., 2001). In support of 
these findings, exon skipping and exon retention were present in astrocytes of the 
grey matter of the spinal cord, in both control and SALS patients (Meyer et al., 1999; 
Flowers et al., 2001). The normal EAAT2 transcripts (EAAT2+4 and EAAT2+9) and 
the aberrant EAAT2 transcripts (EAAT2 Δ4 and EAAT2 Δ9), both showed a trend of 
increased expression in ALS patients with the C9ORF72 expansion. The lack of a 
significant association might be due to the small number of samples in each group 
and the case-to-case variation within the SALS cases in expression of the C9ORF72 
gene. The aberrant RNA metabolism of EAAT2 in ALS C9ORF72 expansion carriers, 
might provide early evidence for aberrant RNA metabolism to occur as part of the 
pathogenic mechanism (Lin et al., 1998; Renton et al., 2011).  
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Since the C9ORF72 repeat is known to sequester HnRNPs (Cooper-knock et al., 
2014), it is likely to influence splicing behaviour in some way and hence there may be 
an impact on previous results where the distinction was not made between 
ALS/C9ORF72-positive and ALS/C9ORF72-negative cases. 
The LCM-isolated MNs required optimisation of the techniques for RNA preparation, 
RT-PCR and their restriction digests. Initially, GLUR2, GLUR5 and GLUR6 RT-PCRs 
were optimised on a commercially available universal human reference RNA 
(UHRR). The use of UHRR helped to conserve the valuable human RNA samples 
from the brain bank  and assisted the optimisation of RT-PCR experiments especially 
when working with very low-input quantities of RNA as is required with patient 
samples (Novoradovskaya et al., 2004). Once the PCR conditions for the glutamate 
receptor were optimised on the UHRR, experiments were repeated on FFPE spinal 
cord sections of SALS patients. FFPE material was used because of its superior 
histology, greater availability and the neuropathology of the archive material was well 
characterised. However, tissue fixation reduces the efficiency of PCR because of 
protein cross-linking and RNA degradation. Therefore, RNA isolated from FFPE 
material was found to be a challenge for further molecular analyses (Ludyga et al., 
2012). As a result, frozen spinal cord tissues were used because of its improved RNA 
quality (Ludyga et al., 2012).  
The RNA editing levels of GLUR2, GLUR5 and GLUR6 at Q/R site were quantified 
using restriction digest to determine editing levels of GLURs at Q/R site because of its 
speed and efficiency. An alternative method is to sub-clone PCR products into vectors 
obtained from the PCR products and the editing transcripts analysed by sequencing. 
However, this method is expensive and time consuming because it requires many 
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sequence analyses to perform a reliable statistical analysis (Barbon et al., 2003). A 
more precise and sensitive method to quantify the efficiency of editing is to use qPCR. 
This method discriminates between edited and unedited transcripts in a more precise 
and sensitive manner compared to the other two methods because of time and resource 
restraints (Lyddon et al., 2012). 
In summary, the current study demonstrates that GLUR2 is fully edited in MNs of 
SALS and controls, highlighting that not all SALS cases have abnormal GLUR2 
editing and suggesting other factors contribute to excitotoxicity in ALS. In contrast to 
GLUR2, GLUR5 and GLUR6 had lower levels of RNA editing in all tissue examined 
suggesting that these editing levels were not only found in ALS but also in other 
neurological diseases. Other factors contributing to excitotoxicity may include the 
abnormal regulation of ADAR2 and/or aberrant EAAT2 transcripts. ADAR3 neither 
competes with ADAR2 nor is found to be linked to RNA editing of GLUR2, GLUR5 
and GLUR6. Although these data were not statistically significant owing to the small 
number of cases (n=15) and variation in post-mortem tissue, however, it may give a 
clue to understand some of the key mechanisms in ALS. Future work to examine RNA 
editing in a larger cohort as well as studying the expression of GLUR2 and ADAR2 in 
MNs is required. 
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Chapter 4: Neuropathological characterisation of ALS tissue 
 
4.1 Introduction 
One of the proposed pathogenic mechanisms of ALS is selective motor neuron (MN) 
death mediated by excitotoxicity resulting from an AMPA receptor subunit with 
deficient or unedited GLUR2 (Carriedo et al., 1996; Kwak & Kawahara, 2005; 
Kawahara et al., 2006). GLUR2 editing is catalysed by ADAR2, and is believed to be 
complete at birth. However, it is suggested that incomplete GLUR2 editing might be 
linked to sporadic ALS disease (Kwak & Kawahara, 2005; Kawahara et al., 2006).  
As discussed earlier, GLUR2 editing is mediated by the ADAR family of enzymes 
specifically ADAR2. Whereas, ADAR3 has shown to be catalytically inactive however, 
studies have suggested that ADAR3 might have a role in ALS with C9ORF72 
expansion repeats in iPSNs. A group has found ADAR3 within the complex of the 
C9ORF72 repeats in the iPSNs tissue of ALS C9ORF72 without further 
characterisation of the role of ADAR3 in ALS with C9ORF72 nor its relation to RNA 
editing (Almeida et al., 2013; Donnelly et al., 2013; Todd & Paulson, 2013). 
Additionally, ADAR3 has been suggested to compete with ADAR1 and ADAR2 for 
binding substrates thereby changing the editing profile (Savva et al., 2012). 
 Studies have demonstrated that expression of ADAR1 and ADAR2 are associated 
with the nucleolus and ADAR3 is localised in the nucleolus and cytoplasm of human 
tissue (Desterro et al., 2003; Sansam et al., 2003; Savva et al., 2012).  The localisation 
of ADAR2 has been shown to be exclusively in the nuclear fraction of human cortex 
tissue, and is further supported by the nucleolar ADAR2 immunoreactivity observed 
in the nuclei of motor neurons of control human spinal cord (Aizwa et al., 2010). It 
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should be noted that ALS patients’ neurons which displayed ADAR2 nuclear 
immunoreactivity were devoid of TDP-43 inclusions. (Aizawa et al., 2010). 
Conversely ADAR2-negative neurons contained TDP-43 positive inclusions, 
suggesting that reduced ADAR2 activity is linked to the formation of TDP-43 
inclusions by altering GLUR2 Q/R site-editing or some other editing behaviour in 
motor neurons of SALS patients (Aizawa et al., 2010; Hideyama et al., 2012a; 
Yamashita & Kwak, 2013). TDP-43 is cleared from the nucleus to form inclusions in 
the cytoplasm under the following stress conditions: (i) over expression, (ii) 
interference with its nuclear localisation signal, and (iii) when the individual has a 
pathogenic TDP43 mutation. These TDP-43 cytoplasmic inclusions are typical for the 
phenotype of ALS (Neumann et al., 2006a; Lagier-Tourenne & Cleveland, 2009; Ince 
et al., 2011a) and FTLD.  Abnormal TDP-43 cytoplasmic inclusions are associated 
with both ubiquitin positive and tau-negative cortical neurons of FTLD patients and 
motor neurons of SALS patients (Arai et al., 2006). TDP-43 and p62 compact and 
skein-like inclusions have also been demonstrated in the spinal cord of ALS and in 
FTLD cases, both with and without the C9ORF72 mutation (Al-Sarraj et al., 2011; 
Cooper-Knock et al., 2012).  
A further contributory factor in the potential excitotoxic cascade that leads to ALS 
may include dysfunction of EAAT2 which plays an important role in regulating 
glutamate at the synapse (Rothstein et al., 1990; Lin et al., 1998). Studies have 
demonstrated dramatic increases in glutamate levels in the cerebrospinal fluid of ALS 
patients and reduced EAAT2 in isolated synaptosomes from the motor cortex and the 
spinal cord (Rothstein et al., 1992). In support of these findings, immunohistochemical 
and western blot analysis has revealed a significant loss of EAAT2 protein both in the 
motor cortex and spinal cord of ALS patients (Rothstein et al., 1995). In contrast no 
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significant difference in either EAAT1 or glial fibrillary acidic protein (GFAP) has 
been detected in ALS patients, indicating that the defective change is specific to 
EAAT2 glutamate transporter expression (Bristol & Rothstein, 1996). Although some 
studies have suggested that aberrant transcripts of EAAT2 play  critical roles in the 
downregulation of EAAT2 protein levels in ALS patients (Lin et al., 1998; Meyer et 
al., 1998; Meyer et al., 1999), others have shown that these aberrant transcripts are 
also present in neurologically normal controls (Honig et al., 2000; Flowers et al., 
2001). The EAAT2 alternatively spliced variants that have been described are exon 4 
(EAAT2Δ4) and exon 9 (EAAT2Δ9) skipping. Normally,  exon 4 and exon 9 encode 
regions of EAAT2 involved in the trafficking of glutamate from the extracellular space 
into the cytosol of astrocytes (Yernool et al., 2004; Reyes et al., 2009). The literature 
is currently lacking investigations on exon 9 and 4 excluded transcripts (EAAT2Δ9, 
EAAT2Δ4); both encoding crucial motifs, in relation to a deficient or total loss of 
EAAT2 expression in ALS/C9ORF72-positive compared to ALS/C9ORF72-negative 
ALS patients. Such an investigation may identify changes in excitotoxic pathways 
which contribute to neurodegenerative pathology.  
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Hypothesis 
 MNs from ALS/C9ORF72-positive patients have more inclusions than 
ALS/C9ORF72-negative patients.  
  GLUR2 protein levels dose not contribute to GLUR2 editing.   
 Decreased ADAR2 and EAAT2 expression in ALS contributes to 
excitotoxicity mediated MN loss. 
  Altered ADAR3 expression is not linked to ADAR2 and GLUR2 editing.  
Aim 
Identify the neuropathological features of motor neurons and astrocytes in the thoracic 
spinal cord of a well characterised cohort of ALS/C9ORF72-positive and 
ALS/C9ORF72-negative compared to non-neurological controls.  
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4.2 Results 
4.2.1 Cases used in this study 
In this chapter FFPE ALS tissue with and without C9ORF72 repeat expansion (n=10) 
and non-neurological controls (n=5) were used to study the following proteins; p-
TDP-43, p62, GLUR2, ADAR2, ADAR3, GAFP and EAAT2 (see table 4.1). 
Table 4.1: FFPE thoracic spinal cord tissue of ALS cases. 
Available FFPE thoracic spinal cord of ALS/C9ORF72-positive and ALS/C9ORF72-
negative cases and controls free from neurological disease. Cases were matched 
closely as possible in their clinical information, spinal cord location. The p-TDP-43, 
p62, GLUR2, ADAR2, ADAR3, GAFP and EAAT2 proteins were characterised by 
immunohistochemistry. Abbreviation: n/a-not available.   
 
 
Case 
number 
Block  
Number 
Area/Level Site of onset PMI  in 
hours 
Sex Age  at 
onset 
Age   at 
death 
ALS/C9ORF72-positive cases 
LP83/10 34 T11 Limb 13 Male 67 79 
LP081/09 29 T11 Limb 60 Male 57 59 
LP041/04 6 T11 Bulbar 48 Male 62 64 
LP039/11 26 T11 Limb 96 Male 70 72 
LP040/11 25 T11 Limb 10 Female 72 77 
ALS/C9ORF72-negative cases 
LP014/11 24 T11 Limb n/a Male 49 51   
LP005/11 30 T11 Limb 40 Female 62 67  
LP023/10 7 T11 Limb 24  Female 34 42 
LP005/10 23 T11 Limb 96 Male 38 40 
LP094/09 25 T11 Bulbar 48 Male 62 63 
Controls 
LP005/07 13 T11 n/a 12 Male n/a 64 
LP085/07 25 T11 n/a 5 Female n/a 82 
LP098/07 25 T11 n/a 63 Male n/a 67 
035/96 8 T11 n/a 14 Female n/a 87 
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4.2.2  p-TDP43 and p62 pathology in ALS patients 
Detailed analysis of MN pathology in the anterior horn of human thoracic spinal cord 
sections was compared between non-neurological control cases, ALS/C9ORF72-
positive and ALS/C9ORF72- negative cases (see table 4.1).  
Proteasomal degradation marker (p62) and p-TDP-43 proteins were assessed blinded 
to any clinical information using a semi-quantitative manual scoring system based on 
the distribution and immunoreactive pattern of protein expression. Negative and 
isotype antibody controls confirmed the specificity of the immunostaining profile.  No 
inclusions were observed in any of the 5 controls (see figure 4.1a & 4.2a).  
MNs of ALS cases contained p62+ and p-TDP-43+ cytoplasmic inclusions. These 
included compact round (see figure 4.1c & 4.2d) or filamentous skein-like bodies (see 
figure 4.1d). Compact inclusions were occasionally observed in the cytosol of small 
oval shaped glia (see figure 4.1e & 4.2d).  
p62+ inclusions were only observed in ALS cases, p=0.0102. One out of 5 
ALS/C9ORF72-negative cases contained p62+ inclusions (1.67 ± 3.73) (mean ± SD).  
All ALS/C9ORF72-positive cases (5 out of 5) examined had p62+ inclusions in MNs 
(11.80 ± 10.94). ALS/C9ORF72-positive cases contained significantly more MNs 
with p62+ inclusions than MNs in ALS/C9ORF72-negative patients, p=0.0016 (see 
figure 4.4a).  
3 out of 5 of the ALS/C9ORF72-negative cases had MNs containing TDP-43+ 
inclusions (8.61 ± 15.75), in contrast to the other 2 cases of the same ALS/C9ORF72-
negative cohort which did not contain any inclusions. All ALS/C9ORF72-positive 
cases also displayed MNs containing inclusions (5 out of 5) (11.80 ± 10.94). The 
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number of MNs with p-TDP-43+ inclusions was significantly different in ALS cases 
compared to controls p= 0.0378 (see figure 4.3b), but did not significantly differ 
between ALS/C9ORF72-negative and ALS/C9ORF72-positive patients (p=0.0633) 
(see figure 4.4b).  
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Figure 4.1: p62 reactivity in MNs of the spinal cord of ALS patients.  
MN in non-neurological control cases did not contain p62 inclusions (a), in 
contrast to both ALS/C9ORF72-negative cases (b-c) and ALS/C9ORF72-
positive cases (d-e). MNs contained skein-like bodies (b, d) and compact 
inclusions (c). Compact inclusions were also detected in some glia (e), scale 
bars =50 µm. 
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Figure 4.2: p-TDP-43 reactivity in MNs of the spinal cord of ALS patients.  
MN in non-neurological control cases did not display any immunoreactivity for 
phosphorylated- TDP-43+, the pale cytoplasmic staining represents non-specific 
lipofuscin granules (a) in contrast to both ALS/C9ORF72-negative (b-c), 
ALS/C9ORF72-positive cases (d-e). MNs contained dense skein-like bodies (b-c, e) 
and compact inclusions (arrow) (d). Glia containing compact inclusions were also 
observed (box) (d), scale bar =50 µm. 
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Figure 4.3: p62 and p-TDP-43 inclusions in MNs of ALS cases. 
Analysed immunohistochemical staining of the spinal cord of ALS patients and 
controls. The percentage of MNs with inclusions was significantly higher in ALS 
patients compared to control samples, both for p62+ (p=0.0102) and p-TDP-43+ 
inclusions (p=0.0378). * denotes statistical difference using student T-Test 
(p˂0.05). 
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Figure 4.4: p62 and p-TDP-43 inclusions in MNs of ALS with and without 
C9ORF72 expansion.  
ALS/C9ORF72-positive cases displayed a significantly greater proportion of 
MNs with inclusions compared to ALS/C9ORF72-negative patients p=0.0016. 
(a), No difference in TDP43 pathology was observed between the 2 ALS groups 
(b), Data measured by one-way ANOVA.  
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4.2.3 The expression of GLUR2 in ALS patients 
The expression of GLUR2 in MNs was investigated using immunohistochemistry. The 
optimal working dilution of GLUR2 antibody which gave a highly specific staining 
pattern and minimal background staining was 1:50 (see figure 4.5a). Negative controls 
displayed no immunoreactivity, thereby confirming the specificity of the staining.  
Intense punctate immunopositive GLUR2 was observed in the endoplasmic reticulum 
(see figure 4.6 a-b), and the membranes of MN (see figure 4.6a-c). Occasionally, non-
specific pale granule staining of lipofuscin in the cytoplasm was observed, but was 
easily distinguishable from specific GLUR2 immunoreactivity (see figure 4.6b).  
MNs displaying no GLUR2 immunoreactivity were detected in ALS cases (mean ± 
SD: 1.73 ± 0.71) and in controls (2 ± 0.72). However, there was no statistical 
significance in the number of GLUR2- MN between ALS patients and controls 
(p=0.5884). ALS cases and controls showed similar levels of GLUR2+ staining in the 
membrane of 1.53 ± 1.14 and 1.53 ± 1.27 (p˃0.999), respectively. In contrast, MNs 
with GLUR2+ immunoreactivity associated with the ER were higher in controls (5.73 
± 1.96) compared to ALS cases (2.4 ± 1.69) (p=0.0127) (see figure 4.7).  
GLUR2 expression in ALS cases was further interrogated and any differences in 
staining between ALS/C9ORF72-negative and ALS/C9ORF72-positive cases was 
assessed. GLUR2-negative MNs were a feature of both controls (2 ± 0.72), 
ALS/C9ORF72-negative cases (1.6 ± 0.69) and in ALS/C9ORF72-positive cases 
(1.84 ± 0.79), p=0.7769. MNs with positive GLUR2+ membranes were observed in 
controls (1.53 ± 1.27), ALS/C9ORF72-negative patients (1.45 ± 1.02) and 
ALS/C9ORF72-positive patients (1.6 ± 1.2). Similarly, MNs with GLUR2+ 
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endoplasmic reticulum were also a feature of control cases (5.73 ± 1.86), 
ALS/C9ORF72-negative cases (1.75 ± 1.59) and ALS/C9ORF72-positive cases (2.92 
± 1.5594). There was no significant difference between controls, ALS/C9ORF72-
negative and ALS/C9ORF72-positive groups, either in the number of GLUR2 
negative MN (p=0.7769) or in the number of MN with GLUR2+ positive membrane 
staining (p=0.9836). In contrast, the number of MN with GLUR2+ positive 
endoplasmic reticulum significantly differed between controls, ALS/C9ORF72-
negative patients and ALS/C9ORF72-positive patients, p=0.0313 (see figure 4.8).  
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Figure 4.5: Optimisation of GLUR2 staining in the cingulate gyrus of a non-
neurological control case.  
The antibody against GLUR2 was used at the optimal dilution of 1:50, which gave 
positive GLUR2+ staining of both the endoplasmic reticulum (black arrow) and the 
membrane (red arrow) of neurons, with some GLUR2 negative neurons also observed 
(in box) (a).  This pattern of staining reduced as the dilution factor of the GLUR2 
antibody increased, giving a very weak signal in neurons when used at a dilution of 
1:400, which was difficult to distinguish from the non-specific staining of lipofuscin 
(black arrow) (b), scale bar=100µm. 
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Figure 4.6:GLUR2 staining of MNs in the anterior horn of spinal cord of ALS.   
Two patterns of GLUR2 immunoreactivity were detected in MNs, intense staining of 
the membrane (black arrow) and punctate, granular staining of the endoplasmic 
reticulum (green arrow) (a-c). MN negative for GLUR2 (in circle) as well as lipofuscin 
staining in the cytoplasm (red arrow) was also seen (b), scale bar=100µm.  
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Figure 4.7: The expression of GLUR2 in MNs of ALS. 
Panel (a) shows negative GLUR2 staining in MNs and panels (b) shows positive 
staining in the membrane. Panel (c) shows positive staining in the ER. No significant 
difference in the proportion of GLUR2- MNs was observed between ALS patients and 
controls (p=0.5884). GLUR2 staining in the membrane of MNs did not show any 
statistical significance in ALS and controls (p˃0.999). Whereas GLUR2 staining in 
ER was significantly higher in controls than ALS patients (p=0.0127). The statistical 
analysis was carried out by student T-Test. 
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Figure 4.8: The expression of GLUR2 in MNs of ALS with and without C9ORF72 
expansion. 
 Neither the proportion of GLUR2- (a), nor MN with GLUR2+ membrane 
immunoreactivity showed any significant difference across the three groups (b). In 
contrast, only GLUR2 
+endoplasmic reticulum showed statistical significance between 
controls, ALS/C9ORF72-negative and ALS/C9ORF72-positive cases p=0.0313 (c), 
as measured by one-way ANOVA.  
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4.2.4  ADAR2 and ADAR3 localisation in ALS 
Expression of ADAR2 and ADAR3 was investigated using immunohistochemistry. 
ADAR2 and ADAR3 antibodies were optimised to 1:100 and 1:200 respectively, 
selected because of the high specificity of the staining pattern and minimal background 
(see figure 4.9a & 4.10a). Negative controls confirmed the specificity of the staining 
pattern observed. ADAR2 immunoreactivity was exclusively associated with the 
nucleolus of MN. In contrast ADAR3 was predominantly detected in the cytosol, in 
addition to some nucleolar immunoreactivity. ADAR2 and ADAR3 were assessed 
semi- quantitatively and differences in the staining pattern analysed by student T-test.  
Weak and non-specific staining of lipofuscin was present in all cases, but was easily 
distinguished from the intense ADAR2 specific immunoreactivity. ADAR2 positive 
(see figure 4.11a) and negative (see figure 4.11e) nucleoli were observed in MNs 
throughout all controls (n=5) and ALS groups (n=10).  
ADAR3 displayed an intense punctate staining in the cytoplasm (see figure 4.12a) 
and/or positive staining in the nucleolus (see figure 4.12d) of MNs in both controls 
and ALS groups. Interestingly, ADAR3 was occasionally observed in the axons of 
MN (see figure 4.12f). 3 out 5 of controls had ADAR3+ staining in the nucleolus of 
MNs (mean ± SD: 1.43 ± 1.65) while 2 out of 5 of these cases were devoid of ADAR3+ 
staining. In 10 SALS patients compared to 5 controls, the expression of positive 
ADAR2 (p=0.9468) and ADAR3 staining (p=0.0834) in the nucleolus or ADAR3+ 
staining in the cytosol (p=0.6965) did not reach statistical significance (see figure 
4.13).  
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In controls, the total number of MN which had ADAR2 immunopositive nucleoli was 
25.19 ± 10.43. Similar to controls, ALS/C9ORF72-negative patients had also positive 
ADAR2+ nucleoli in MN (31.97 ± 11.58). ALS/C9ORF72-positive patients also had 
ADAR2+ in 19.28 ± 15.14 of MNs, except one case which lacked any ADAR2+ 
nucleoli. The difference in ADAR2 expression between all groups did not reach 
significance (p= 0.3974) (see figure 4.14a).  
All ALS/C9ORF72-negative cases (4.12 ± 3.32) and ALS/C9ORF72-positive cases 
(8.27 ± 5.70) had ADAR3+ in the nucleolus. ADAR3+ positive staining was seen in 
the cytosol of controls (48.42 ± 10.63), in ALS/C9ORF72-negative patients (37.08 ± 
42.64) and in ALS/C9ORF72-positive patients (71.69 ± 28.96). There was no 
significant difference between controls, ALS/C9ORF72-negative and 
ALS/C9ORF72-positive groups in either the number of MN with ADAR3+ nucleoli 
(p=0.0879) or cytosolic staining (p=0.2595) (see figure 4.14b & c). 
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Figure 4.9: Optimisation of ADAR2 antibody dilution.  
ADAR2 antibody was best optimised at a dilution of 1:100 using a microwave for the 
antigen retrieval. Positive nucleolar staining of MN (black arrow) (a). A similar pattern 
of staining was observed using an alternative method of antigen retrieval,  ADAR2+ 
nucleolar staining was detected (black arrow) and non-specific lipofuscin staining was 
observed (red arrow)  with non-specific staining in the back ground staining when the 
sections were pressure cooked, antibody 1: 100 dilution (b), scale bar=100µm  
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Figure 4.10: Optimisation of ADAR3 antibody dilution.  
ADAR3 antibody was best optimised at a dilution of 1: 200 and using a pressure 
cooker for the antigen retrieval. Punctate immunoreactivity was observed in the 
cytosol (black arrow), with no staining of the nucleolus (red arrow) (a). In contrast, a 
reduced intensity of staining and increased non-specific lipofuscin staining was 
observed in MNs using the microwave for the antigen retrieval (b), scale bar= 100µm. 
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Figure 4.11: Pattern of ADAR2 reactivity associated with MNs of spinal cord.  
ADAR2 was associated with nucleoli in MNs in non-neurological control cases (black 
arrow) (a-b), ALS/C9ORF72-negative (c-d) and ALS/C9ORF72-positive (e-f). Non-
specific lipofuscin was observed in the cytoplasm (box), but was easily distinguished 
from specific immunoreactivity (d-e). MNs contained ADAR2 positive (black arrow) 
(a-d, f) and ADAR2 negative nucleoli (red arrow) (c, e-f), scale bar= 50 µm.  
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Figure 4.12: Pattern of ADAR3 reactivity associated with MNs of spinal cord.  
Non-neurological controls (a-b), ALS/C9ORF72-negative (c-d) and ALS/C9ORF72-
positive (e-f) displayed punctate cytoplasmic staining positive for ADAR3 (black 
arrow) and negative nucleoli (green arrow) in these MNs. Lipofuscin was observed in 
the anterior horn of spinal cord (box) (c). ADAR3 immunopositive staining extending 
to the axons of MNs (f), scale bar represents 100um in b, e-f and 50um in a, c-d.  
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Figure 4.13: Expression levels of ADAR2 and ADAR3 in MNs of ALS patients. 
There was no statistical significance between ALS patients and controls in the 
proportion of ADAR2 (p=0.9468) and ADAR3 immunoreactive nucleoli (p=0.0834) 
(a-b) or ADAR3 immunoreactivity in the cytosol (p=0.6965) (c). The statistics was 
carried out using student T-test. 
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Figure 4.14: Expression levels of ADAR2 and ADAR3 in MNs of ALS patients 
with and without C9ORF72 expansion.  
No significant differences in the proportion of MNs positive for ADAR2 were detected 
in the nucleoli of controls, ALS/C9ORF72-negative and ALS/C9ORF72-positive 
cases, p= 0.3974 (a). Similarly, the proportion of ADAR3 positive MNs in the nucleoli 
(b) and in the cytosol (c) did not differ across the 3 groups, p=0.0879 and p=0.2595, 
respectively as measured by one-way ANOVA. 
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4.2.5 Expression of glutamate transporter EAAT2 in 
astrocytes of ALS cases 
Detailed characterisation of the astrocyte phenotype was performed to assess changes 
in astrocyte gliosis and function between the controls, ALS/C9ORF72-positive and 
ALS/C9ORF72-negative cases. GFAP and EAAT2 expression were quantified using 
image analysis.  
GFAP+ astrocytes were present throughout both the grey and white matter in both 
controls and ALS cases (see figure 4.15 & 4.16). GFAP immunolabelled distinct 
astrocyte cell bodies and processes throughout the grey matter (see figure 4.15). Loss 
of motor neurons and dense astrogliosis were observed in the grey matter of ALS cases 
(see figure 4.15b-c), while the white matter displayed a denser immunoreactive profile 
(see figure 4.16), with few individual astrocyte cell bodies readily identifiable in 
control cases (see figure 4.16a).  
EAAT2 immunolabelled delicate astrocyte processes in the grey matter of controls 
and ALS groups (see figure 4.17). Whereas, white matter showed weak staining of 
astrocyte process in controls (see figure 4.17a) and negative staining of EAAT2 in the 
ALS groups (see figure 4.17b-c). Loss of EAAT2+ astrocytes surrounding motor 
neurons was observed in the grey matter of ALS cases compared to controls (figure. 
4.17b-c). Very little staining of EAAT2 was observed in the white matter of ALS cases 
compared to controls (see figure 4.18).  
GFAP immunoreactivity was assessed in ALS patients (n=10) compared to controls 
(n=5), and analysed using student T-Test. Levels of GFAP+ immunoreactivity were 
significantly higher in ALS patients compared to controls, both in the grey matter 
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(p=0.0393) and the white matter (p=0.0198) (see figure 4.19 a-b). A decrease in 
EAAT2 protein was observed in both the grey matter of ALS patients (n=10) 
compared to controls (n=5) (p=0.4140) and in the white matter of these cases 
(p=0.7157), though this was not significant (see figure 4.19 c-d).  
GFAP expression in ALS cases was further interrogated and any differences in 
staining between ALS/C9ORF72-negative and ALS/C9ORF72-positive cases was 
assessed.  There was no significant difference in GFAP immunoreactive profiles in 
either the grey (p=0.1291) or white matter between controls, ALS/C9ORF72-negative 
and ALS/C9ORF72-positive cases (p=0.0742) (see figure 4.20a-b). Like GFAP, 
EAAT2 staining showed no statistically significant difference between controls, 
ALS/C9ORF72-negative and ALS/C9ORF72-positive cases in either the grey 
(p=0.4584) or white matter of the spinal cord (p=0.4734) (see figure 4.20 c-d).    
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Figure 4.15: GFAP reactivity in the grey matter of spinal cord of ALS patients. 
Control cases displayed intense GFAP immunoreactivity surrounding motor neurons 
(a). GFAP immunolabelled distinct astrocyte cell bodies and process in both 
ALS/C9ORF72-negative and ALS/C9ORF72-positive cases (b-c). The scale bar 
represents 100 µm on the left panels and 50 µm on the right. 
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Figure 4.16: GFAP reactivity in the white matter of spinal cord of ALS patients. 
Dense astrogliosis was observed in the white matter of control (a), ALS/C9ORF72-
negative (b) and ALS/C9ORF72-positive cases (c). A 100 µm scale bar prospective is 
presented on the left panels and a 50 µm scale bar prospective is presented on the right.  
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Figure 4.17: EAAT2 reactivity in the grey matter of spinal cord of ALS patients 
Control cases displayed a confluent pattern of EAAT2 throughout the grey matter (a). 
ALS/C9ORF72-negative cases displayed intense patchy, distinct EAAT2 staining 
surrounding motor neurons (b). ALS/C9ORF72-positive sections contained little 
EAAT2 staining, lipofuscin was observed in motor neurons (c), scale bar=100µm  
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Figure 4.18: EAAT2 reactivity in white matter of spinal cord of ALS patients 
Control group depicting of weak immunoreactive EAAT2 staining (a). Both 
ALS/C9ORF72-negative and ALS/C9ORF72-positive groups exhibiting almost non-
reactive white matter to EAAT2 (b-c), scale bar =100μm 
 
 
 
 
` 
153 | P a g e  
 
 
Figure 4.19: GFAP and EAAT2 reactivity in the grey and white matter of ALS 
patients. 
In the grey matter of spinal cord sections, GFAP immunoreactivity in the grey matter 
was significantly higher in ALS cases compared to controls (p=0.0393). Similarly, in 
the white matter of the spinal cord, GFAP immunoreactivity was significantly higher 
in ALS patients compared to controls (p=0.0198). In contrast, EAAT2 
immunoreactivity in both the grey and white matter of the spinal cord did not show 
any significant difference between the two groups (p=0.4585 and p=0.4734, 
respectively). The data was analysed using student T-Test. 
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Figure 4.20: GFAP and EAAT2 reactivity in the grey and white matter of ALS 
patients with and without C9ORF72 expansion. 
Levels of GFAP immunoreactivity between the 3 groups did not significantly differ in 
either the grey matter (p=0.1291) or the white matter of the spinal cord (p=0.0742) (a-
b). Similarly, levels of EAAT2 immunoreactivity did not significantly differ between 
the three groups in either the grey (p=0.4140) or white matter (p=0.7157), as measured 
by one-way ANOVA (c-d). 
 
 
 
 
 
 
 
 
` 
155 | P a g e  
 
4.3 Discussion 
The present study describes the detailed characteristics of MN pathology in the 
anterior horn of spinal cord of ALS patients, both with and without the C9ORF72 
mutation, in comparison to non-neurological controls. ALS cases contained 
significantly higher numbers of MN containing p62 and p-TDP43 inclusions than 
controls.  In contrast controls contained greater expression of GLUR2 associated with 
the ER. ALS cases were associated with increased astrogliosis and a reduction in 
EAAT2 immunoreactivity. 
TDP-43 is a DNA/RNA binding protein that is predominantly found in the nucleus. 
TDP-43 is involved in RNA regulation mechanisms including mRNA transport, 
stability, and splicing. However, the role of TDP-43 in the brain is poorly understood 
(Mackenzie et al., 2014). The formation of TDP-43 inclusion bodies is associated with 
the substantial reduction in the normal physiological TDP-43 nuclear staining. 
Additionally, pathological forms of TDP-43 undergo abnormal post-translational 
modifications including ubiquitination, N-terminal truncation and 
hyperphosphorylation (Neumann et al., 2006a; Neumann et al., 2009). Moreover, 
TDP-43 contributes to cell death via loss-of-function and gain-of-function 
mechanisms (Mackenzie et al., 2014). Any mutations or disruption of many ALS-
linked genes involved in protein homeostasis pathways such as p62 lead to TDP-43 
mislocalisation forming inclusions in the cytoplasm of  MNs of ALS patients (Seelaar 
et al., 2007; Cooper-Knock et al., 2012; Stewart et al., 2012).  
 In line with previous studies, the results of the current study demonstrate the 
pathology of ALS patients with C9ORF72 expansion (ALS/C9ORF72+) is 
indistinguishable from typical sporadic ALS patients (ALS/C9ORF72-), with 
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predominant MN degeneration and TDP-43 positive neuronal and glial cells 
inclusions. These pathological inclusions are consistently seen in the MNs of the 
spinal cord as well as upper motor neurons and lower brainstem (Mackenzie et al., 
2014). Evidence has shown TDP-43 pathology in a wide range of neuroanatomical 
regions including frontal and temporal cortex, hippocampus, thalamus, striatum, 
midbrain and substantia nigra (Murray et al., 2011; Hsiung et al., 2012). Interestingly, 
the current study demonstrates ALS/C9ORF72-positive patients have significantly 
higher levels of p62 positive inclusions compared to ALS/C9ORF72-negative 
patients, which confirms reports that this is a feature of cases containing the C9ORF72 
repeat expansion where higher levels of p62 were detected in neurons and glia in the 
anterior horn of the spinal cord, cranial nerve motor nuclei and motor cortex (Cooper-
Knock et al., 2012). These p62 positive inclusions were not only found in the 
cytoplasm of neurons but also in glial cell of ALS patients with the C9ORF72 repeat 
expansion (Al-Sarraj et al., 2011; Mackenzie et al., 2014). In 5 ALS/C9ORF72-
negative cases, only one case showed p62 immunorectivity in the thoracic spinal cord 
suggesting p62 inclusions. However, upon further analysis this case might be 
explained by the fact that the area of onset might be different. 
Although levels of p-TDP-43 were significantly increased in ALS cases compared to 
controls, in contrast to p62 the current study did not demonstrate any significant 
difference in the TDP-43 expression between ALS/C9ORF72-positive and 
ALS/C9ORF72-negative cases, which might reflect the presence of TDP-43 in an 
immature form which has not yet been sequestered in to inclusions, and/or possible 
abnormality in autophagy (Boillée et al., 2006; Cruts et al., 2013). p62 plays an 
important role in protein degradation by ubiquitin-proteasome system and 
autophagosome-lysosome pathways. When autophagy functions at normal rates, the 
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role of p62 is to deliver ubiquitylated proteins for autophagosomal damage.  However, 
when autophagy is compromised under pathological conditions, including 
neurodegenerative diseases, p62 binds non-selectively to ubiquitylated proteins and 
prevents their delivery to the proteasome for degradation. Therefore, the accumulation 
of p62 makes it difficult to serve as a substrate for the proteasome with its narrow 
catalytic pore (Korolchuk et al., 2010).  In the current study, MN of ALS patients with 
the C9ORF72 expansion contain higher levels of p62 inclusions compared to those 
SALS cases without the expansion.  This may be in part explained by three pathogenic 
mechanisms: (i) haploinsufficiency where loss of function occurs as a result of the 
C9ORF72 repeats, (ii) the expression of mutant C9ORF72 protein results in a gain of 
protein toxicity or (iii) RNA toxicity caused by the production of RNA repeats (La 
Spada & Taylor, 2010). Additional pathogenic mechanisms caused by the C9ORF72 
expansion might occur due to complementary repeat containing RNA produced by 
bidirectional transcription or dipeptide-repeat proteins resulted from non-ATG (RAN) 
translation (Ling et al., 2013; Mann et al., 2013) eventually leading to the production 
of potential toxic RNA and protein species.  
As previously mentioned, ADAR2 edits the double-stranded RNA of GLUR2 in a site-
specific manner (Bass, 2002; Keegan et al., 2004). Several lines of evidence have 
shown that decreased ADAR2 activity correlates with reduced GLUR2 editing at Q/R 
site in MNs of SALS patients and in mouse models of disease (Higuchi et al., 2000; 
Aizawa et al., 2010; Hideyama et al., 2010; Hideyama et al., 2012a; Yamashita & 
Kwak, 2013; Kubota-Sakashita et al., 2014). In agreement with these findings, the 
current study demonstrates that GLUR2 is significantly decreased in the endoplasmic 
reticulum of MNs of ALS/C9ORF72-negative and ALS/C9ORF72-positive cases 
compared to control cases. The present study did not find any significant difference in 
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ADAR2 and ADAR3 levels between control and SALS cases, which may reflect the 
small number of cases used (n=15). Extending the study to include a larger cohort 
would provide more insight. 
Recent studies have demonstrated a link between a reduction or absence of ADAR2 
in the nucleus of MNs and the formation of cytoplasmic TDP-43 inclusions in ALS 
(Aizawa et al., 2010; Hideyama et al., 2012a; Yamashita & Kwak, 2013). It has been 
suggested that TDP-43 is not an upstream event of inefficient GLUR2 RNA editing at 
Q/R site in the MNs of SALS patients but that deficient ADAR2 in these MNs occurs 
before abnormal GLUR2 editing and TDP-43 pathology (Hideyama et al., 2012b). 
TDP-43 over expression, TDP-43 knockdown and TDP-43 C- terminal fragments or 
TDP-43 mutations do not alter ADAR2 expression (Yamashita et al., 2012b). 
Interestingly, our data showed that the expression of ADAR3 protein was increased in 
the nucleolus and cytoplasm of MNs in ALS cases with the C9ORF72 expansion, this 
requires further investigation since the role of ADAR3 is not clear it is difficult to 
predict what effect it might have. As yet there is no literature on the subject.  
ADAR3 was found to colocalize with C9ORF72 repeats in induced pluripotent stem 
cells (iPSCs) that were derived from ALS/FTD patients with C9ORF72 repeats and 
mutant SOD1-ALS patients. Moreover, knocking-down ADAR3 expression results in 
the decrease of RNA foci, which implies that there is a functional interaction between 
ADAR3 and RNA repeats in vivo (Almeida et al., 2013; Donnelly et al., 2013; Todd 
& Paulson, 2013). Together these findings may provide a clue for the mechanism by 
which a member of the RNA editing enzyme family, namely ADAR3, may contribute 
to ALS pathology, in particular in ALS/C9ORF72-positive cases.  
 In line with previous reports, the grey matter in the spinal cord of ALS patients 
exhibited astrogliosis and increased of GFAP content were associated with loss of 
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MNs (Vargas & Johnson, 2010). These features of astrocytic response to injury have 
been observed in neurodegenerative diseases including ischaemia and Alzheimer’s 
disease (Simpson et al., 2010; Vargas & Johnson, 2010). 
 
Glutamate transporter dysfunction plays an important role in excitotoxicity-mediated 
MN degeneration. In the current study we demonstrate a reduction of EAAT2 
expression in the spinal cord of ALS patients, though this was not significant. This  is 
in agreement with previous reports of the decreased EAAT2 expression in the spinal 
cord and motor cortex of ALS patients, and in the hSOD1 mouse model (Rothstein et 
al., 1995; Milton et al., 1997; Vargas & Johnson, 2010). The non-significant 
difference in EAAT2 expression between controls and SALS groups likely reflects the 
small number of cases tested (n=15). Future experiments would require increased 
number of cases. 
The presence of p62 and p-TDP-43 inclusions in MNs in the grey matter of spinal cord 
is hallmark for ALS disease. The loss of EAAT2 surrounding MNs in the SALS cases 
is clear feature of excitotoxicity and neuronal death in ALS. ADAR2 protein was not 
associated with reduced GLUR2 protein in SALS cases however, sufficient GLUR2 
has to be edited to impact anion channel permeability. Data did not suggest if there is 
any interaction between ADAR2 and ADAR3. Future investigation of the detailed 
neuropathology of a larger cohort may help to elucidate the mechanism of MN injury 
in SALS.   
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Chapter 5: Next generation sequencing  
 
5.1 Introduction 
Illumina sequencing by synthesis (SBS) derived from the original work of 
Balasubramanian and Klenerman (Illumina). They used fluorescently labelled 
nucleotides to visualise the movement of DNA polymerase at a single molecule 
resolution. The synthesised DNA was immobilised to a solid substrate.  
This technology led to the formation of Solexa which was derived from the first SBS 
machines and was used to sequence the whole genome of the bacteriophage phiX-174 
in 2005, as a result, sequencing more than 3 million bases in a single run. The SBS 
technology was further developed by Illumina and is now able to generate gigabytes 
of data in a single run and sequence the entire genome in matter of days 
(http://www.illumina.com/technology/next-generation-sequencing/sequencing-
technology.html). 
 The fundamental architecture of this technology consists of flow cells that are 
composed of a series of channels running through a glass slide. The inside of the 
channels are arrayed with single stranded oligonucleotides that are the binding site for 
the material to be sequenced.  The library is derived from a fragmented double 
stranded DNA sequence, which may be fragments of DNA isolated using short 
nucleotide bait sequences, native genomic DNA or cDNA. 
The fragmentation is achieved by sonication or enzymatically when it is termed 
tagmentation. The double-stranded molecules are fragmented to sizes of around 150 
to 300 bases and have attached to each end a short index or barcode sequence and the 
complementary strand to the adapters that are arrayed on the flow cell. The index 
sequence is unique to each sample to allow the identification of samples in the 
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analysis. The library is applied in flow cell lane by lane followed by hybridisation 
using a piece of technology called the C-bot which enhances binding between target 
DNA and adaptor. The density of the hybridisation is critical and requires each strand 
to be distinct from its neighbour. 
As can be seen in figure 5.1, the Illumina system involves single-stranded DNA 
fragments to be ligated to adaptors, which then attach to glass surface flow cells. The 
process by which hybridization of DNA to the oligonucleotides on the flow cell occurs 
is by the active heating and cooling system. This is followed by and incubation with 
reactants and an isothermal PCR to amplify the fragments in a cluster on the surface. 
Within the sequencer, the flow cell is placed onto a movable stage and supplied with 
polymerase and distinct fluorophores for each labelled nucleotide. Labelled 
nucleotides are attached at a 3’-OH modified to ensure single base incorporation. This 
is followed by imaging to determine the incorporated nucleotides at each cluster and 
removing the fluorophore and the 3’-OH end at the beginning of the next cycle. The 
obtained data is analysed by filtering the low quality reads between 32 and 40bp, with 
each run yields yielding 40-50 million sequences (Mardis, 2008).  
The benefit of using this system allows production of large volumes of data in a time 
efficient manner. It enables sequencing small genomes without aligning to a reference 
sequence (also called de novo sequencing). However, de novo sequencing creates short 
single read sequencing that if continued leads to increased number of gaps in the data 
where no reads align. Consequently, fragmentation of sequence reads leads to data 
being obtained from a poor quality sample. 
Paired-end (PE) sequencing overcomes some of the issues encountered in de novo 
sequencing since it reads from both ends of a DNA fragment, thereby enabling greater 
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alignment especially in repetitive sequences. It yields longer fragments and fills gaps 
in sequences resulting in complete overall coverage (see figure 5.2) (Mardis, 2008; 
Fullwood et al., 2009). Additionally, little input DNA is sufficient to produce a library 
and sequence the paired ends of a given fragment. In this manner each molecule 
generates many reads that are dependent upon the amount of material in the original 
sample. In order to gain valuable information the right amount of sample must be 
determined. 
Short molecules require a small number of reads, while longer molecules need an 
increased number of reads. These longer molecules will have a number of possible 
variations including very rare occurrences, therefore an increased number of reads is 
necessary to determine the levels of all variants.   
Herein, RNA extraction was repeated three times to improve the RNA concentration. 
RNA was extracted from 200 MNs of 9 samples (4 ALS/C9ORF72-positive cases, 3 
ALS/C9ORF72-negative cases and 2 controls). The improved RNA concentration 
varied from 2ng/µl to 7ng/µl. 10ng of RNA was cleaned up to remove ribosomal RNA 
using MessageBooster whole transcriptome kit. RNA was sequenced and appeared to 
be read accurately and an appropriate depth was reached in a single lane. A read depth 
of greater than 30x for each sample was expected to be generated using paired end 
sequencing which should increase confidence in the accuracy of the data.  
The data is analysed as soon as it is generated by the sequencing analysis viewer 
software, (Illumina), which allowed real time monitoring of the quality control. 
Afterwards, the image files (BCL) is converted into usable format by another Illumina 
software bcl2fastq. The obtained sequences in the fastq text format are aligned to the 
known human sequence to determine variations and their levels.  
` 
164 | P a g e  
 
Previously, we have explored the levels of RNA editing of GLUR2, GLUR5 and 
GLUR6 in the spinal cord and MNs of SALS patients using restriction digests. We 
found complete editing of GLUR2 in both MNs and spinal cord in all sample groups. 
Whereas, GLUR5 and GLUR6 were found to be less edited in spinal cord and MNs of 
controls and patient groups. In this chapter, it was hoped to assess the levels of RNA 
editing with an independent method using next generation sequencing.  
 
Figure 5.1: The workflow of Illumina genome analyser. 
The workflow consists of single stranded hybridisation, bridge formation and cluster 
generation. One strand is cleaved and the other strand is sequenced via the adaptor by 
the addition of fluorescent nucleotides. The sequencing data is obtained by recording 
many images throughout the flow cell with every cycle or nucleotide added. This 
figure was obtained from (Mardis, 2008) with permission 3501860851558.  
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Figure 5.2: Sequencing of Paired-End libraries. 
This method enables the read of sequences from both ends to accurately align 
repetitive regions that are difficult to sequence, modified from Illumina, 2013 
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Hypothesis 
Use of next generation sequencing will allow in-depth analysis of the GLUR2, GLUR5 
and GLUR6 as well as ADAR2, ADAR3 and EAAT2 RNA species. 
Aim 
To develop new methodology to look at different levels of expression that might exist 
in ALS. 
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5.2 Results 
 
To accurately quantify editing status of GLUR2, GLUR5 and GLUR6, a DNA library 
was prepared from 9 cases; 3 ALS/C9ORF72-positive and 3 ALS/C9ORF72-negative 
and 2 controls (see table 5.1). The DNA library was quantified by qPCR and DNA 
chip bioanalyser. The qPCR did not show any results whereas, DNA chip bioanalyser 
was able to examine the library (see figure 5.3). In this study we are going to focus on 
two libraries that was believed to be prepared at a different DNA concentration; 
10pmol and 5pmol. Library of 10pmol library was loaded in lane 7 and half of the 
same library of 5pmol DNA concentration was loaded in lane 8.  
Table 5.1: Cases used in the study 
Available thoracic spinal cord of ALS/C9ORF72-positive and ALS/C9ORF72-
negative patients and controls. Abbreviation: N/A- not available  
 
 
 
Case 
number 
Block  
Number 
Area/Level Site of 
onset 
PMI  in 
hours 
Sex Age  at 
onset 
Age   at 
death 
ALS/C9ORF72-positive cases 
LP081/09 29 T11 Limb 60 Male 57` 59 
LP041/04 6 T11 Bulbar 48 Male 62 64 
LP039/11 26 T11 Limb 96 Male 70 72 
LP040/11 25 T11 Limb 10 Female 72 77 
ALS/C9ORF72-negative cases 
LP014/11 24 T11 Limb n/a Male 49 51   
LP005/10 23 T11 Limb 96 Male 38 40 
LP094/09 25 T11 Bulbar 48 Male 62 63 
Controls 
LP005/07 13 T11 n/a 12 Male n/a 64 
117/04 n/a n/a n/a n/a Male n/a 58 
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As shown in figure 5.4, the flow cell containing library formed clusters. Using 
sequence analysis viewer software from Illumina, each nucleotide base (A, T, C, G) 
were coloured with a distinctive colour to differentiate between bases. The intensity 
signal read these bases separately in the 1st DNA strand. The laser loses energy after 
50 cycles where a sharp peak was shown (see figure 5.5). When the reading of the 1st 
DNA strand was finished, Illumina sequencing software reads the 2nd DNA strand at 
100 cycles and more chemicals were added to boost the reading for the 2nd DNA strand 
(see figure 5.5). As shown in figure 5.6, the intensity signal of library number 7 and 
library number 8.  
The Phrd quality score (Q30) assess the accuracy of each step in the process including 
library preparation and reading alignment. It reveals how much of the data is usable 
and sequencing data with low Q30 means increased portion of the reads being 
unusable, which is likely to contain more errors. The percentage of >=Q30 yield of 
bases with Q30 or higher from clusters passing filter divided by total yield of clusters 
passing filter. The Q30 for the total number of 9 libraries were 82.2% (see figure 5.7). 
The signal density and passing filter (PF) did not overlap between signal density and 
PF in lane 7.  However, the signal density and PF were almost overlapped in lane 8 
(see figure 5.8). Additionally, the intensity signal of the 4 bases in lane 7 only were 
less separated and an overlapping between bases were seen in figure 5.9. The Q30 
score of the total samples in lane 7 was 57.2% (see figure 5.10). Bcl2fastq-1.8.4 
software showed 9 samples that had a different adaptors (index sequence). Each 
sample of ALS and controls produced quality control data of Q30 score of ˃ 41% and 
index reads of ˃ 33% in library number 7 on the flow cell (see table 5.2). This library 
was less diluted library with a decreased index values and Q30. Whereas, library 
number 8 on the flow cell had a more diluted library that showed higher Q30 of ˃ 42% 
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and index reads of ˃ 93% (see table 5.3). The percentage of index reads in both 
libraries had 1 mismatch to given index. 
 
 
Figure 5.3: DNA chip bioanalyser for DNA library.  
DNA library was quantified using DNA chip bioanalyser and each peak represent 
different variables; the first peak is a primer dimer, the second peak is an adaptors and 
the third peak is the library. 
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Figure 5.4: Flow cell containing clusters.  
Libraries in flow cells formed clusters, the reading was in two direction vertically and 
horizontally.  
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Figure 5.5: The base call quality of all libraries.  
The intensity signal of 9 libraries were viewed using sequence analysis viewer 
software. The average quality reads of the first, second, third and the fourth base 
degrades over the course of the sequence.  
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Figure 5.6: The quality call of library 7 and library 8. 
The average quality of the 4 bases over the course of the sequence showing high 
intensity signal.   
 
 
 
 
 
` 
173 | P a g e  
 
 
Figure 5.7: Q score heat map of libraries. 
The flow cell had 9 libraries that were run on Illumina Hi scan SQ system. The quality 
control of libraries were assessed by Q30. The green smear represented a high score 
of Q30 of 82.2% in the total number of libraries. 
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Figure 5.8: The level of cluster density and PF in each lane.  
The flow cell showed 9 lanes containing 9 different libraries, our samples are library 
7 (10pmol) and library 8 (5pmol). Cluster density in library 7 did not overlap with PF.  
Whereas, library 8 was almost overlapped between density and PF.  
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Figure 5.9: The base quality call of library number 7. 
The intensity signal of the first, second, third and the fourth nucleotides were less 
separated. This intensity signal was viewed using sequence analysis viewer software. 
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Figure 5.10: Q score heath map of library 7. 
Q30 score assessed quality control of sequencing that was viewed in Illumina Hi scan 
SQ system. Library 7 Q score heat map represented a drop in quality from 100% to 
57.2% 
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Table 5.2:  Quantitation statistics of the sequencing run for less dilute library 
The quality data produced from library number 7 on the flow cell. The most important values are index reads that were ˃ 33% and the Q30 that 
were ˃ 41%. The less dilute library had a decreased index values and Q30 suggesting it formed less cluster density. 
  
 
Lane Sample 
ID 
Sample Ref Index Control Yield 
(Mbases) 
% PF Reads % of raw 
clusters 
per lane 
% Perfect 
Index 
Reads 
% One 
Mismatch 
Reads 
(Index) 
% of >=Q30 
Bases (PF) 
Mean 
Quality Score 
(PF) 
7 005-07 Human TAGGCATG-
TAGATCGC 
N 1,496 100.00 16,090,152 10.59 34.00 63.64 56.60 26.39 
7 005-10 Human CAGAGAGG-
TAGATCGC 
N 1,169 100.00 12,570,684 8.28 33.69 64.09 66.14 28.83 
7 014-11 Human CGTACTAG-
TAGATCGC 
N 1,662 100.00 17,872,240 11.77 33.61 63.97 50.54 24.42 
7 039-11 Human TCCTGAGC-
TAGATCGC 
N 567 100.00 6,095,050 4.01 33.61 62.65 47.43 23.90 
7 041-04 Human CGAGGCTG-
TAGATCGC 
N 2,280 100.00 24,521,456 16.15 34.17 63.92 69.09 29.95 
7 040-11 Human TAAGGCGA-
TAGATCGC 
N 2,547 100.00 27,384,980 18.03 34.09 63.48 54.96 26.00 
7 081-09 Human CTCTCTAC-
TAGATCGC 
N 932 100.00 10,020,296 6.60 33.67 64.01 55.19 25.66 
7 094-09 Human GCTACGCT-
TAGATCGC 
N 1,323 100.00 14,227,020 9.37 33.32 63.56 46.40 23.41 
7 117-04 Human GGACTCCT-
TAGATCGC 
N 1,055 100.00 11,339,190 7.47 33.17 63.06 41.04 22.11 
7 unknown Undetermined 
Clusters with 
unmatched 
barcodes for 
lane 7 
N 
Undetermi
ned_ 
indices 
1,093 100.00 11,755,642 7.74 0.00 0.00 50.00 
` 
178 | P a g e  
 
Table 5.3: Quantitation statistics of the sequencing run for more dilute library. 
The quality data produced from library number 8 on the flow cell. The most important values are index reads that were ˃ 93% and the Q30 that 
were ˃ 42%. For these it appears that the more dilute library has generated better values suggesting it had a better cluster density and that this 
allowed cleaner sequencing. 
 
Lane Sample ID Sample Ref Index Control Yield 
(Mbases) 
% PF Reads % of 
raw 
clusters 
per lane 
%Perfect 
Index 
Reads 
% One 
Mismatch 
Reads 
(Index) 
% of >= Q30 
Bases (PF) 
Mean Quality 
Score (PF) 
8 005-07 Human TAGGCATG-
TAGATCGC 
N 1,051 100.00 11,298,434 11.73 95.04 4.92 63.55 27.96 
8 005-10 Human CAGAGAGG
-TAGATCGC 
N 784 100.00 8,430,244 8.76 95.40 4.56 75.69 31.01 
8 014-11 Human CGTACTAG-
TAGATCGC 
N 1,184 100.00 12,728,112 13.22 95.27 4.69 56.92 25.73 
8 039-11 Human TCCTGAGC-
TAGATCGC 
N 391 100.00 4,204,490 4.37 93.78 6.15 50.97 24.61 
8 041-04 Human CGAGGCTG-
TAGATCGC 
N 1,539 100.00 16,551,410 17.19 95.40 4.56 78.79 32.29 
8 040-11 Human TAAGGCGA-
TAGATCGC 
N 1,673 100.00 17,990,488 18.68 95.00 4.96 61.43 27.47 
8 081-09 Human CTCTCTAC-
TAGATCGC 
N 635 100.00 6,828,498 7.09 95.24 4.71 62.69 27.29 
8 094-09 Human GCTACGCT-
TAGATCGC 
N 795 100.00 8,544,190 8.87 93.62 6.27 50.03 24.05 
8 117-04 Human GGACTCCT-
TAGATCGC 
N 679 100.00 7,306,320 7.59 93.64 6.27 42.78 22.29 
 
8 
 
Unknown 
 
Undetermined 
Clusters with 
unmatched 
barcodes for 
lane 8 
N 224 100.00 2,406,288 2.50 0.00 0.00 50.51 24.41 
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Figure 5.11: DNA chip bioanalyser of library samples. 
 Panel a. is sample 05/07 & panel c. is sample 81/09, both had shown two peaks; one 
is adaptor dimer and the second is a library. Whereas, panel b. is sample 40/11 and 
panel d. is 14/11, both showed only adaptor dimer with no library detected.  
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Reads were mapped to the human genome UCSC hg19 using Bowtie (Langmead et 
al., 2009). Expression values for transcripts were generated using Bitseq (Glaus et al., 
2012). In particular, we utilised an implementation of transcript expression inference 
utilising Variational Bayes algorithmics within Bitseq 
(http://arxiv.org/pdf/1308.5953.pdf).  
The percentage of mapped reads was very low, <0.1% for most samples; however in 
certain cases the number was higher. The reason for this is unclear, perhaps the 
degraded RNA extracted from post-mortem laser captured neurons was too degraded 
to provide accurate mapping. The samples with mapped reads were 40/11 (5.4%), 
14/11 (21%), 81/09 (25%) and 05/07 (10%) samples however, only samples 05/07 and 
81/09 had shown a library to be mapped to the human genome whereas, samples 41/11 
and 14/11 did not show a library therefore the percentage of mapping reads were not 
accurate and maybe mapped to adaptor dimers (see figure 5.11). 
As can be seen in table 5.4, ENST00000529637 is transcript from ENSG00000090686 
gene which is an ubiquitin specific peptidase 48. ENST00000270722 is also transcript 
for ENSG00000142611 gene which is a PR domain containing 16. Both transcripts 
were mapped to human genome and demonstrated high reads similar to the 
comparative data set (see appendix II). Most of the data showed very similar levels of 
expression for all transcripts including those of interest. However, some transcripts as 
indicated in figure 5.11 were variable demonstrating a low level of differential 
expression. 
Table 5.4: Mapping reads to the human genome. 
 
Gene 005-07 
Control 
014-11 
ALS/C9ORF72
negative 
041-11 
ALS/C9ORF72
positive 
081/09 
ALS/C9ORF72
positive 
Comparative 
data set 
ENST00000529637 6.36E-07  2.93E-07   4.38E-07  6.68E-05 6.68E-05 
ENST00000270722 6.36E-07  4.40E-07  7.00E-07  4.38E-07  6.12E-07 
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5.3 Discussion 
Next generation sequencing was used in order to try and study the differential 
expression of GLUR2, GLUR5 and GLUR6 editing and ADAR2, ADAR3 in ALS 
tissue. However, this approach was not successful due to poor quality and quantity of 
RNA that were used which did not allow generation of full data set. The methodology 
found to be valid in other libraries but optimisation of the conditions to generate more 
accurate data sets was needed. There might be a number of reasons for unsuccessful 
reads in next generation sequencing. (i) The production of adapter dimer led to 
unsuccessful alignment to the human genome. (ii) Very short reads were also observed 
and paired-end sequencing was not successful in some of the samples. (iii) Small 
number of MNs and degraded RNA tissue is likely to have contributed to the 
unsuccessful experiment. Future studies require repetition of the experiment with 
better library preparation. Other potential quality control that could be performed prior 
to running the experiment is align trimmer that removes aligned sequences of adaptors, 
primers and barcode indexes in both ends of sequence reads. Such alien sequences 
improve the quality of results for downstream analyses (Criscuolo & Brisse 2013). 
To conclude, there was no differential gene expression in GLUR2, GLUR5 and 
GLUR6 or in ADAR2, ADAR3 and EAAT2. However, the fact that some differential 
expression was observed indicated that the methodology might be valid in a future 
experiment with greater optimisation. 
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Chapter 6: General Discussion 
 
6.1 Discussion 
 
The vulnerability of MNs to injury in sporadic ALS may result from excitotoxicity 
mediated by abnormal Ca+2-permeable AMPA receptors. Abnormal RNA editing of 
AMPA receptor GLUR2 at the Q/R site is a plausible pathogenic mechanism leading 
to MNs death in ALS (Kwak & Kawahara, 2005). Therefore, the current research 
tested the hypothesis that altered glutamate receptor editing in MNs is relevant to the 
pathogenesis of ALS. Whilst GLUR2 mRNA editing was 100% in MNs, the protein 
levels were reduced in the ER of these MNs in ALS cases, both with and without the 
C9ORF72 expansion, demonstrating that RNA editing of GLUR2 is not linked to the 
observed reduction of GLUR2 protein.  
These findings are in contrast to reports of abnormal GLUR2 editing in MNs of SALS 
cases (Takuma et al., 1999; Kawahara et al., 2004; Kwak & Kawahara, 2005), which 
likely reflect the pre-mortem hypoxia-associated ADAR2 changes arising from 
prolonged duration on a respiratory machine (Nevo-Caspi et al., 2011). Furthermore, 
these studies investigated RNA editing of small number of MNs, which may not 
represent the dominant status of GLUR2, GLUR5 and GLUR6 editing in the MN 
population. Moreover, these reports also studied GLUR2 editing in the spinal cord, 
specifically the ventral and dorsal horn of the grey matter of the spinal cord as whole 
tissue in SALS cases and controls. Additionally, they have also examined MNs from 
5 SALS cases of a cohort that was not well defined (Takuma et al., 1999; Kawahara 
et al., 2004). In contrast to these reports, the current study clearly and consistently 
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demonstrates complete GLUR2 editing in SALS patients, both with and without the 
C9ORF72 expansion.  
The RNA editing levels of GLUR5 and GLUR6 in MNs of SALS cases, both with and 
without the C9ORF72 expansion, were also examined since they too are catalysed by 
ADAR2. The RNA editing levels in GLUR5 and GLUR6 were not consistent in MNs, 
spinal cord, frontal cortex and motor cortex and/or in multiple ALS cohort including 
ALS cases with and without C9ORF72 expansion. 
Whilst GLUR5 and GLUR6 editing has, to date, not been investigated in ALS, the 
observed variability of RNA editing levels within our cohort are similar to those 
reported in the hippocampus from epileptic patients (Kortenbruck et al., 2001), 
suggesting that a mixed level of editing of these subunits is not specifically linked to 
certain anatomical brain regions or specific disease entities.  
ADAR2 edits the double-stranded RNA of GLUR2 (Bass, 2002; Keegan et al., 2004). 
Elevated expression of ADAR2 mRNA was detected in the spinal cord of SALS cases, 
both with and without C9ORF72 expansion, compared to controls. In contrast, MNs 
showed reduced ADAR2 protein in SALS cases with C9ORF72 expansion, which may 
reflect faulty regulation of ADAR2 to compensate for a reduced level of ADAR2 
protein by the editing of its own pre mRNA (Rueter et al., 1999; Feng et al., 2006; 
Wahlstedt et al., 2009). It is not clear why ADAR2 levels are reduced in MN of SALS 
cases with the C9ORF72 expansion and not in those cases without the expansion, but 
this observation might be amenable to further examination.  
ADAR2 interact with the RNA binding protein hnRNP (Garncarz et al., 2013). Thus, 
it has been shown that hnRNP colocalizes with RNA foci in motor neurons of 
ALS/C9ORF72-positive cases, suggesting sequestration of RNA binding proteins, 
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inhibition of mRNA splicing as a result of depleted RNA processing proteins and 
tagging of expanded C9ORF72 pre-mRNA for nuclear export leading to cytoplasmic 
repeat associated non-ATG translation and potentially formation of toxic dipeptide 
repeat protein. (Cooper-Knock et al., 2014). 
The mRNA expression levels of ADAR3 did not show any change in SALS cases, 
either with or without C9ORF72 expansion, compared to controls. This finding may 
reflect low expression levels of ADAR3 in the spinal cord (Chen et al., 2000), and may 
also reflect the small number of cases used in the study (n=15). However, in contrast 
the mRNA expression, ADAR3 protein levels were increased in the MNs of SALS 
cases with C9ORF72 mutation compared to both SALS cases without the mutation 
and controls. The function of ADAR3 is as yet unknown, however, it has been 
suggested that ADAR3 may play a role in ALS with C9ORF72 expansion repeats. A 
recent study has demonstrated the interaction between ADAR3 and ALS C9ORF72 
repeats in iPSNs of ALS/FTD which results in RNA foci formation. This is validated 
with knockdown studies of ADAR3 which show reduction of RNA foci (Donnelly et 
al., 2013). However, this report did not characterise the role of ADAR3 specifically in 
ALS with C9ORF72 and its relationship with RNA editing. Future studies are required 
to fully elucidate the role of ADAR3 in ALS cases with the C9ORF72 expansion.  
In an attempt to investigate ADAR2 and ADAR3 mRNA expressions in MNs, qPCR 
was used. However, this approach was not successful likely due to the poor RNA 
quality in post-mortem tissue as well as the small number of MNs used in the study 
(n=15). It was hoped that using an alternative method, next generation sequencing, 
would overcome this problem. However, on this occasion the next generation 
sequencing approach proved unsuccessful. 
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The protein levels of ADAR2 in the nucleolus of MNs are decreased and ADAR3 
levels in the nucleolus are increased in ALS cases with C9ORF72 expansion. The 
inverse correlation between the protein levels of ADAR2 and ADAR3 suggests a 
competitive interaction or a novel role of ADAR3 in RNA editing of GLUR2, GLUR5 
and GLUR6 (Savva et al., 2012; Tomaselli et al., 2013; Washburn, 2014). Therefore, 
it was suggested that there is a relationship between ADAR2 and ADAR3 protein. 
Future studies should elucidate the link between ADAR2 and ADAR3. 
Several studies have demonstrated a link between a reduction of ADAR2 in the 
nucleus of MNs and the formation of cytoplasmic TDP-43 inclusions in ALS (Aizawa 
et al., 2010; Hideyama et al., 2012a; Yamashita & Kwak, 2013). It has been shown 
that increased Ca+2 influx from the Ca+2-permeable AMPA receptor activates calpain, 
Ca+2 -dependent cysteine protease, which cleaves TDP-43 into aggregation-prone 
fragments (Yamashita et al., 2012a). 
In the current study, SALS cases contained significantly higher numbers of MN 
containing p62 and p-TDP43 inclusions than non-neurological controls which have 
been shown previously. Interestingly, ALS cases with the C9ORF72 expansion 
contain significantly higher levels of p62 positive inclusions compared to ALS cases 
without C9ORF72 expansion, supporting a previous report that increased p62 
inclusions in MNs and glia is a feature of ALS cases with the expansion. (Cooper-
Knock et al., 2012). It is still unknown yet whether the formation of TDP-43 
aggregation is a cause or a consequence of MNs degeneration in ALS. 
The grey matter in the spinal cord of ALS patients exhibited astrogliosis, a reduction 
in EAAT2 protein and increased mRNA expression of aberrant EAAT2 transcripts. 
This is in agreement with previous reports that found reduced EAAT2 protein in the 
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motor cortex SALS cases linked to the presence of intron 7 retention and exon 9 
skipping in astrocytes of the grey matter in the spinal cord (Rothstein et al., 1995; 
Milton et al., 1997; Meyer et al., 1999; Flowers et al., 2001; Vargas & Johnson, 2010). 
Increased extracellular glutamate and loss of EAAT2 were shown to be a characteristic 
feature of at least 40% of sporadic ALS patients. It has been shown that changes in 
astroglia including downregulation of EAAT2 expression occurs before MNs 
degeneration (Howland et al., 2002). Astrogliosis surrounding MNs may not be ALS-
specific and arise from long hypoxic distress in some terminal patients (Vargas & 
Johnson, 2010). This feature has been observed in other neurological diseases 
including Alzheimer’s disease (Simpson et al., 2010). The loss of EAAT2 can cause 
excitotoxic MN degeneration and lead to the formation of free radicals which in itself 
causes oxidative stress and excitotoxicity (Rothstein et al., 1996). Oxidative stress can 
also damage DNA encoding EAAT2 or damage DNA repair proteins and eventually 
lead to alterations of EAAT2 in sporadic ALS (Howland et al., 2002). 
In an attempt to examine the RNA editing levels of one SALS in different region of 
the CNS using different treated tissue; FFPE spinal cord and frozen frontal cortex. 
These two regions could not be compared due to low RNA quality in the FFPE tissue. 
Whereas, the frozen frontal cortex showed fully edited GLUR2 and reduced levels of 
GLUR5 and GLUR6 editing. Similarly, fully editing GLUR2 was also observed in the 
frontal cortex and in spinal cord of control case. Also, reduced GLUR5 and GLUR6 
editing in both regions. 
However, our data did not reach statistical significance which may reflect the small 
number of samples in each group, as well as the case-to-case variation within the 
SALS cases in the expression of C9ORF72 gene. Future experiments would require 
increased number of cases and using mass spectrometry as an alternative method 
` 
188 | P a g e  
 
because it is more sensitive and quantitative method compared to 
immunohistochemistry. Western blot might be another cheaper approach to quantitate 
protein levels in the tissues. However, the disadvantage of these techniques was that 
it does not show protein localization within the tissue therefore, 
immunohistochemistry was used in our study as a better option to quantify proteins 
and also show its localization in MNs. 
LCM proteomic is another method that and it has been attempted by Professor Ros 
Banks at University of Leeds (personal communication). However, it was concluded 
that this approach is far more labor intensive to be used successfully.  
In conclusion, immunohistochemistry was used in this study to determine the 
protein levels of the following; ADAR2, ADAR3, GLUR2, EAAT2. The editing 
enzyme ADAR2 showed increased mRNA and reduced protein in ALS cases with 
C9ORF72 expansion. The ADAR3 protein was inversely related to ADAR2. 
Additionally, RT-PCR was performed in GLUR2, GLUR5, and GLUR6, ADAR2, 
ADAR3 and EAAT2 transcripts. The GLUR2 was fully edited in MN of ALS cases and 
in controls and EAAT2 alternative transcripts were increased in ALS cases with the 
C9ORF72 expansion. Next generation sequencing was used to supplement these 
findings but were not appropriately successful.  
6.2 Future Work 
Future work will investigate ADAR1 as it is the other editing enzyme to edit GLUR2. 
Increasing sample size to enable analysis within specific groups of patients as well as 
using the same patients throughout experiments to allow the data to be combined from 
all sections. Repeating the use of next generation sequencing and troubleshoot the 
library DNA concentration to ensure better amplification.  
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The attached CD contains an excel file of mapping reads to the human genome.  
 
 
